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ABSTRACT 
 
The subject of this thesis relates to the realisation of a novel biochip for sensors based 
on optical principles. In particular, affinity biosensors for antigens (IgG/anti-IgG), for a 
transcription factor, and for mRNA were studied and developed. The interrogation of 
the biosensors implied the development of a novel and innovative optical platform 
based on fluorescence which was designed, implemented and thoroughly characterised. 
The biosensors developed were integrated within an optical biochip connected to an 
innovative platform. The optical biochip was fabricated from polymethylmethacrylate 
(PMMA) formed by two pieces of PMMA complementary shaped in order to obtain 
four micro-channels. The lower part included the micro-channels and the inlet and 
outlet for the fluidic, while the sensing biolayer was immobilised on the upper part. The 
optical signal comprised the fluorescence emitted by the layer, which was 
anisotropically coupled to the cover and suitably guided by the chip. Several chemical 
treatments of the surface were investigated to obtain the most effective distribution of 
carboxylic groups for the covalent immobilisation of antibodies. Deposition of the 
polymers, in particular by Langmuir-Blodgett method, can enhance the performances of 
the chip going through lower detection limits.  The potential of the optical chip as a 
biosensor was investigated in depth by means of a direct IgG/anti-IgG interaction 
carried out inside the flow channels. Following this, bioassays for the determination of 
the NF-kB transcription factor and for the mRNA that codifies for MGMT protein were 
implemented on the optical platform. The development and characterisation of the 
biosensors, the identification of the protocol for the bioassays and the design and 
characterisation of the optical platform were performed at the Institute of Physics 
Applied Carrara of National Research Council (IFAC-CNR), Firenze, Italy. The 
research devoted to the development of biosensing surfaces for the realisation of 
affinity biosensors able to detect and quantify antigens, transcription factors and RNA 
sequences were carried out at the laboratories of the Institute of Clinical Physiology of 
National Research Council (IFC-CNR), in Pisa, Italy. Langmuir-Blodgett deposition of 
polymers, Atomic Force Microscopy imaging and further fluorescence measurements 
of proteins covalently bound on the surfaces were performed at Cranfield University in 
Silsoe, England. The overall project starts from a first characterisation of the optical 
system, and comprehend the enhanced optimisation of the biochip performances until 
the realisation of the biosensors previously mentioned.   
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1. PREFACE 
 
Affinity biosensors allow the detection of affinity based interactions between bio-
molecules and their corresponding components (e.g., avidin/biotin, antigen/antibody, 
complementary single-stranded DNA sequences). A suitable design of the biosensor 
ensures that binding of target molecules and their corresponding components takes 
place on the transducer surface. The sensors are thus implicitly heterogeneous. A key 
aspect in the development of biosensors concerns the interaction between inorganic 
(i.e., the transducer) and organic material (i.e., the biological receptors). The increasing 
miniaturisation of biosensor transducers (and thus of their active areas) and the demand 
for high sensitivity, require a covalent and tailored coupling of bio-molecules to the 
transducer surface. In order to meet the requirements of miniaturised affinity based 
biosensors regarding sensitivity, selectivity, stability and reproducibility, tailored bio-
interfaces have to be developed and evaluated. Affinity biosensors have generally 
proved more amenable to optical detection methods [1]. As for the optical approach, a 
major distinction can be made between label-free sensors [2-4], in which the interaction 
analyte/sensitive layer gives rise to a modification of the optical signal due to a change 
in the refractive index of the layer deposited on the substrate, and label-based sensors 
[5-8], in which fluorescent labelling is used to obtain an optical signal that depends on 
the analyte investigated. There are both advantages and disadvantages with these two 
methods. The main advantage of a direct detection method is its capability to make 
analyses without the application of labels [9]. In fact, fluorescence-based biosensors 
require either multi-step detection protocols or delicately-balanced affinities of 
interacting biomolecules for displacement assays, which can cause sensor cross-
sensitivity to non-target analytes. However, for complex sample monitoring, the label-
free methods continue to be susceptible to problems such as low sensitivity and 
increased backgrounds due to non-specific binding. Therefore, in clinical applications 
in which the sample matrix can be very complex (as in the case of whole blood and 
even serum) the use of a label-based system may be preferable [10].   
In particular, affinity biosensors for the IgG/anti-IgG, for the NF-kB transcription 
factor/DNA consensus sequence and for complementary RNA/RNA sequences, one of 
which is the mRNA codifying for MGMT protein, were studied and developed.  
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The interrogation of the biosensors implied the development of a novel and innovative 
optical platform based on fluorescence which was designed, implemented and 
thoroughly characterised.  
The biosensors developed were integrated within an optical biochip connected to the 
optical platform.  
The optical signal comprised the fluorescence emitted by the layer, which was 
anisotropically coupled to the PMMA cover and suitably guided by the PMMA chip.  
Several chemical treatments of the PMMA surface were investigated. In particular the 
deposition of one copolymer of PMMA by Langmuir-Blodgett method, offers an 
impressive enhancement of the performances of the biochip.   
The potential of the optical chip as a biosensor was investigated in depth by means of a 
direct IgG/anti-IgG interaction carried out inside the flow channels. The mouse-IgG 
was covalently immobilised on the internal wall of the PMMA cover and the Cy5-
labeled anti-mouse IgG was used for the specific interaction.  
Bioassays for the determination of the NF-kB transcription factor and for the mRNA 
that codifies for MGMT protein were implemented on the optical platform.  
An improvement in the sensitivity of the system and a lower limit of detection (linear 
range 1 ng/ml- 1mg/ml) for the IgG/anti-IgG assay was revealed with the PMMA chip. 
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2. INTRODUCTION 
 
2.1 General features of biosensors 
 
According to the modern definition [11-12], a biosensor is an analytical device 
comprising a biological or biologically derived sensing element either integrated within 
or intimately associated with a physicochemical transducer which generates selective and 
reversible signals reflecting the concentration of analytes present in the sample.  
The general principles of operation of an affinity biosensor are shown in Fig. 2.1 and it is 
conceptually easy to understand: the bioreceptor immobilised on a surface of a solid 
support takes part in one or more processes that determine the variation of a chemical, 
physical or physical-chemical parameter, which are then converted by the transducer into 
an electrical signal that can be amplified, elaborated and visualised.  
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Figure 2.1 General constituents of a biosensor (left) and list of possible types of bioreceptor, transduction 
systems and signal (right). 
 
For most modern industrial production methods, process monitoring plays a key role; 
bioprocess systems are no exception to this rule. Effective methods of control are 
required so that the development and optimisation of efficient biosensors is a key 
component for biological process monitoring. An optimised biosensor should lead to a 
streamlined procedure, reducing material costs and improving performance in the control 
of several parameters. A number of bioprocess monitoring instruments and kits have been 
developed for industry quality control over many years, in particular biosensors capable 
of measuring physical or chemical parameters. The challenge in this branch of research is 
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to develop cost-effective and robust devices capable of measuring a much wider range of 
parameters, providing process operators with a deeper insight into their processes.  
In addition to the variety of monitoring devices available, a number of methods for 
carrying out the measurement exist. Sampling and sample handling is a vital issue, 
affecting both the accuracy and frequency of measurement [13]. Broadly, the main 
approaches to sampling can be described in one of several ways: 
1) “Off-line monitoring” involves taking a sample from the measuring site and carrying 
out the measurement at a different location, usually under laboratory conditions. Off-line 
sampling suffers from the disadvantages of high cost and low efficiency. Manually 
removing and measuring a sample requires technical labour, involves the introduction of 
possible errors during the sample transportation and implies a delay between sampling 
and the measurement. 
2) “At-line monitoring” involves decentralised equipment and allows measurements to be 
made simply close to the production process reducing lot of delays associated with the 
sample transportation and laboratory analysis.   
3) “On-line monitoring” involves automatic sampling facilitated by the proximity of the 
analytical instrumentation. 
4) “In-line monitoring” involves the use of sensors placed directly in situ inside the 
bioprocess vessel.  
The use of in situ sensors has long been established in the bioprocess industry [14] where 
immersed devices are used to monitor a number of parameters such as pH and dissolved 
gas concentrations. A number of advantages are gained by operating sensors in this 
fashion, including “real-time monitoring” (delays due to sampling are eliminated) with 
the sensors operating continuously (any change in the analyte concentration can be 
readily observed), and problems of contamination being significantly reduced. However, 
in situ sensors can have a number of drawbacks, for example, if the sensor lifetime is 
short and the sensing element looses its recognition properties, it has to be easily renewed 
or replaced, which may be difficult during a process run. Methods of “on-line 
monitoring” involve the automatic removal and measurement of sample or sample stream 
from the bioreactor. One example of this has been the development (since the early 
1980s) of flow injection analysis. This is a liquid handling technique that has proved 
flexible in adapting to most chemical and biochemical reaction procedures [13], 
representing an effective compromise between the desirability of in-situ monitoring and 
off-line measurements. The main advantages of on-line methods include the following: 
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sensor sterilisation can be readily accomplished, sample pre-treatment (e.g. dilution, 
removal of interferents) and sensor calibration can be performed on the system.  
The main disadvantage is represented by a need for an effective and reliable sampling 
system; the frequency of measurements is limited by the overall flow-injection analysis 
arrangement.  
Further developments came from wireless technologies that now allow sensors to be 
controlled directly from a portable device at an affordable price using appropriate 
software. The improvement of this technology allows a much more constant frequency 
rate and can avoid certain discontinuities of the signal due to previously used slower 
telecommunications. In summary, all of these methods have their advantages and 
disadvantages. The choice of an appropriate approach depends on a number of factors, 
not least of which will be the availability of both sensor and system. Eventually effective 
monitoring will lead to better control systems, providing costs and quality benefits. For 
any measurement technique, there are a number of criteria that the device must satisfy if 
it is to be accepted by commercial bioprocess operators. The following subset covers the 
main characteristics of a monitoring process [15]:  
 
Reliability  
 
Reliability is a key issue for bioprocess monitoring equipment. Confidence in the ability 
of an instrument to maintain its credibility in terms of performance is a fundamental 
parameter. This encompasses a number of features relating to the operation of the 
instrument, for example, ease of use, maintenance, repair and replacement. A successful 
monitoring instrument will have a low failure rate. 
 
Accuracy 
 
Accuracy can be described as the relationship between the measured value (by the 
instrument) and the actual value of a bioprocess variable.  
An accurate instrument will achieve a low percentage error between these two values. 
Generally this can be stated as:              
 
% error = (measured value - true value) / true value 
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Precision 
 
Precision is a measure of instrument reproducibility, that is, the ability to obtain the same 
value with repeated measurements of a process variable (at constant level, such as in the 
same buffer solution). A precise instrument may not be accurate. Therefore it is important 
to distinguish between these two parameters. 
 
Response time 
 
The measurement of any process variable will entail a time delay between change in the 
parameter and display of the measured value. This response time should be appropriate 
for the progress of the bioprocess, particularly if the measurements are linked to a control 
action. Response times will be affected not only by the type of instrument but also by the 
method of measurements. Off-line sampling and measuring can involve a number of time 
consuming steps. In contrast, an in situ device can provide a real-time measurement.  
According to IUPAC (International Union of Pure and Applied Chemistry) the response 
time is based on the differential quotient ∆signal / ∆time (where signal is normally 
expressed in volts).  
The IUPAC recommendations outline two experimental procedures for measuring the 
response time. In the “dipping method”, the sensor is instantaneously immersed into a 
solution of known activity of the test analyte. With the “injection method”, the sensor is 
kept immersed in a solution and after beginning to record the response, a measured 
aliquot of a concentrated solution of the analyte is added.  
The response time determined by the first procedure has been termed “the static response 
time”, whereas, the approach delivers the “dynamic response time”.  
The response time is not a univocal parameter and it depends on the particular working 
conditions [16]. 
 
Calibration 
 
In order to maintain the accuracy of a sensor it is desirable to carry out a calibration step. 
The effects of calibration can damage the process, or, in other words, it may be difficult 
to carry out calibration of an in situ sensor, whereas an online device could easily 
incorporate calibration steps during routine running. 
 6
 Linearity 
 
Under ideal condition the output signal from a sensor would be directly proportional to 
the analyte concentration. However, this is not always the case and other models have to 
be used to reach a true value. Despite this drawback, linearity is not an overriding 
prerequisite for a successful monitoring instrument. In fact, developments in modern 
software can be adapted to compensate for non-linearity.  
 
Sensitivity  
 
Sensitivity is the magnitude of the output signal per unit change in the target analyte 
concentration. The lowest level of detection is related to the sensitivity and the signal-to-
noise ratio. A number of factors influence the sensitivity of a monitoring device, 
including sensor design, the operating environment, periods of maintenance, and 
interfering noise levels. The sensitivity will influence the dynamic range above which the 
device becomes saturated; the highest level of detection will be the threshold limit for the 
device. The limit of detection (LOD) and limit of quantification (LOQ) are defined by 
IUPAC as three times and ten times respectively the average of the single noise value 
signal (standard deviation). 
 
Selectivity  
 
Selectivity indicates how free from interferences the method of measurement is. In 
practice, all analytical methods can be perturbed by interfering species and this effect has 
to be minimised in order to obtain higher accuracy of the measurement.   
 
Specificity  
 
It is a statistical measure of how well a binary classification test correctly identifies the 
negative cases, or those cases that do not meet the condition under study. Specificity is 
defined as the number of true negatives divided the total sum of true negatives and false 
positives.  
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   2.2 General features of optical biosensors 
 
The argument of this thesis will refer to the use of different types of bioreceptors to 
characterise the potentiality of a novel optical biochip, measuring the signals in 
absorption and mainly focusing on fluorescence (Fig. 2.1).  
In literature are plenty described various systems obtained following precise conditions 
dictated by opto-chemical rules involved in the engineering of an instrumental device.      
In this chapter several optical principles and literature references are reported and 
illustrate an overall idea of the recent thirty years development in the field of optical 
biosensors. 
In literature various optical technique for detecting and monitoring antibody-antigen 
reactions at a solid-liquid interface are reported.  
Extremely important are the theoretical studies and the applications developed 
determined by the study of the optical coupling of the laser light with a surface 
chemically modified.   
This part will start from formulations on the general principles of internal reflection 
spectroscopy, models for refractive index, evanescent wave and fluorescence theory in 
immunoassays, going towards modern optical systems such as fluorescence capillary fill 
device.  
Satisfactory results were also obtained based on surface plasmon resonance sensors, 
optical biosensors, resonant mirror, array biosensor, flow injection analysis, fiber optic 
sensor, near infrared sensor, fluorescence sensor and dipstick sensor.  
Recently a comparison between two modern techniques (optical biosensors and ELISA) 
to measure a protein assay was also considered and discussed.  
Lateral flow biosensors, fluorescence enhancement due to metal nanoparticles, and the 
presentation of a multi-analyte array biosensor product in the market were the last articles 
reported.  
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2.2.1 Internal Reflection Spectroscopy (IRS) 
 
Between two transparent media when a light beam strikes the interface from the medium 
with a higher refractive index (n1 > n2), total internal reflection occurs [17] (Fig. 2.2A) if 
the angle of reflection θ is larger than the critical angle θC, defined as:  
 
θC = arcsin (n2 / n1)      
 
In this case the evanescent wave penetrates a distance (dP), on the order of a fraction of a 
wavelength, beyond the reflecting surface into the rarer medium with the lower refractive 
index n2. According [17] to Maxwell’s equations, a standing sinusoidal wave, 
perpendicular to the reflecting surface, is established in the denser medium (Fig. 2.2B). 
        
 
Figure 2.2 Generation of the evanescent wave at an interface between two optical media: (A) Where n1 > n2 
and θ > θc the critical angle at which refraction occurs, the evanescent wave is generated at the point of 
reflection. (B) Plotted on a different axis (where E = field strength, Z = distance into the rarer medium), the 
evanescent wave is represented as a standing sinusoidal wave perpendicular to the reflecting surface with a 
characteristic generation depth (dP). [17] 
 
Although [17] there is no net flow of energy into the non absorbing, rarer medium, there 
is an evanescent, non propagating field in that medium, the electric field amplitude (E) of 
which is largest at the surface interface (E0) and decays exponentially with distance (Z) 
from the surface: 
 
E = Eo ·exp(-Z/dP)      
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The depth of penetration (dP), defined as the distance required for the electric field 
amplitude to fall to exp (-1) of its value at the surface, is given by: 
 
 2/12
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nd P −= θπ
λ    
 
Starting from 90°, as θ approaches θC, dP becomes infinitely large and, at a fixed angle, 
increases with closer index matching (i.e., as n2/n1 Æ 1).  
Also, because dP is proportional to wavelength, it is greater at longer wavelengths.  
Thus, by an appropriate choice of the refractive index n1 of the transparent support 
material, the incident angle, and the wavelength, one can select a dP to promote optical 
interaction mainly with compounds close to or affixed at the interface, and minimally 
with the bulk solution.  
For example, if the denser medium is a quartz microscope slide (n1 = 1.54) and the rarer 
medium is aqueous sample solution (n2 = 1.34), θ is 70°, and if λ is either 495 nm or 310 
nm, thus the dP  is approximately 145 nm or 90 nm, respectively. 
One [17] can enhance assay sensitivity by combining the evanescent-wave principle with 
multiple internal reflections. The number of reflections (N) for both sides of the slide is a 
function of the length (L) and thickness (T) of the waveguide and of the angle of 
incidence (θ): 
 
θcot/ ⋅= TLN      
 
In 1985, optical techniques for monitoring immunological reactions on continuous 
surfaces were investigated and reviewed [18]. Techniques such ellipsometry, light 
scattering, surface plasmon resonance and more general internal reflection spectroscopy 
(IRS) systems were discussed.  
The latter includes attenuated total reflection (ATR) and total internal reflection 
fluorescence (TIRF). Overall, it was considered that the IRS systems and ellipsometric 
approaches offered the most promise for the design of a specific immunosensor device.  
In particular. the ellipsometric methods are the most sensitive but also the most 
vulnerable to non-specific signal interference. Although lacking in extreme sensitivity, 
the IRS approaches reviewed were more robust in signal transduction. [18] 
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2.2.2 Models for refractive index  
A recent well appreciated formulation [19] in a an asymmetric slab (planar) waveguide 
setup (Fig. 2.3) was plenty explained on a clear class with the equations shown on the:  
1) Determination of the core thin film refractive index, ncore .  
2) Calculation of the superstrate refractive index, nsuperstrate, if ncore is known.  
3) Calculation of the effective refractive index, (neff)p, if ncore is known.  
 
Figure 2.3 A typical coupling arrangement in a an asymmetric slab (planar) waveguide. [19] 
 
Derivation of these equations were referred previously [20], and applications of these 
procedures are well reported elsewhere [21-23]. 
Again another exhaustive formulation in the excitation of a planar waveguide using a 
grating coupler (Fig. 2.4) was discussed [24] on the:  
1) Determination of the core thin film refractive index, ncore;  
2) Determination of an analyte solution, i.e. the superstrate, refractive index, nsuperstrate;  
3) Calculation of the effective refractive index, (neff)p, if ncore is known; 
 
 
 
 
Figure 2.4 A typical coupling arrangement in a grating coupling sensor is shown. [24] 
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2.2.3 The evanescent wave 
 
Fluorescence emission generated at a waveguide-liquid interface can be monitored at the 
waveguide output. 
Fluorescence emission in a waveguide/liquid interface must be considered as an 
evanescent wave as depicted by the theory of reciprocity, and demonstrated with dye 
molecules in both monomolecular layers [25] and in monodispersed spheres [26].  
In effect, excitation of fluorescence by an evanescent wave produces fluorescence 
emission generating an internally reflected beam of fluorescent light.  
The direction of fluorescence emission is mainly a function of the respective refractive 
index ratio and has the major feature [25] that photon emission has a distribution of 
“preferred” angular probability close to the critical angle (θC).  
Practically the fluorescence can be monitored at the output of the waveguide in the same 
optical plane as the excitation light. Theoretically, this has the advantage to concentrate 
the fluorescent emission intensity within a small angle, called anisotropic angle; also, 
these fluorescent photons do not pass through the bulk of the solution and thus are not 
subject to major optical interference (e.g., absorption, scattering).[27] 
Antibodies covalently immobilized onto the surface of either a planar (microscope slide) 
or cylindrical (fibre optic) waveguide made of quartz were described in literature.[27]  
The reaction of immobilized antibody with antigen in solution was detected through use 
of the evanescent wave, which has a characteristic depth of penetration of a fraction of a 
wavelength into the aqueous phase, thus optically interacting, as previously mentioned, 
with substances bound or located very close to the interface and only minimally with the 
bulk solution.  
An immunoassay for methotrexate (MTX) was monitored by the decrease in 
transmittance at 310 nm and achieved a detection limit of about 270 nmol/l; a two-site 
immunofluorometric assay for human IgG was able to detect until 30 nmol/l; binding of 
fluorescein-labeled antibody was monitored by the increase in signal at > 520 nm ( λ exc. 
= 495 nm).  
With both immunoassays the signal-generating phase was monitored kinetically and was 
completed within 15 min. The completion time in a procedure for an immunoassay 
(commonly due to the biological response of the bioreceptor to the analyte) represents 
one of the most important parameters in a point-of-care unit device.  
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Following the pioneering work of Berson and Yalow in 1959 [28], immunoassay 
procedures have rapidly assumed a major role in the clinical investigation of disease and 
monitoring of therapy [29, 30]. Extremely important is the optimization of the chemical 
protocol which can ensure robust performances of detection in a short period of time.  
 
The evanescent field technique was used to monitor the deposition of inorganic 
compounds at various solid-liquid interfaces [31, 32].  
Similarly, the generation of thin protein films at solid liquid interfaces has been 
investigated by infrared spectroscopy techniques [33, 34] and fluorescence [35]. 
 
In particular fluorescent detection in antibody-antigen reactions has been demonstrated in 
1975 when the monitoring of fluorescein-labeled antibody bound to antigen (phenyl 
arsonic acid) immobilized on a quartz waveguide has been reported [36].  
In 1983 an examination of the binding kinetics of rhodamine-labeled antibodies to 
dinitrophenol, immobilized to a quartz waveguide, was also presented [37].  
 
Elsewhere [38] were presented data using the evanescent wave to measure human IgG, 
captured by an immobilized antigen, by the increase in light scattered perpendicular to 
the optical axis.  
Moreover, in 1984, another application [39] based upon theoretical principles, described 
an optical detection technique for monitoring antibody-antigen reactions at a quartz-
liquid interface.  
 
A two-site immunofluorescent assay for human IgG is described using fluorescein.  
The assay detection limit is approximately 0.8 µg/ml and individual fluorescence 
measurements were completed in this case within 10 min [39]. 
 
Going towards the development of commercial biomedical devices, a U.S. Patent, in 
1987 was registered describing a waveguide placed in contact with an illuminated 
sample; fluorescence from bound material produces an evanescent wave above the 
critical angle. Fluorescence from unbound material is refracted at the interface, and can 
therefore only exit the waveguide at an angle below the critical angle [40]. 
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2.2.4 Fluorescence Capillary Fill Device 
 
In 1987, detail of a novel type of optical biosensor for immunoassays, the fluorescence 
capillary-fill device (FCFD), was reported [41]. This is based on a straightforward 
adaptation of the technology used to mass manufacture liquid-crystal display (LCD) cells 
to give cheap disposable immunosensors. The optical characteristics of the FCFD were 
described on a competitive immunoassay for human immunoglobulin G (hIgG).  
The demonstration of this assay resulted in a significant achievement, because the format 
of the FCFD, its manufacturing process and its instrumentation were modern and deeply 
studied [41]. 
In addition, sensors that exploit the evanescent field associated with the reflection of light 
at dielectric/ dielectric interface or at dielectric/metal interface enhanced optical 
biosensing [42]. 
The development [43] of FCFD, in which the additional reagent was temporarily 
immobilized has removed several shortcoming and the use of a metal/dielectric interface 
at which a surface plasma wave was generated has provided a robust idea in the biosensor 
construction.  
Immunosensors make use of antibodies and can be extremely specific if appropriate 
monoclonal antibodies are used. The development [44] of an optical immunosensor based 
on the detection of rubella antibody in serum, plasma and whole blood was reported in an 
assay time of less than 10 min.  
Optical technologies currently proved very attractive ideas for the construction of reliable 
biosensors in a fast response time.  
Using FCFD, in 1991 was developed [45] an assay for human chorionic gonadotrophin 
(hCG) for a variety of body fluids (whole blood, serum, urine and saliva) demonstrating 
the enhanced versatility for the assay performances of this method.  
Maximum analytical performance from an optical immunosensor which uses whole blood 
as the sample matrix, needs a rigorous selection of the fluorophore and this was studied in 
1995 [46].  
Three fluorophores, allophycocyanin (APC), carboxymethylindocyanine succinimidyl 
ester (CY5) and fluorescein isothiocyanate (FITC), were evaluated in whole blood and 
serum assays using the FCFD immunosensor. FITC is a well known and readily available 
fluorophore; however, the wavelengths of its fuorescent spectrum coincide with the 
intrinsic fluorescence of human serum and it was suspected that the performance of 
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assays using FITC would suffer accordingly. APC and CY5 were evaluated as alternative 
fluorophores because of their longer excitation and emission wavelengths. APC is a 
phycobiliprotein extracted from algae whilst CY5 is a synthetic dye whose properties are 
similar to those of APC. APC and CY5 gave the best result in terms of analytical 
performance using FCFD setup [46]. Whole-blood patient samples were assayed using 
APC as  label and an excellent correlation was obtained with a commercially available 
immunoassay.  
A most desirable feature of such sensors would be the ability to use untreated whole 
blood samples thus removing the need, with associated time, cost and safety implications, 
for the preparation of serum and/or plasma samples prior to analysis.  
The use of whole blood is also advantageous from an optical point of view because the 
self-fluorescence of the sample was much reduced.  
The samples were examined again by FCFD, discriminating between fluorophores bound 
to the surface and free in solution without the need for a wash and/or separation step.  
The model analyte chosen [46] for this study was prostate-specific antigen (PSA). PSA is 
a glycoprotein of approximately 30 000 molecular weight which is secreted exclusively 
by the prostate gland in the male and finds an important role in the diagnosis of prostate 
disease [47].  
The FCFD is currently undergoing rigorous product developments targeting the point-of-
care market of biomedical instruments.  
 
 
2.2.5 Surface plasmon resonance 
 
Surface plasmons are electromagnetic waves that propagate parallel along a 
metal/dielectric  interface [48]. The antibody was immobilised on a metal surface on 
which the surface wave was generated. On binding a large analyte the refractive index 
within the region of the surface plasmon evanescent field changes, and the matching 
requirements for surface plasmon generation are correspondingly alterations which may 
be observed, e.g. as a change in the angle of the incident light required to achieve 
resonance.  
Immunosensors have dominated those biosensors that exploit an evanescent field. Most 
workers see decentralized testing as the natural market niche for evanescent field 
biosensors, e.g. testing within the doctor's office, rapid screening within blood collection 
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centres and, possibly, home monitoring. Anyway, such applications are less demanding 
than in vivo monitoring.  
Nonetheless, there are still many problems to solve in this area. Non-specific binding is 
one of the major troubles in surface plasmon resonance (SPR) biosensing because any 
large molecule that diffuses into the evanescent field will cause a change in the resonance 
shift. [48] 
An attractive approach, that embodies the philosophy to join plasmon effects and 
fluorescence technique, was to combine them to give an SPR enhanced 
fluoroimmunoassay [49]. 
 “Indirect” sensors (for example, those employing a fluorescently labelled reagent) 
overcome many problems of non-specific binding and poor sensitivity to small 
molecules, but they require more sophisticated and expensive instrumentation because of 
the low power of the light detected.  
In an attempt to combine the best features of these two techniques, an indirect SPR 
fluoroimmunoassay (SPRF) technique was investigated in 1991. The surface field 
intensity enhancement produced by SPR was used to boost the emission from a 
fluorescently labelled immunoassay complex on a metal surface.  
The potential of the method was demonstrated by assaying for human chorionic 
Gonadotrophin (hCG) in serum. Enhanced sensitivity over conventional using total 
internal reflection fluorescence (TIRF) and SPR techniques was achieved. [50] 
  
2.2.6 Optical biosensors 
Biosensors are increasingly becoming practical and useful, if not essential, tools in 
medicine, food quality control, environmental monitoring and research. In principle, they 
can be tailored to match individual analytical demands for almost any target molecule or 
compound that interacts specifically with a biological system.  
A biosensor makes use of a biological molecule that is immobilized in proximity to a 
transducer to detect an analyte, and ultimately transduces the chemical signal produced 
by the interaction into a measurable response, most often an electronic signal. The 
immobilization of robust biomolecules permits the regeneration of a biosensor, and 
allows a simplification of the analytical apparatus. [51] 
It has long been known that spontaneously formed structures such as bilayer lipid 
membranes can be used as models of biological membrane. This has led to the 
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development of biosensors based on structures similar to bilayer lipid membranes, which 
are films composed of multiple layers of organized lipid-like molecules. Insoluble, 
amphiphilic molecules (i.e. those having a hydrophilic end and a hydrophobic end), 
including phospholipids and fatty acids, will spontaneously form a monolayer film if 
deposited at an air-water interface. Bilayer lipid membrane structures may be 
immobilized on surfaces by transferring the amphiphilic monolayers from an air-water 
interface using the Langmuir-Blodgett (LB) method [52].  
This transfer is usually accomplished by slow insertion, or withdrawal, of the support 
through the air-water interface. Repeated insertion/withdrawal cycles can be used to 
obtain bilayers and multilayers. An important characteristic of immobilized films is that, 
while they are stabilized on the surface, there is still a high degree of lateral mobility of 
membrane molecules which simulates the behaviour in natural membranes. Films 
prepared by the LB method have been deposited on both electrochemical [53] and optical 
[54] supports, and used for the detection of analytes in solution.  
However, further investigations were required before practical biosensors using LB 
membranes became available. [55]  
Optical systems depend more on traditional immobilization methods that were developed 
some time ago, when immobilized enzymes on substrates such as porous glass were 
thought to be the next generation of industrial catalysts. Research has demonstrated the 
possibility in the past that functioning biological molecules could be encapsulated in 
silicate glasses using the sol-gel method. The sol-gel entrapment process is a relatively 
gentle chemical procedure that is carried out at room temperature so that many of the 
molecules can survive entrapment.  
In the sol-gel procedure, the silicate matrix is formed by hydrolyzing an alkoxide 
precursor, such as tetramethyl orthosilicate (TMOS), followed by condensation, to yield a 
polymeric oxobridged SiO2 network. Therefore, if a protein is added after the partial 
hydrolysis of the TMOS precursor, a porous matrix is formed around the protein 
molecule, entrapping it in an aqueous microenvironment.  
It should be noted that the structure and properties of the gel continue to change as long 
as solvent remains in the pores, since cross-linking is still taking place in the solid 
amorphous phase.  
The control of cross-linking to produce a sol-gel with reproducible and controllable pore 
sizes must be achieved before the procedure can be considered for practical applications 
in biosensor construction [55]. In many sensor applications the sol-gel film is used to 
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provide a microporous support matrix in which analyte-sensitive fluorophores are 
entrapped and into which smaller analyte species may diffuse and interact [56, 57]. 
Sol-gel films have many advantages as support matrices over polymer supports, including 
for example, strong adhesion, good mechanical strength, and excellent optical 
transparency.  
The versatility of the process facilitates tailoring of the physicochemical film properties 
to optimize sensor performance. For example films can be designed to have optimum 
porosity while minimizing leaching of the fluorophore.   
 
 
2.2.7 Resonant mirror 
 
The potential of a new compact optical biosensor, the so called resonant mirror (RM), for 
detecting whole cells was demonstrated in 1994 [58]. The RM is a biosensor based on 
frustrated total internal reflection which combines the enhanced sensitivity of waveguide 
devices [59] with the facile construction of surface plasmon resonance sensor for the 
study of biomolecular interactions at interfaces. A thin (circa 100 nm) layer of a high 
refractive index dielectric material, such as titania or hafnia, and a thicker layer (circa 1 
µm) of a low refractive index material, such as silica, were deposited on a prism of high 
refractive index glass.  
At certain angles of incidence, light is coupled into the high refractive index dielectric 
layer where it undergoes multiple total internal reflections at the top interface, allowing 
the evanescent wave, to penetrate into the sample overlayer.  
The angle at which this resonance occurs is sensitive to changes in refractive index and 
thickness in the biological overlayer within a few hundred nanometers of the interface. 
On reflection, the light undergoes a 2π phase change, and by monitoring the angle at 
which this occurs, it is possible to detect changes within the evanescent field.  
As the two components of the light, the transverse magnetic (TM) and the transverse 
electric (TE), undergo this phase change at different angles, one mode can be utilized as 
the reference for the other. By interference of the two components, a bright resonant peak 
can be generated, the position of which can be monitored to detect changes in the 
biological overlayer [58]. 
The biosensor surface was functionalized with an aminosilane and IgG immobilized via a 
glutaraldehyde linker. Subsequent addition of S. aureus (Cowan-1) cells produced a shift 
 18
in resonance position proportional to the cell concentration applied from 8·l06 to 8·l07 
cells / ml . Sensitivity was increased to 8·103 cells / ml by using colloidal gold-IgG 
conjugates in a sandwich assay format. The specificity of the method was also 
demonstrated by measuring S. aureus in milk by the colloidal gold-IgG conjugate 
sandwich assay. The Staphylococcus aureus strain Cowan-1, which expresses protein-A 
at its surface, can be detected by binding to immobilized human immunoglobulin G 
(IgG), whereas the non-protein-A expressing S. aureus strain Wood-46 produced no 
significant resonance shift. [58] 
 
 
2.2.8 Anisotropic emission 
 
A novel model configuration for fluorescence-based optical sensors was presented in 
1998 [60]. The fluorescence emitted from a dye-doped sol-gel film was captured 
efficiently and guided along a planar waveguide. The study on anisotropy of the 
fluorescence emission brought to the best angular separation between the excitation light 
and the fluorescence emission.  
In the spectroscopic mechanisms which may be employed in  biosensors construction, 
fluorescence is the still probably the most attractive because of its simplicity and 
inherently low detection limits. So, with the increasing trend towards miniaturised, low 
cost and disposable devices, there is a great interest in optical configurations which are 
compatible with mass production and inexpensive components [60].  
The general principle is the efficient capture of fluorescence emitted from a coating on a 
planar waveguide. This allows the realisation of compact and low cost devices where the 
discrimination of excitation and emission light is performed without the use of expensive 
optical filters.  
A schematic drawing of an extremely interesting and simple optical setup is shown in 
Fig.2.5.  
The sensing element was a multimode waveguiding substrate (for example, a simple 
microscope slide) coated with a sol-gel film made of a fluorescent reagent entrapped in a 
polymer matrix.  
The fluorescent reagent used in this work was ruthenium II-tris (4,7-diphenyl-1l-o-
phenantroline) which has been widely used in optical oxygen sensors based on 
fluorescence quenching. The dye was excited in the blue region of the spectrum (λexc = 
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450nm) and emitted in the orange (λem = 600nm). The sol-gel process [61, 62] was used 
to produce glass-like coatings from the hydrolysis and condensation polymerisation of a 
silicon alkoxide precursor. This precursor solution was doped with the fluorescent dye. 
The microscope slide was then dip-coated by withdrawal from the doped sol, and after 
thermal treatment a thin layer of fluorescent porous glass was obtained on the surface of 
the slide [60]. A substantial fraction of the fluorescence emitted in the thin film was 
captured by the microscope slide, which acts as a waveguide. The guided fluorescence 
was detected at the end-face of the slide by a photodiode which was placed at an angle θ 
to the plane of the slide (Fig. 2.5).  
 
Figure 2.5 Schematic drawing of experimental setup. Fluorescence emitted in the thin film was captured 
by the microscope slide, which acts as a waveguide [60] 
 
The detection angle θ was a very important parameter in this optical setup. Plots of the 
fluorescence intensity collected by the photodiode against the angle θ, for various coating 
refractive indices, were also investigated (Fig. 2.6) in this experiment. 
 
  
Figure 2.6 Angular dependence of light detected at end-face for range of coating refractive index values: 
ncoating  = (i) 1.44, (ii) 1.47, (iii) 1.50, (iv) 1.51. Dotted lines indicate the maximum. [60]  
 
A device where fluorescence was captured and detected at the end face of a waveguide 
has been also reported elsewhere [63].  
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However, no mention was made before this article on the refractive index optimisations 
or on the angular distribution of the detected fluorescence. The performance of a 
d into the slide, mainly by scattering. Thus, by selecting an optimum 
on, was evidenced [60].  
s 
all, portable instruments for analysis of immunofluids and are 
esigned for ease of use by untrained personnel, for rapid assay times, and for sensitivity 
g but demonstrate the detection of only a single analyte 
 wells [72], or dipsticks [73], to detect multiple analytes simultaneously.  
fluorescence-based sensor can be significantly improved by exploiting the optimum 
angular dependence. The fluorescence was captured preferentially by the high order 
modes of the waveguide, thereby indicating that it was based on the evanescent wave 
mode coupling.  
Contrary to the fluorescence, only a very small amount of the excitation light from the 
LED was couple
angle for detection, a spatial separation of fluorescence and excitation light, thereby 
eliminating the need for optical filters was accomplished [60]. 
As a proof of principle, this concept was applied to the sensing of oxygen. The sensitivity 
of this economic device, particularly at low oxygen concentrati
This technique was able to achieve a good separation of fluorescence and emission light 
without the use of optical filters. The device obtained was simple and compact and wa
successfully applied to the sensing of oxygen in the market of biosensors [60].  
 
 
2.2.9 Array biosensor  
 
Array biosensors are sm
d
comparable to ELISA methods. In recent years, the fabrication of biosensors able to 
distinguish multiple analytes in a single sample has become an increasingly well 
recognized research goal [64].  
There are several recent reports describing multianalyte immunosensors. Many describe a 
method for multianalyte sensin
[65-69].  
Others combine discrete sensing substrates, such as optical fibers [70], capillaries [71], 
microtiter
Another general approach employs different capture molecules in different regions of a 
sensing substrate and detects binding using a label-free approach [74, 75].  
These label-free methods were initially susceptible to low sensitivity and increased 
backgrounds due to non-specific binding.  
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Such problems were avoided by using fluorescent tracer antibodies and performing a 
measurement insensitive to non-specifically bound proteins (other than the tracer 
antibody).  
However, while this example used a single substrate with multiple capture spots, the 
individual tracer antibodies were added in sequential steps [76, 77]. 
The array biosensor [78] utilised a standard sandwich immunoassay format: antigen-
specific capture antibodies were immobilized in a patterned array on the surface of a 
planar waveguide and bound analyte was subsequently detected using fluorescent tracer 
antibodies. Mixtures of analytes were also assayed to demonstrate the sensor’s ability to 
detect more than a single specie at the same  time.  
The biosensor array developed was employed also in other studies [79] and it was 
relatively simple in its configuration.  
It was consisted of a thermoelectrically cooled CCD camera, a microscope slide 
(waveguide) coated with vertical columns of capture antibody, a diode laser with a line 
generator to launch light into the end of the waveguide, and a removable poly-
dimethylsiloxane (PDMS) flow cell for introduction of samples and fluorescent tracer 
antibody.  
Also in this case the array biosensor utilised evanescent wave excitation to interrogate 
patterns of fluorescent compounds immobilized on a planar waveguide.  
The array biosensor analyzed multiple samples simultaneously and detected mixtures of 
different types of analytes in buffer in the multianalyte format and in a number of 
physiological fluids [79] and was relatively unaffected by non-specifically bound 
components from complex samples.  
The array biosensor was able to identify samples containing bacterial spores, virus 
particles, or protein antigens in a statistically significant number of blind samples [78]. 
Moreover the biosensor performed the assays quickly and in a format that is amenable to 
automation and portability.  
Simultaneous immunoassays performed on the array biosensor correctly detected and 
identified bacterial, viral, and protein analytes in 126 blind samples, each containing a 
single analyte.  
Limits of detection and sensitivities were similar to those obtained with confirmatory 
ELISA but with significantly shorter assay times (14 min versus several hours) [78]. 
These experiments exemplified a significant reduction in the complexity of performing 
multianalyte assays.  
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The planar waveguide provided a vehicle not only for simultaneously assaying a sample 
for multiple analytes but also for assaying multiple samples in parallel.  
Combining several analyte-specific reagents into a single solution reduces both the assay 
time and complexity of the fluidics (compared to sequential addition of the reagents).  
This approach may be scaled up to accommodate a potentially unlimited number of 
analytes for which antibodies can be generated.  
The image analysis has been successfully automated and will be followed by the 
automation of the fluidics for increased ease of use and reproducibility of quantitative 
determinations [78]. 
Effective process control and modelling is a basic requirement for the optimal utilization 
of biological material. Automated systems can provide a continuous stream of 
information instead of repeated sampling and off-line analyses.  
Optical systems do not interfere with the metabolism of the cells, permitting non invasive 
in vivo monitoring and offering intracellular information that is nearly impossible to 
obtain with other methods [80]. 
Measurements of both intracellular and extracellular analytes can be performed, to 
provide both qualitative and quantitative data.  
For measuring cell growth and biomass concentration, the on-line and off-line optical 
density were often used as reference method.  
Commercially available in situ optical sensors for the on-line determination of microbial 
growth measure light absorption (turbidity) or scattering (nephelometry) continuously in 
the visible and near-infrared (NIR) ranges [80]. 
These devices can allow accurate on-line determination of cell density with no need for 
intermittent calibration procedures.  
Commercially available on-line and in situ probes for monitoring cell density, including 
experimental observations, are reported. [81–84].  
This optimization procedure seems to be a very promising development for optical sensor 
systems in general [85-87]. 
On-line characterization of cell populations in bioreactors can also be performed by in 
situ microscopy and, is important to remember that cell-concentration measurements are 
already performed in this way.  
A microscope can be mounted directly in a port of a bioreactor to generate in situ images 
from the agitated broth using pulsed illumination.  
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This technique was successfully tested during yeast fermentations and gave optimal 
results that correlated well with those obtained from a hemocytometer.  
This technique also allows morphological parameters of cells to be determined on line 
[80, 88].  
 
 
2.2.10 Fiber-optic sensors 
 
Improving the reliability of in situ biosensors for industrial applications and the 
integration of biosensors into flow-injection analysis (FIA) brought towards the 
developments directed to overcome some of the common disadvantages of biosensors 
[89]. 
Evanescent-wave sensor integrated with a flow injection system was used to detect 
DNA–DNA hybridization in real time.  
Biotinylated oligonucleotide probes were immobilized on the sensor surface and 
hybridization of a complementary target oligonucleotide was monitored.  
The limit of detection was lower than other optical biosensors using surface-plasmon 
resonance, fiber-optic fluorescence or light-activated potentiometric devices [89]. 
Fiber optic sensors (known as optodes) are based on a change in the optical properties 
(such as absorption, fluorescence or luminescence) of a particular indicator molecule.  
For example fiber optic oxygen sensors are produced by the immobilization of suitable 
oxygen-sensitive dyes at the tip of an optical fiber.  
The principle of these measurements is the decrease in fluorescence intensity of an 
organometallic dye, caused by the interactions with oxygen.  
A blue LED is guided through an optical fiber, on the tip in which the dye is 
immobilized; the fluorescence of this dye is back scattered from the tip and offers 
information about the oxygen concentration [89]. 
Sensors of this type have their highest sensitivity at lower oxygen concentrations (<20%).  
In contrast to conventional amperometric sensors (Clark type), no oxygen was consumed 
and the signal was not dependent on the stirring rate or velocity of the media.  
Biosensors for glucose or H2O2 can be manufactured by adding biological compounds 
such as oxidases to the optode [80, 89]. 
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2.2.11 Near-infrared biosensors 
 
NIR spectroscopy are used to measure the concentration of certain organic species, even 
in complex media. Biologically important bonds (aliphatic C–H, aromatic or alkene C=C, 
amine N–H and O–H) absorb in the NIR range, at 2.0 to 2.5 µm. Each chemical structure 
is related to a specific position, shape and size of the analyte’s absorption bands.  
Because the absorption bands are very similar, advanced data-analysis algorithms are 
required to extract the analytical information in a reliable manner. Multivariate 
calibration models generated by using partial-least-squares (PLS) analysis provide 
analytical information from NIR measurements. A pre-processing digital-Fourier-filtering 
step improves the results and, with this technique, glucose, glutamine, ammonia, lactate 
and glutamate were measured simultaneously in aqueous solution [90].  
By NIR methods were measured glucose, glutamine and lactate concentrations also 
during the cultivation of human prostate-cancer cells [91].  
NIR spectroscopy was used for glycerol, ammonium and acetate monitoring for control 
and fault analysis of an industrial high-cell-density E. coli cultivation [92].  
During lactic acid production in batch, fed-batch and continuous fermentation processes, 
this technique was used on line to measure the lactic acid, glucose and biomass 
concentrations, and the results agreed well with those obtained by conventional methods 
[93].  
Moreover, a fiber refractometer was used as a sensing element for NIR spectrometry 
applied to the in-line determination of fermentable sugars during the mashing process in 
breweries [80, 94].  
 
 
2.2.12 Fluorescence biosensors  
 
Fluorescence sensors based on the measurement of the reduced form of nicotinamide 
adenine dinucleotide phosphate (NADPH), were studied for in vivo measurements [80]. 
The use of these sensors is thus limited to cultivation processes with a well-defined 
medium and so, generally, restricted to special applications [80].  
More information can be obtained by in situ scanning fluorimetry [95]. A number of 
different fluorophores (e.g. aminoacids, vitamins) can be detected simultaneously. A 
fluorescence spectrometer has been developed for the on-line monitoring of different 
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cultivation of Cyathus striatus, Eurotium cristatum and Crinipellis stipitaria. The 
excitation and emission wavelengths were set independently, using a diode array to detect 
the fluorescence. The spectrometer was connected by a quartz light guide to the reactor, 
and it was possible to detect several fluorophores simultaneously, including aromatic 
amino acids, NADPH and polycyclic aromatic hydrocarbons (PAHs), in situ and on line 
[95]. 
A fluorescence spectrometer has been used to measure the total culture fluorescence.  
The spectrometer was connected to the bioreactor by a bifurcated liquid light guide, one 
end of which was placed inside the cuvette in the spectrometer and the other end in a 
standard port of the reactor with quartz window. A sensor for 2D-fluorescence 
measurements with multiple excitation and emission wavelengths was developed. [96] 
This is the so called BioView™ sensor which demonstrated to be highly robust and well 
suited to use in a process environment. It was optimized for fully automatic fluorescence 
measurements under industrial applications. A liquid light guide is used to link the 
spectrometer with the bioreactor. Contamination and sterilization problems are avoided 
by mounting the light guide into a standard port in the reactor, sealed with a quartz 
window. Interference filters are used to select the different excitation and emission 
wavelengths. Although several factors may interfere with measurements in complex or 
poorly defined culture media, this technique, in combination with modern chemometric 
methods, offers a number of interesting features for non-invasive process monitoring. 
Special filter combinations allow both fluorescence measurements and the turbidity 
measurements. The optical density and the biomass concentration can thus be estimated, 
rather than needing to use specialized turbidity sensors and it has been tested on different 
cultivation processes at laboratory and pilot-plant-scale conditions, and it was found that 
this sensor showed a high level of signal reproducibility during cultivations with S. 
cerevisiae, Claviceps purpurea, Acremonium crysogenum, Schizosaccharomyces pombe, 
Tetrahymena thermophila, Bacillus licheniformis, Enterobacter aerogenes, 
Sphingomonas yanoikuyae and E. coli. [96]. 
Other process parameters such as enzyme activity, product formation and consumption of 
substrates could be observed by their fluorescence intensity.  
In combination with scanning fluorimetry, time resolved fluorimetry has a high potential 
for resolving individual components of complex mixtures [97]. 
Oxygen, pH, CO2 and glucose modern sensors were compared with their phase-
fluorimetric alternatives. Oxygen levels in spinner flasks used for hybridoma growth 
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were monitored in situ by fluorescence-lifetime measurements. The change in lifetime of 
a donor fluorophore induced by fluorescence resonance energy transfer (FRET) to a pH-
sensitive non fluorescent acceptor, was used [98] to measure carbon dioxide in the 
exhaust gas of a bioreactor.  
The fluorescence decay times of polycyclic aromatic hydrocarbons in sea water was 
examinated [99], and Szemacinski and Lakowicz [100], have described two simple 
methods for fluorescence lifetime measurements in highly scattering media.  
These measurements can be performed in correlation to a reference fluorophore with a 
known lifetime. Alternatively, an intensity-decay law can be used that take in account the 
time delays and pulse-broadening effects of multiple light-scattering events. [80] 
Another nice configuration after the results obtained in the 1998 [60], was accomplished 
in 2000 by the group directed by McCraith [101]. 
A dual-analyte optical chemical sensor platform based on the surface patterning of 
fluorescent dyes immobilized in sol–gel thin films was demonstrated as a proof of 
principle for a potential multi-analyte detection system with implications for lab-on-a-
chip technology. A combination of hot embossing and an eccentric spin-coating 
technique was used to achieve discrete deposition of oxygen and carbon dioxide sensitive 
zones on a single wave guiding platform (Fig. 2.7A). Imaging of fluorescence from the 
oxygen and carbon dioxide sensing areas were performed using a low-cost CCD camera 
(Fig. 2.7B) and fluorescence quenching on analyte exposure was characterized [101]. 
  
                     A         B  
Figure 2.7. A) I) Frontal view of the sensor. II) Central cut view. III) LED optical coupling to the sensor. 
B) Section view of the oxygen and carbon dioxide chamber with a CCD camera faced on a window [101].  
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 Many chemical sensors and biosensors are based on the fluorescence emitted from thin 
layers or patterned arrays of fluorophores deposited on a dielectric interface, such as a 
waveguide surface or a transparent substrate [102]. For example, a wide range of 
fluoroimmunosensors that are based on the evanescent wave excitation of fluorescently 
labeled antibodies immobilized on the surface of decladded optical fibers has been 
reported [103]. 
It was found that the interface enhances the energy transfer of the radiating dipole, which 
results in a shortening of the fluorescence lifetime. Another important effect of the 
interface that is more relevant to optical sensor applications is the significant alteration in 
the angular distribution of the radiated intensity when the distance of the radiating dipoles 
is small or comparable with the wavelength of radiation of the dipole. It was shown 
experimentally that the angular distribution of the radiated intensity exhibits considerable 
anisotropy [104]. 
 
2.2.13 Anisotropic emission theoretical approach 
 
A qualitative explanations of this phenomenon has been proposed but there are quite 
limiting theories due to the consideration of single dipole behaviour near a dielectric 
interface [105] or a metal layer [104].  
However, many optical sensor configurations employ a layer of dipoles in which the 
layer thickness is comparable with or greater than the wavelength of the radiation of the 
dipole. Moreover, the optical properties of the media adjacent to the dipole layer may be 
of greater complexity, such as in a multilayer system.  
Therefore a rigorous electromagnetic theory that can predict the direction of the radiation 
produced by dipoles embedded inside an arbitrary multilayer system was necessary. First, 
a single dipole (or a very thin layer of the dipoles) of the order of 0.01 λ was considered, 
such in the articles mentioned above, and the expressions for the radiated electromagnetic 
field and intensity were derived. Then, under the assumption of mutual incoherence of 
the dipole radiation, the calculations were extended to a layer of radiating dipoles.  
Expressions for the angular distribution of the intensity that is radiated by a single dipole 
as well as by a layer of dipoles into the surrounding media are quite complex and rich in 
parameters and are discussed elsewhere. In particular, this study seeks to establish 
expressions for the functions I0(θ, φ) and IN +1(θ, φ) that represent, respectively, the 
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angular distributions of the signal in the media with refractive-index values n0 and nN+1 
(Fig. 2.8). 
 
Figure 2.8 Schematic drawing of the radiating dipole placed within a multilayer system. The dipole, 
depicted by the bold arrow, is placed at the interface of the j0 and the (j+1) layer. Media with refractive 
indices n0 and nN+1 are semi-infinite toward -∞ and +∞, respectively. The interface between the medium n0  
and the first layer is at z = 0. [102] 
 
In sensor applications involving luminescent coatings, one typically has a thin dielectric 
layer doped with radiating dipoles. Therefore it is useful to find expressions for the 
radiated intensity produced by an ensemble of dipoles that are distributed across a layer 
that is embedded inside a multilayer system. Expressions that represent the distributions 
of the intensity radiated by a single dipole and by a layer of dipoles embedded inside a 
multilayer system were depicted and a rigorous theory of the radiation of a dipole placed 
inside a multilayer system consisting of layers of arbitrary optical properties separated by 
plane interfaces was proposed. [102] 
Assuming that an arbitrarily oriented dipole is the only source of the electromagnetic 
field across a multilayer system and that the generated field does not influence the dipole 
radiation, an explicit formula for the electromagnetic field radiated outside the multilayer 
system was derived. Because of its form, the expression for the radiated field of an 
oscillating dipole inside a multilayer system can be used for derivation of the 
electromagnetic field produced by any set of radiating dipoles embedded inside a 
multilayer system of arbitrary complexity. [102] 
Assuming that the radiated dipoles are evenly distributed across a layer inside the 
multilayer system and that any of two dipoles radiate mutually incoherently, an 
expression that describes the angular distribution of the intensity radiated by an ensemble 
of dipoles embedded inside the layer was derived. [102] 
This theoretical formula can be used to calculate the distribution of the intensity produced 
by dipoles with an arbitrary distribution of orientations. In addition to the general theory, 
 29
a number of specific system configurations and found implications that could be 
important for the design of opto-chemical sensors and biosensors that use luminescent 
coatings was considered. [102] 
In the case of configurations that use a thin dielectric layer doped with fluorescent dipoles 
coated on top of a bulk substrate, a relatively large amount of energy radiated by means 
of the so-called [e0 p1 p2] modes propagating in the higher-refractive-index medium and it 
is shown in Fig. 2.9.  
 
 
 
Figure 2.9 Distributions of normalized intensity I(θ)/T1 radiated by a layer of randomly oriented dipoles 
that are evenly distributed across a layer with a refractive index of n1= 1.43 and a thickness T1. This layer is 
surrounded by media with refractive indices of n0=1.0 and n2 = 1.515. The solid, dashed and dashed dotted 
curves correspond to thicknesses = 1.5 λ, 0.3 λ, 0.01 λ, respectively. Angles θc02 = 41.3° and θc12 = 70.7° 
represent the critical angles of the n0-n2  and n1-n2 interfaces, respectively. The values of I(θ)/T1 for the 
angle ranges between 0 and 180° correspond to the radiation into the media with refractive indices n2 and n0 
respectively. [102] 
 
 
 
This result suggested that one should detect the fluorescence at angles of θc02 > θ >  θc12 
rather than at angles outside this interval to optimize the optical efficiency.  
In particular, the critical angles depend on the refractive indexes of the surrounding 
media;  
 
θc02 = arcsin(n0/n2) 
 
θc12= arcsin(n1/n2). 
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A particularly important example concerns the case of a layer of fluorescent dipoles 
deposited on the top of a dielectric substrate, e.g., a glass slide, in which the whole 
system is surrounded by air (or some other material, the refractive index of which is 
lower than that of the glass slide).  
The fact that a relatively large amount of radiated energy is coupled into the [e0 p1 p2] 
modes suggests that it is not very efficient to detect the fluorescence emitted into the air 
above the dipole layer or below the substrate.  
Instead, because the electromagnetic field of the [e0 p1 p2] modes is totally reflected by 
the glass–air interface and thus guided along the glass slide, better results should be 
provided by the detection of the fluorescence at the edge of the glass-slide (Fig. 2.10). 
This particular configuration and its efficiency were also reported previously [60].  
 
 
 
Figure  2.10 Configuration of an optical sensor with a dipole layer that is coated on top of a glass slide. 
The fluorescence should be (preferably) detected at the edge of the glass slide rather than at its sides. D= 
detector. [102] 
 
 
Although only the modes propagating in the higher-refractive-index medium at angles 
θc02 > θ > θc12 are considered, the statement is valid for modes propagating in the entire 
range of angles 90° > θ > -90°.  
In general terms this study establishes a theoretical framework for optimizing the design 
of optical chemical sensors and biosensors that are based on luminescent coatings 
offering a clear and detailed explanation of radiation of dipoles within a multilayer 
system. [102] 
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2.2.14 Dipstick sensor  
 
The design and performance of a rugged dissolved oxygen (DO) probe, which is based on 
phase fluorometric detection of the quenched fluorescence of an oxygen-sensitive 
ruthenium complex, was fabricated [106].  
The complex was entrapped in a porous hydrophobic sol-gel matrix that has been 
optimised for this application (Fig. 2.11). The LED excitation and photodiode detection 
were employed in a dipstick probe configuration, with the oxygen-sensitive film coated 
on a disposable PMMA disc, which in turn is designed to guide light into the film by total 
internal reflection.  
A key element of the design is the common mode rejection of phase between the signal 
and reference channels, requiring careful selection of the relevant optoelectronic 
components.  
The advantages of the phase fluorimetric approach over intensity measurement are 
highlighted. [106] 
The determination of oxygen concentration is important in many areas of industry, 
medicine and the environment.  
The amount of oxygen dissolved in water is an indication of the quality of the water and 
careful control of oxygen levels is important in waste-water management and in 
fermentation processes. Sensor operation is usually based on the quenching of 
fluorescence in the presence of oxygen.  
The fluorescent ruthenium complex, [RuII-Tris(4,7-diphenyl-1,10-phenanthroline)]2., 
(Ru-(Ph2phen)32+) was chosen as dye and entrapped in a porous sol-gel film. 
The oxygen quenching process is described by the following Stern-Volmer equations:  
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pOKSV ⋅+=τ
τ  
where τ is the excited state lifetime of the fluorophore, τ0 denotes the absence of oxygen, 
KSV the Stern-Volmer constant and pO2 the oxygen partial pressure.  
The measured lifetime is an intrinsic property of the fluorophore which, unlike intensity, 
is virtually independent of external perturbations. [106] 
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Figure 2.11 Schematic view of dipstick sensor. A compact probe configuration was used to be compatible 
with the requirements of the particular application (waste-water monitoring). The probe measures 
approximately 15 cm in length with a diameter of 4 cm. Apart from the optoelectronics and sensor film, a 
compact preamplifier is also housed in the probe. The excitation source is a blue LED filtered using a blue 
glass BP filter. The second LED is part of an internal dual referencing scheme and is also filtered by a 
bandpass (BP) filter. The detector is a silicon photodiode. The PMMA was chosen as a substrate for the 
sensor film because of the ease of machining and with a view to ultimately designing an injection moulded 
sensor cap to facilitate mass production. [106] 
 
 
2.2.15 optical biosensor and ELISA comparison for a recombinant protein assay 
 
The development of label-free optical biosensor technologies, based on either surface 
plasmon resonance technology (SPR) [107] such as BIAcore AB (Sweden) or resonant 
mirror technology [108] IAsys, Affinity Biosensors, (UK) dominate the market and so 
were compared to ELISA ones [112]. The BIAcore biosensors, which is capable of rapid 
monitoring of recombinant product concentration in crude fermentation broth was used 
[109], although IAsys sensors have been used for a similar purpose [110].  
The principle of the assay is described in Figure 2.12.  
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Figure 2.12 Principle of the optical biosensor assay using surface plasmon resonance technology. (a) A 
schematic representation of the technology. Capture ligand is covalently linked to the surface of the sensor 
chip. Analyte solution is passed over the bound ligand in a continuous flow. As binding occurs, polarized 
white light is totally internally reflected, leading to the formation of an evanescent wave. This results in a 
change in refractive index (a sharp dip in the intensity of reflected light at a specific resonance angle) 
detected at an optical interface [111]. (b) A typical realtime optical biosensor response. As biosensor output 
(measured as resonance units) is directly related to the amount of analyte bound to sensor surface, 
automated data analysis facilitates easy calculation of analyte concentration in solution based on either the 
initial rate of analyte binding (by monitoring the first dew seconds of binding data) or the total change in 
resonance units at equilibrium (requiring minutes of binding data) [112].  
See also: http://www.biacore.com and http://www.affinity-sensors.com.  
 
Advantages of the BIAcore optical biosensor assay include the abolition of ligand or 
analyte labeling and multiple flow cells for rapid (<10 minutes) quantification of 
undiluted proteins and key contaminants. Both manual and fully automated systems are 
available in the market.  
A variety of sensor chip chemistries are available: carboxymethyl-dextran, amino, 
hydrophilic and hydrophobic surfaces, biotin (IAsys) and streptavidin, lipophilic and 
metal chelated surfaces (BIAcore). Consumables such as the sensor chips themselves are 
moderately expensive but are reusable and can remain viable for several months.  
A disadvantage of the BIAcore systems is the requirement for specific training before the 
full benefit of its state-of-the-art software can be appreciated. [112] 
Specific measurement of recombinant protein titer in a complex environment during 
industrial bioprocessing has traditionally relied on labour-intensive and time-consuming 
immunoassays.  
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In recent years, however, developments in analytical technology have resulted in 
improved methods for protein product monitoring during bioprocessing.  
The advantages of optical biosensors for measuring both small and large recombinant 
therapeutic proteins were compared with a conventional enzyme-linked immunosorbent 
assay (ELISA) technique. [112] Given that conventional ELISA-based immunoassays are 
labour intensive and typically take 3–5 hours to complete, alternative means of 
monitoring recombinant protein products have been developed. 
Ultimately, robust and rapid monitoring techniques are needed that are as effective and 
easy to use as a modern home pregnancy test, which measures the concentration of the 
pregnancy hormone human chorionic gonadotrophin (hCG) in urine, for example [1]. The 
home pregnancy test is specific, rapid and provides the required data (albeit a semi-
quantitative ‘yes/no’ answer) in <5 min. The technology uses sterilized freeze-dried anti-
hCG antibodies encased in a specific polymer coating that maintains sterility in situ until 
it is dissolved on contact with urine[112]. Following the development of monoclonal 
antibody production, which led to the creation of antibody clones specific for a single 
target antigen, ELISA became increasingly popular in the 1980s and 1990s.  
This assay provided sensitivity and specificity without the requirement for radioactive 
labeling of ligands. ELISA is still widely used for many industrial and non-industrial 
applications to provide an accurate and sensitive test for a particular antigen of interest 
(Fig. 2.13). ELISA was performed in the protein range 0–200 ng/ml. [112] 
 
 
Figure 2.13. Principle of a simple sandwich ELISA. Following non-covalent binding of a purified primary 
ligand (green) to a solid phase, a blocking reagent is added to prevent any non-specific binding. The test 
solution containing antigen (Ag) is then allowed to bind specifically to the primary ligand. Unbound 
proteins are then removed by washing and a secondary antibody (black) conjugated with a reactive enzyme 
(e.g. horseradish peroxidase) is added. Following a wash step to remove unbound secondary ligand, the 
extent to which a chromogenic substrate is converted to a soluble colored product by the conjugated 
enzyme in a given time is determined by spectrophotometry using a standard microplate absorbance reader. 
[112] 
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New developments in ELISA include the numerous companies providing off-the-shelf 
ELISA formats that require very little optimization for a given recombinant or natural 
protein product.  
Fast semi-automated plate-washing and reader systems are available, which reduce 
handling-associated errors. In addition, 96 samples per plate can be assayed 
simultaneously, thus assay time per sample is very economical. [112] 
As previously described, potential problems associated with ELISA can include long 
assay development times and, particularly for smaller molecules, low dynamic linear 
ranges.  
In addition, the requirement for extensive sample dilution (and the associated risk of 
fluid-handling-derived errors) is an undesirable feature of most ELISA-based assays. 
ELISA can also require large amounts of substrate and other non-recoverable 
consumables.  
Availability of assays targeting recombinant products in development or production in 
the current pharmaceutical market is limited and can only be purchased in many cases at 
considerable cost. [112] 
 
 
2.2.16 Optical biosensor vs ELISA assay performance summary  
 
Except at very low concentrations (below 1 µg/ml), the instrument provided reproducible 
wide dynamic linear ranges concomitant with very low within- and between assay 
variation. The automated assay, once set up, was easy to use but data analysis took many 
hours and required a moderate amount of training before use. The assay required few 
consumables other than the BIAcore sensor chip, which is stable for 3–6 months. 
In this comparison, it was provided an overview of the current major technologies for 
rapid monitoring of recombinant protein production. Each has advantages and 
disadvantages that are particular to the assay design and instrumentation. With respect to 
assay format, it is important to note that both ELISA and microplate 
electrochemiluminescence permitted assay of up to 24 samples in triplicate (including 
internal standards) per microwell plate. This is not possible using the optical biosensor. 
For example, if you want to monitor a bioprocess in real-time, then single quick assays 
taking <15 mins might be preferable (optical biosensor). However, to monitor multiple 
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samples retrospectively, or for another purpose, then ELISA or chemiluminescence can 
be better choices. ELISA assays generally gave higher coefficients of variation than the 
optical biosensor assay format [112].  
 
    
Table 2.1 Comparison between performances of ELISA and optical biosensor [112] 
 
 
2.2.17 Lateral flow biosensors 
 
Lateral flow (LF) biodetectors facilitate low-cost, rapid identification of various analytes 
at the point of care. The LF cell consists of a porous membrane containing immobilized 
ligands at various locations. There are many examples of the application of LF reactors in 
the health care industry [114].  
It was listed just a few examples such as home pregnancy tests, human fecal occult blood 
detection, HIV-1 diagnostics, mycobacterium tuberculosis diagnostics, and detection of 
drugs of abuse. Although LF immunoassay technology is widely used in the health care 
industry, in home care, and in the monitoring of the quality of the water and food supply, 
the format suffers from certain shortcomings such as signal saturation and eventual 
decline when the target analyte concentration increases.  [113] 
The lateral flow (LF) immunoassay was invented as a popular diagnostic tool because it 
eliminates the need for trained personnel and expensive equipment. [114] 
Various antibodies and/or oligonucleotides, to which we refer collectively as ligands, are 
immobilized at predetermined locations (capture zones) along the porous membrane.  
A sample containing target analytes is mixed with a buffer solution and preengineered 
reporters such as colloidal gold, carbon black, dyed polystyrene, phosphor, and dye-
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encapsulating liposomes. The mixture then is introduced into the membrane by capillary 
forces (Fig. 2.14).  
As the mixture flows along the capture zones, the analytes and/or the reporters bind to the 
immobilized ligands. Two common formats are the sandwich and the competitive assays. 
When the sandwich assay is used, some of the target analytes bind to the reporters and 
some remain free in the solution. When the mixture passes through the capture zone, both 
unbound analytes and bound analytes bind to the ligands.  
After some time, the LF strip is scanned and the concentration of the reporters is 
measured as a function of location. An elevated concentration in the capture zone 
indicates the presence of the target analytes.  
The sandwich assay has the advantage that the presence of a signal indicates the presence 
of target analytes. Unfortunately, this is not true at high target analyte concentrations. 
Once the target analyte concentration exceeds a certain critical value, further increases in 
the target analyte concentration lead to a reduction in the signal.  
LF immunoassay technology is widely used in hospitals, laboratory medicine, life science 
research, and the monitoring of water and food quality. [114] 
 
 
 
 
Figure 2.14 In the first format of competitive assay, the target analytes bind to the ligands in the capture 
zone and block the ligands from binding to the reporters. The control site consists of an immobilized ligand 
that can bind to the reporter but not to the target analytes. [114] 
 
 
Confirmatory detection of diseases, such as HIV and HIV-associated pathogens in a rapid 
point-of-care (POC) diagnostic remains a goal for disease control, prevention, and 
therapy.  
If a sample could be analyzed on-site with a verified result, the individual could be 
counseled immediately and appropriate therapy initiated. In this article [115] is described 
the development of a microfluidic "lab-on-a-chip" that simultaneously identify antigens, 
antibodies, RNA, and DNA using a single oral sample.  
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Lateral flow (LF) strips were developed for the detection of human antibodies against 
human immunodeficiency virus type-1 and -2 (HIV-1 and -2) with additional capture 
zones to detect antibodies against Myobacterium tuberculosis (TB) and hepatitis C Virus 
(HCV).  
The bench-top CF format was converted to a microfluidic platform and a first prototype 
semi-automated chip capable of performing CF was presented [116].  
A similar lab-on-a-chip system for detecting bacterial pathogens in oral fluid samples was 
again considered. The microfluidic chip hosts a fluidic network for cell lysis, nucleic acid 
extraction and isolation, PCR, and labeling of the PCR product with bioconjugated, 
upconverting phosphor particles for detection on the lateral flow strip [117]. 
 
 
2.2.18 Fluorescence enhancement due to metal nanoparticles 
 
In 2005, was reported [118], on the so-called plasmonic enhancement effect, that the 
presence of metallic surfaces or particles in the vicinity of a fluorophore can dramatically 
alter the fluorescence emission and absorption properties of a fluorophore. The effect, 
which was associated with the surface plasmon resonance of the metallic surface, 
depends on parameters such as metal type, particle size, fluorophore type, and 
fluorophore-particle separation.  
Ordered arrays of metallic nano-islands were fabricated on glass substrates by a process 
of natural lithography using monodisperse polystyrene nanospheres. The metal particle 
dimensions were tailored in order to tune the plasmon resonance wavelength to match the 
spectral absorption of the fluorophore. The fluorophore, Cy5 dye, which was widely used 
in optical immunoassays and had a medium quantum efficiency, was used in preliminary 
studies on the plasmonic enhancement effect. [118] 
A fluorescent dye (FD) in the proximity of the NP senses the altered electromagnetic 
field and its fluorescence properties are changed. There are two enhancement effects: an 
increase in the excitation of the FD and an increase in the quantum efficiency (QE) of the 
FD. The biggest technical challenge in achieving plasmonic enhancement is in the 
preparation of the metallic nanoparticles (NPs). Several methods exist and are quoted in 
the literature, such as electron beam lithography [119], atom-light interaction lithography 
[120], chemical production of nanoparticles [121,122], electro-deposition of metal 
nanoparticles [123], and electrochemical template synthesis of metal nanoparticles [124].  
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 2.2.19 Enhanced detection efficiency in luminescence-based sensors 
 
 
Fluorescent labels (such as cyanine dyes and quantum dots) are employed routinely in 
bio-assays to transduce the biomolecular binding event. Such sensors, often referred to as 
microarray biochips, are of significant interest, especially in applications such as point-
of-care testing, water quality monitoring and biowarfare detection [125].  
The biochips are typically fabricated from glass or polymer, often incorporate 
microfluidic functionality, and are treated as single-use disposable components. This 
platform is generic in nature and is compatible with microfabricated, mass produced 
biochips, especially in the case of polymer materials. The enhancement strategy that was 
presented in this article [126] had major significance for the future design and fabrication 
of low-cost, high sensitivity platforms.  
For example, the particular case where the thin luminescent layer is sol-gel-derived silica 
doped with a luminescent indicator and deposited on a glass substrate is shown in Fig. 
2.15. This Figure illustrates the spatial emission pattern as a 2-D cross-section. A 
comparison of Fig. 2.15a and b indicates the sensitivity of the mission pattern to the 
superstrate, air or water respectively, refractive index.  
 
 
 
Figure 2.15 Angular properties of luminescence radiated from a thin luminescent spot deposited on a glass 
membrane over air (a) or over water (b).[126] 
 
Consequently, in the case of planar substrates with parallel sides as shown, this light will 
undergo total internal reflection at the bottom interface and become substrate-confined 
(SC) or trapped in a ‘conventional’ detection technique, where a detector is placed above 
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or below the substrate in the vicinity of the luminescent layer, it is clear that a significant 
amount (the majority) of the generated luminescent signal will be waveguided away as 
SC modes and will go undetected.  
The modes radiated from the luminescent spot are redirected towards the detector (Fig. 
2.16) placed below the substrate. [127]  
 
 
 
Figure 2.16 Cross section of the configuration facilitating improved efficiency of luminescence capture. 
The configuration exploits a frustrated cone located at the top side of the substrate.    
 
 
2.2.20 A multi-analyte array biosensor product 
 
With recent advances in surface chemistry, microfluidics, and data analysis, there are 
ever increasing reports of array based methods for detecting and quantifying multiple 
targets.  
However, only a few systems have been described that require minimal preparation of 
complex samples and possess a means of quantitatively assessing matrix effects.  
The first one is the NRL Array Biosensor, [128] which was developed with the goal of 
rapid and sensitive detection of multiple targets from multiple samples analyzed 
simultaneously.  
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Figure 2.17 Portable array biosensor components: (a) CCD camera, (b) diode laser, (c) RS32 interface 
board, (d) power supply, (e) laser power switch, (f) mirror, (g) slide mount, (h) removable reservoir 
modules, (i) peristaltic pumps, (j) waste and buffer reservoirs. Electronic control boards for pumps and 
valves are not visible. The valves are underneath the reservoir modules [129]. 
 
 
The NRL Array Biosensor was developed [128] to analyze multiple samples for multiple 
analytes and was designed to be portable and easy to use for untrained personnel (Fig. 
2.17). The sensor system consists of a 50 W power supply, a cooled CCD camera, 
peristaltic pumps and valves, and machined fluidics chambers.  
Also contained within the carrying case is a 635 nm diode laser equipped with a line 
generator to spread the laser beam into a fan pattern. The expanded laser beam is 
launched into the edge of the microscope slide waveguide, thus providing even 
fluorescence excitation.  
The CCD images the fluorescent array on the microscope slide through a 700 ± 35 nm BP 
filter and a 665 nm longpass filter. The image was acquired through a Firewire (IEEE 
1394) connection, eliminating the need for a bulky frame grabber board and allows all 
aspects of sensor function to be controlled by a laptop. [128] 
The NRL Array Biosensor has recently been used in the development of multiplexed 
assays for screening of human sera for antibodies directed against bacterial and viral 
antigens, including SEB, tetanus toxin, diphtheria toxin and hepatitis B. Such a biosensor 
could potentially be used in a clinical setting to monitor individuals for exposure to 
various pathogens or to study the efficacy of vaccination. [128] 
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Three companies, Hanson Technologies, Constellation Technology Corp. and Precision 
Photonics Corp., have licensed the technology relevant for operating the NRL Array 
Biosensor and are producing the biosensor to sell for a host of different applications. 
[128] 
Hanson Technologies (www.hansontechnologies.com) has modified the NRL Array 
Biosensor laboratory prototype into an instrument ready for commercial production (Fig. 
2.18a).  
A proprietary software control interface is now provided for ease of operation and test 
result interpretation. The software is combined with a much improved series of fluidic 
sections for 
consistent and repeated operation of the instrument. The result is a rugged, easy to use, 
and reliable biosensor. It can be used both by skilled and highly educated laboratory staff, 
and by less skilled technicians in a commercial environment. [128] 
Constellation Technologies (www.contech.com) has developed a completely automated 
and self-contained (no external computer) instrument, called the CT-ABS (Fig. 2.18b), 
which allows a user in the field to manually execute the immunoassay process or to 
integrate the CT-ABS unit into an automated biodetection system.  
The CT-ABS consumables are contained in mass producible cartridges. One cartridge 
contains the waveguide patterned with capture antibody and the flow chamber. A 
separated cartridge contains detection antibody reservoirs. These cartridges allow a user 
in the field to easily replace consumables. After sample introduction, the unit 
automatically executes all the CT-ABS immunoassay steps, as well as analyzes the 
resulting image and provides the user with a positive or negative evaluation. 
Constellation has demonstrated the CT-ABS integrated with a number of sample 
collection devices including an aerosol-to-hydrosol air collector and a filter/concentrator 
for biological agent detection in water systems. Over a dozen assays, which provide 
results in 10 – 15 minutes, have been developed for the CT-ABS unit.  
Manufacturing of the CT-ABS and cartridges has progressed significantly. Constellation 
now uses an automated non-contact dispensing machine to mass produce patterned 
waveguides. The design of the CT-ABS unit has been optimized for cost, reliability, and 
manufacturability. [128] 
Precision Photonics (www.precisionphotonics.com) is adapting the NRL Array Biosensor 
for clinical detection of disease markers, with an emphasis on point-of-care diagnostics in 
resource limited settings, ranging from clinics in developing countries to the frontlines of 
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a bioterrorist attack. To date the technology has been used for detection of both proteins 
and antibodies. When adapted for detection of antibodies, the platform provides a useful 
test for HIV and its common coinfections, a key set of tests to manage clinical treatment 
(Fig.2.18c). [128] 
 
   
             a)                                                b)                                  c) 
Figure 2.18 a) The Hanson Technologies Leopard array biosensor. b) The Constellation Technologies 
corp. A) the ABS unit, B) Consumable reagent kit and waveguide. c)  Results from a set of six tests from 6 
patient sera using Precision Photonics instrument. The first patient has negative serology, while patients 2 -
6 are positive for HIV and patient 5 is positive for HCV. Each test strip shows six potential spots with 
reactivity. As labelled, the first two are positive controls, the third is a negative control, and the last three 
test for reactivity to the viral antigens.   
 
The design of a microfluidic lab-on-a-chip system for point-of-care cancer screening and 
diagnosis of oral squamous cell carcinoma (OSCC) was also described in literature [130].  
The chip was based on determining a approximately 30-gene transcription profile in 
cancer cells isolated from oral fluid samples. Microfluidic cell sorting using magnetic 
beads functionalized with an antibody against cancer-specific cell-surface antigens was 
described. A comprehensive cancer diagnostics chip will integrate microfluidic 
components for cell lysis, nucleic acid extraction, and amplification and detection of a 
panel of mRNA isolated from a subpopulation of cancer cells contained in a clinical 
specimen. [130] 
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2.3 General immunology: 
 
2.3.1 Lymphocytes 
 
The immunologic response towards an antigen depends on the interaction between an 
antigen and two classes of lymphoid cells, named B lymphocytes and T lymphocytes; 
both originate from primitive stem cell in the bone marrow [131, 132]. B Lymphocytes 
are derived from lymphoblast of the lymphoid tissue in the bone marrow and here they 
differentiate into mature B cells. In contrast, T lymphocytes are derived from 
lymphoblast previously differentiated in the thymus gland. Lymphocytes are present at 
various levels in organs, lymphatic tissues and blood. They act against infections through 
two different mechanisms. Firstly, they work against external antigens (i.e. toxic 
products, viruses etc); in the extra cellular environment, the immunological response is 
mainly represented by a humoral immunoresponse governed by B lymphocytes (although 
activated by a specific population of T lymphocytes) that are able to interact with the 
antigen through a mediation with antibodies. Secondly, lymphocytes work against 
internal antigens (i.e. viral proteins); in the intracellular environment of an infected cell, 
where antibodies cannot penetrate, a cell-mediated immunoresponse by a particular 
population of T lymphocytes act directly to destroy the infected cell. B lymphocyte 
receptors are molecules (approximately 105 per cell) identical to the antibody that the cell 
is programmed to produce, and that differ only in a specific configuration of the variable 
region. Humoral immunoresponse occurs when an external antigen interacts, on one side, 
with the specific receptor of B lymphocytes, and, on the other side, with other cells ( 
macrophagocytes ) that are able to phagocytes the antigen and to present it to the T 
lymphocytes in a contest called “antigen presenting cell” (APC) [132]. 
Hence, T helper lymphocytes, using their specific receptors, recognize the antigen 
presented by APC, and cause the conversion of lymphocytes B into plasma cells able to 
produce antibodies specific for the antigen of interest, and further “memory” B 
lymphocytes, are able to enter into the  interaction to generate an eventual recall 
response. Plasma cells possess a relatively short lifetime (one week) and during this 
period they produce a great quantity of antibodies with a lifetime of six months in 
biological fluids (blood and lymph). Memory B lymphocytes, in contrast, have a lifetime 
of several years, and dispose themselves to be transformed rapidly into plasma cells 
(producing antibodies) in  the presence of antigens.  
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 2.3.2 Immunoglobulins 
 
Antibodies are serum molecules produced by B lymphocytes; they represent the soluble 
form of specific receptors for the antigen expressed by B lymphocytes [131, 132].  
In cooperation with the complement system (a complex cascade reaction that activates 
identification of bacteria, so that phagocytes can recognise and eliminate them), 
antibodies are the mediators of the humoral immunity [133] and their presence on the 
surface of mucous membranes provides resistance and prevents multiple infections. 
In plasma subjected to electrophoresis, antibodies are found as proteins related to the 
gamma fraction, the highest in molecular weight (globulins) portion. Hence, the protein 
fraction that contains antibodies is usually called immunoglobulin or Ig.  
Different types (fig. 2.19) of Ig exist: IgG, IgA, IgM, IgD, IgE. All the antibodies have 
the same base structure, but they differ in the region that binds the antigen i.e. the Fab 
region. Another region of the antibody binds to phagocytes or other proteins of the 
complement system and is called the Fc region. Hence, an antibody can be phagocyted 
using Fc segments, if it binds to an antigen. 
 
 
Figure 2.19 Structure of immunoglobulin classes. V = variable domain; C = constant domain; L = light 
chain; H = heavy chain; Fab = Fragment antigen binding; Fc= fragment crystallisable. Source of diagram is 
[133]. 
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The IgG molecule is a typical example of the structure of every immunoglobulin.  
In 1962, Rodney Porter proposed [132] a structural model of immunoglobulins: four 
chains, constituted by two light chains and two heavy chains (Fig. 2.20).  
Every light chain (L) has a molecular weight of 25 kDa and both chains are the same for 
all immunoglobulins. In 1965, Hilschmann and Craig found that the light chain has two 
regions: the COOH terminal region constant (called region CL), of 107 amino acids and 
the N-terminal region variable (called region VL) of 105 amino acids. Heavy chains 
present four internal disulphuric bridges, whereas light chains have two. The N terminal 
region of an IgG is characterised by variability for the heavy chain as well as for the light 
chain (VH and VL). The other part of the macromolecule has constant sequences such as 
CH1, CH2, CH3, called domains. Antibodies bind to the antigens in the variable region. 
The flexibility of the clasp region permits the two sites to act separately, where antigens 
can bind. Carbohydrates bind to the CH2 domain. 
 
 
Figure 2.20 On the left part is shown a common immunoglobulin IgG. In red are shown the disulphuric 
bridges. On the right part is shown the light chain. Source of figure is [133]. 
 
 
IgG are the most prevalent immunoglobulins in human serum (75 % of total Ig in serum); 
IgG present in all biological fluids are the most important class of antibodies in response 
to bacterial toxins and extracellular viruses. IgG’s comprise four distinct subclasses: 
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IgG1, IgG2, IgG3, IgG4 [131-133]. These subclasses are distinguished by the number of 
disulphuric bridges that bind together the heavy chains (HC). These subclasses of IgG 
differ also in some biological features. IgG1 and IgG3 possess better efficiency in the 
recognition of the antigen (“opsonisation”) and in the complement activation. IgG2 are 
produced against polysaccharide antigens present on the surface of various bacteria such 
as Streptococcus pneumonia.  
IgA represent 15-20% of the immunoglobulins present in human serum [133]. In human 
beings IgA are 80% monomer proteins, whereas in other mammals IgA prevail in the 
dimeric form; Ig in dimeric form is prevalent in man as antibodies in the intestinal 
mucous membrane.  The IgA of secretions (sIgA) is in the dimeric form and is associated 
with a short polypeptide chain called secretor component. The concentration of sIgA in 
serum is really low, whereas in the secretions of intestine, it is really high. The IgA’s 
consist of two different subclasses of molecules which possess different heavy chains: 
IgA1, IgA2 [131].  
IgM represents 10% of total immunoglobulins in serum; the molecule is a pentamer of 
five immunoglobulins linked together by Fc segment. IgM’s are present in the serum and 
represent an antibody class prevalent in the primary response towards microorganisms 
complexed by antigens. IgD’s represent 1% of all immunoglobulins in serum and they are 
present in huge quantities on the surface of lymphocytes B; these immunoglobulins are 
involved in the process of differentiation of lymphocytes. IgE’s represent 0.002 % of the 
total immunoglobulins in serum; they are located on the surface of mastocytes and 
basophiles cells of mucous membranes and bronchial tubes. They are really important in 
the defence against parasites and in relation with bronchial asthma and allergic rhinitis.  
General properties that concern the variability of the heavy chain, the concentration of 
immunoglobulin in serum, the sedimentation constant, and other parameters of interest 
are shown in the Table 2.2. 
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Table 2.2 Properties of general immunoglobulins. Source of table is [133]. 
 
 
2.3.3 Antigen/Antibody interactions 
 
Antigenic molecules are surrounded and trapped inside a pocket formed by the light and 
heavy chains of an antibody. This is called the combinatory site and is where a protein 
can be captured (i.e. Fig. 2.21).  
 
 
 
Figure 2.21 A human IgG can trap a protein of myeloma called g-hydroxyl vitamin K in 12 different 
aminoacidic points. The instrument used to detect this type of 3-D interactions is the X-ray crystallography.  
Source of the image (132). 
 
The union between an antigen and an antibody is the result of non-covalent interactions 
between the amino acidic residuals of the antigens and of the combinatory site of the 
antibody. These bonds are weak interactions (Figure 2.22) of different types such as 
hydrogen bonds, electrostatic forces, Van der Waals forces and hydrophobic interactions 
[133], but they contribute all together to a binding of relevant energy. The strength of 
these bonds depends critically on the distance d between reagent groups. This strength is 
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proportional to 1/d2 in the case of electrostatic forces and 1/d7 in the case of Van der 
Waals forces.  
 
 
Figure 2.22 Overview of the forces that take place in antigen-antibody interactions. Image adapted by 
[133] 
 
 
2.3.4 Specificity, affinity, avidity  
 
If the electronic clouds of the antigen-antibody residuals overlap but do not fit exactly, 
repulsive forces, which are proportional to 1/d12, prevail on the attractive weak forces 
[133]. These forces play an important role in the determination of the specificity of an 
antibody to a particular antigen and the strength of the bond decreases suddenly if 
something changes in the complementary ideal fit form (Fig.2.23).       
 
 
 
Figure 2.23 The ideal fitting of an antigen in the antibody is shown on the left image. Specificity of an 
antibody to its antigen is ensured by the fact that a non ideal overlapping causes greater repulsive forces 
compared to smaller internal forces. Image adapted by [133].   
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The affinity of an antibody towards an antigen can be expressed by the strength of 
repulsive and attractive forces (Fig.2.24). An antibody with high affinity for an antigen 
fits perfectly to its specific antigen. The law of mass action can be used to calculate the 
affinity which is given by the equilibrium constant KA.   
 
 
 
Figure 2.24 Affinity depends on the affinity constant value. Equilibrium constant KA is defined as the 
affinity constant. Image adapted by [133]. 
 
An antibody has two combinatorial sites for an antigen; this means that antibodies are 
potentially polyvalent to form bonds with an antigen. Antigens can be monovalent (such 
as haptens) or polyvalent (such as microorganisms). When a polyvalent antigen binds to 
an antibody, the total energy of the bond is higher than the normal strength of a single 
bond. This total force is called the avidity of the antibody and differs from affinity which 
is related to a single combinatory site for a single antigenic determinant (see table 2.3). In 
physiological conditions avidity is fundamental because almost all the antigens are 
polyvalent.  
 
 
 
Table 2.3 Multi-valence bonds between antigen and antibody (avidity) increase stability in comparison to 
mono-valence bonds. This effect is defined as positive effect of multivalence. The gain in polyvalence 
corresponds to 103 if both binding sites of IgG are occupied and 107 if the sites of IgM are occupied 
simultaneously. Table source is adapted by [133]. 
 51
 
 
2.4 Transcription factors 
 
A transcription factor is a protein that has the capability to enter inside the nucleus and 
binds to specific parts of DNA using DNA binding domains and is part of the system that 
controls the transcription of genetic information from DNA to RNA [134-135].  
Transcription factors perform this function alone or by using other proteins in a complex, 
by increasing (as an activator), or preventing (as a repressor) the presence of RNA 
polymerase, the protein is responsible for genetic transcription [136, 137]. 
The genome contains thousands of genes and an enormously diverse regulatory system is 
necessary to obtain induction or repression of the expression of the right gene at the right 
time. The expression of a gene can be regulated at many different levels, e.g. initiation 
and elongation of transcription, RNA processing, RNA transport, RNA stability, 
initiation and elongation of translation, post-translational modification, protein transport 
and protein activity. The first step, initiation of transcription, represents a major control 
point for the regulation of gene expression.  
The transcription of a gene X depends on which transcription factor binding sites are 
present in the control regions of gene X, and on whether an appropriate set of 
transcription factors which is capable of binding those DNA sequences is expressed and 
active in the cell type in question. Thus, the control of the activity of transcription factors 
plays an important role in transcriptional regulation and is achieved at distinct levels in 
response to signals. For example, the nuclear factor-kappa B (NF-kB), a transcription 
factor involved as important regulator of the host immune and inflammatory response and 
also in protecting cells from apoptosis, is regulated at the level of sub-cellular 
localisation. Phosphorylation has been shown to affect transcription factors at many 
levels, such as nuclear transport, DNA binding activity and transactivating function [138, 
139]. A transcription factor is a protein that binds DNA at a specific promoter (that is a 
DNA sequence that enables a gene to be transcribed) or at an enhancer region (a short 
region of DNA which can be bound with proteins to enhance transcription) or at a site, 
where it regulates transcription. Transcription factors can be selectively activated or 
deactivated by other proteins.  
 
Transcription factors are classified in three main groups: basal, upstream and inducible 
transcription factors [140]. The first class is comprised of the group of proteins that 
 52
directly interact with RNA Polymerase. This mechanism is directly responsible for 
transcription. The upstream factors are unregulated proteins that bind somewhere 
upstream of the initiation site to stimulate or repress transcription. These are ubiquitous 
factors that increase the efficiency of transcription initiation. Finally, some factors are 
turned in a temporal or spatial manner, or directly in response to the environment. These 
factors provide the final link in controlling gene expression. The inducible factors act in 
the same manner as an upstream factor but their synthesis is regulated in a temporal or 
spatial manner. In particular, NF-kB, the transcription factor which is studied in this 
thesis, is part of this category. A more general and complete list of transcription factors is 
reported on the web-site: http://www.gene-regulation.com/pub/databases/transfac/cl.html
 
 
2.4.1 The transcription factor NF-kB 
 
The Transcription Factor NF-kB represent a signalling system evolutionarily conserved. 
Crystallographic-structure studies of NF-kB binding DNA have shown that each subunit 
consists of two immunoglobulin-like domains connected by a 10 aminoacid flexible 
linker. Dimers are formed through a β-sheet sandwich of the carboxy-terminal domains. 
Unlike most DNA-binding proteins, which use α-helices for base-pare recognition, NF-
kB dimers use loops from the edges of the N- and C-terminal domains to mediate DNA 
contacts. 
Secondary structures of the subunits are equivalent, apart from 32-aminoacid insert in the 
N-terminal part of p50 that adds a second α-helix. Dimerisation in the heterodimer is 
localized to the C-terminal domains and consists of a hydrophobic core stapled by 
various polar interactions. 
NF-kB was first described in 1986 as a nuclear factor necessary for immunoglobulin 
kappa light chain transcription in B cells (hence the name, nuclear factor-kB) [141].  
In mature B cells and plasma cells, NF-kB is localized to the nucleus where it binds a 10 
base-pair region of the kappa intronic enhancer and activates transcription.  
It was originally thought that NF-kB was not produced in other cells, including pre-B 
cells, because it could not be detected in these cell types by a sensitive gel-shift assay 
using the Igκ DNA-binding site. Subsequently however, it was found that the DNA-
binding ability of NF-kB in these cells was masked by the presence of an inhibitor [142]. 
It is now known that NF-kB pre-exists in the cytoplasm of most cells in an inactive form 
 53
bound to the inhibitor, IkB. Since the discovery of NF-kB, its responsive sites (kB sites) 
have been characterised in the promoters and enhancers of numerous genes, making NF-
kB an important component in the inducible expression of many proteins, including 
cytokines, acute phase response proteins, and cell adhesion molecules [143, 144]. 
Nature has not overlooked the elegance of the NF-kB signalling system. Indeed, this 
system has been conserved to operate on divergent genes in many different species [145]. 
In Drosophila three NF-kB molecules have been described: Dorsal, Dif, and relish [146-
148]. The first Drosophila rel protein described was the Dorsal/ventral morphogen, 
Dorsal, which delineates polarity by specifically activating genes on one side of the 
Drosophila embryo and repressing genes on the other [149]. The signal activating Dorsal 
passes through a transmembrane protein called Toll, which bears a remarkable likeness to 
the cytoplasmic domain of the type I IL-1 receptor [150] and passes through a 
serine/threonine protein kinase, pelle, which is also homologous to IRAK (IL-1 receptor-
associated kinase) from mammalian cells [151, 152]. Dorsal, like NF-kB, is retained in 
the cytoplasm by an inhibitory protein called cactus [153, 154]. The release of Dorsal 
from cactus [155] requires the kinase pelle and, although the exact sequence of events has 
not been determined, Dorsal itself is also phosphorylated (151, 156, 157). A more 
striking similarity in function is observed in the case of the second Rel protein described 
in Drosophila, known as Dif [147]. Dif appears to be the fly equivalent of the inducible 
form of NF-kB because it is active only under certain circumstances and upregulates 
transcription of insect immunity genes. Dif pre-exists in the fat body of insects, an organ 
that is thought to be the ancestral equivalent of the liver in vertebrates [158]. 
Interestingly, the liver is the centre for production of the acute phase proteins in the acute 
phase response to inflammation, a condition partly regulated by NF-kB [159]. Dif 
becomes activated as a result of infection; the Dif-activated response is therefore part of a 
primitive innate immune system controlled by rel proteins [158]. 
Although NF-kB sites have been found in the promoters of many of the insect 
antibacterial and antifungal genes, including cecropin, attacin, defensin, diptericin, 
drosocin, and drosomycin, a recent report suggests that not all the genes are regulated by 
Dorsal or Dif [160]. The gene most dependent on Dorsal and Dif was that encoding the 
antifungal protein drosomycin, while the genes encoding the antibacterial proteins 
cecropin, attacin, and defensin were only partly dependent. These results suggested an 
additional signalling pathway in insects that is involved in responses to microbial 
infection [161]. The third known member of the Rel-family in Drosophila is Relish, 
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which appears to be the homolog of the mammalian p105 and p100 proteins, with the 
exception that it has a serine-rich region in the place of the glycine-rich region. This 
protein was reported recently, and as yet very little is known about its regulation except 
that it is highly upregulated upon bacterial infection. Nevertheless, its similarity to p105 
and p100 once again reinforces the striking evolutionary conservation of the Rel/NF-kB 
family.  
An intriguing parallel to the Toll/Dorsal/Dif system exists in plants. The product of the 
plant N gene is homologous to Toll and the IL-1R [162]. This gene encodes a 
transmembrane receptor that confers resistance to tobacco mosaic virus infection 
probably by signalling the upregulation of the pathogenesis resistance proteins. Although 
an NF-kB-like protein has not been described in plants, the N protein may ultimately 
communicate with a similar transcription factor enabling the plant to activate an innate 
type of immune system. Recently, however, the gene encoding the NIM1 (noninducible 
immunity) gene in Arabidopsis, which plays a critical role in systemic acquired resistance 
and disease resistance in plants, has been cloned and found to be homologous to IkB 
[163]. The signalling system of Toll and Dorsal/Dif also led to the search for an 
equivalent system in mammals. It is gratifying that a mammalian Toll homolog has now 
been identified, that appears to be able to induce the expression of cytokines and genes 
known to play an important role in innate and adaptive immunity [164]. Therefore, Toll 
appears to function in vertebrates as a nonclonal receptor that modulates the immune 
response by activating NF-kB. These findings also further strengthen the notion that 
signalling in disease resistance responses from flies to mammals utilises an ancient, 
evolutionarily conserved, and ubiquitous pathway that involves the Toll/NF-kB/IkB 
family of proteins. 
Recent years have witnessed remarkable interest in the study of the cellular pathway of 
transcription factors, due to their abnormal production in the presence of several diseases 
[165, 166]. Therefore, an in depth knowledge of their cellular mechanisms is of great 
importance both at the medical diagnostic and pharmacological level. In particular, the 
transcription factor NF-kB is involved in a wide variety of human diseases including 
inflammation, asthma, atherosclerosis, AIDS, septic shock, arthritis and cancer. NF-kB is 
a protein complex found in all types of cells and is involved in cellular responses to 
stimuli such as stress, cytokines, free radicals, ultraviolet radiation and bacterial or viral 
antigens. This protein is ubiquitously expressed in an inactive form and, after these 
external stimuli, it becomes active and capable to regulate a large number of genes [167]. 
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Thereafter, when a therapy is applied to the above diseases, for which the detection of the 
efficacy of the therapeutic agent is particularly important, the monitoring of NF-kB 
concentration, in cellular extracts, is an important target, especially in pharmacological 
studies where a direct verification of the effectiveness of therapeutic agents is necessary 
[168]. In general, the dramatic difference between a healthy tissue and a chronically 
inflamed one is due to the excessive protein expression that is normally present in the 
organism, but in a limited or controlled amount [169]. The gene expression for the 
synthesis of some of these proteins is activated from the NF-kB, present in the cytoplasm 
in an inactive form and activated by a great variety of inflammatory and injurious stimuli.  
In mammalians five members of the Rel family are known: Rel A (also known as p65), 
Rel B, c-Rel, NF-kB1 (p50 and its precursor p105) and NF-kB2 (p52 and its precursor 
p100) [169]. Hence, various shapes of NF-kB proteins are present in nature in the 
cytoplasm: the p50 and p52 NF-kB members play critical roles in modulating the 
specificity of kB site transcription. Homodimers of p50 and p52 (such as p50/p50, 
p52/p52) are generally repressors of kB site transcription. Instead, if p50 or p52 form 
heterodimers with Rel A, Rel B, or c-Rel (such as p50/p65), these protein complexes 
participate in target gene activation. NF-kB indicates, in general, each homodimer or 
heterodimer of this family, even if the heterodimer p50/p65 is the most represented and 
the most diffuse in mammals [143, 144, 170].  
As previously mentioned, NF-kB was discovered in the nucleus of mature B cells as an 
active protein bound to a 10 base-pair DNA [141]. Briefly, what ensures that NF-kB is 
not active in healthy tissues is its tight association with a specific inhibitory class of 
proteins, called IkB [171], which prevent the crossover in the nuclear membrane and the 
consequent binding of the transcription factor NF to the kB site of DNA. In answer to 
inflammatory stimulations, IkB is detached and the released NF-kB is transported into the 
nucleus, where it begin the gene transcription on the specific sites of DNA (Fig.2.25).  
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Figure 2.25 NF-kB pathway is well known; IkB inhibitor bonded to the heterodimer protein p50/p65, in 
answer to extra cellular inflammatory stimuli, separates from the dimer protein and is degraded from the 
protease. Therefore, the heterodimer p50/p65 is activated and can enter the nucleus of a cell where it causes 
the activation of transcription on the specific Kb site of DNA. The image is available online  at 
http://it.wikipedia.org/wiki/NF-kB and was adapted to show external stimuli, Kb site and gene espression.  
 
 
It was demonstrated that more than 60 pro-inflammatory genes are involved in the 
control provided by NF-kB protein. Among the genes activated by this transcription 
factor, there is also one related to the formation of the IkB inhibitor protein, that it is 
quickly synthesised after its degradation [171]. The inactive complex NF-kB/IkB is 
transported back in the cytoplasm, completing therefore an entire cycle of activation and 
deactivation of NF-kB.  
 
2.4.2 Characteristics of NF-kB in the active and inactive form 
 
The first NF-kB molecule described was a heterodimer of p50 (50 kDa) and p65 (65 kDa) 
subunits (Fig. 2.26). This protein is still what is commonly referred to as NF-kB despite 
the diversity of other members now known. Because the two Rel proteins making up the 
complex each contact one half of the DNA binding site, the slight variations possible in 
the 10 base pair consensus sequence, 5'-GGGRNYYYCC-3' (R is an unspecified purine, 
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Y is an unspecified pyrimidine, and N is any nucleotide), confer a preference for selected 
Rel combinations [172].  
       
 
Figure 2.26 The DNA kb binding site is shown on the top left. The protein p50/p65 bound to DNA kb 
binding site is shown on the top right. At the bottom (left and right) is shown a frontal view where proteins 
bound to DNA are highlighted. The image rendering was executed using Lycos Tripod TM software at 
Cranfield University, UK. These 3D images were captured by Protein Data Bank and refer to the work of 
Ghosh, Chen and Huang published on Nature in 1998 [173].  
 
 
Although most of the NF-kB proteins are transcriptionally active, some combinations are 
thought to act as inactive or repressive complexes. Thus, p50/p65, p50/c-Rel, p65/p65, 
and p65/c-Rel are all transcriptionally active, whereas p50 homodimer and p52 
homodimer repress transcription [174]. Because p50 and p52 lack a variable C-terminal 
domain found in the activating Rel proteins, this domain is most likely responsible for 
transactivation of NF-kB responsive genes. 
The first glimpse of how proteins of the Rel-family bind to DNA came from the crystal 
structure of p50 homodimers bound to a kB site [175, 176]. Each p50 molecule is 
comprised of two domains joined by a flexible link. Dimerisation occurs exclusively via 
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the C-terminal domains where a set of hydrophobic side chains interdigitate, clamping 
these regions together.  
In both immunoglobulin-like domains, β-strands are connected by loops that are 
responsible for an unusual DNA-contact interface. Both N- and C- terminal regions are 
involved in DNA binding, and the dimerisation and DNA-binding contacts of the C-
terminal domain form a novel continuous interface that essentially “locks” NF-kB to the 
major groove. This DNA-binding method is also noteworthy in the extensive number of 
contacts made by the loops to both the sugar-phosphate backbone and the bases (Fig. 
2.27).  
 
Figure 2.27. Schematic model of specific interface between NF-kB p50/p50 homodimer and central 11 
base pairs of DNA [176]. The arrows represent the interaction between p50 and DNA, the red-dot 
represents a water mediated hydrogen bond, # represents asymmetry of residue bonding compared between 
DNA chains and p50 units. 
 
The crystal structure of human NF-kB p52 in its specific complex with the natural kB 
DNA binding site MHC H-2 (major histocompatibility complex proteins) has been solved 
[177]. Compared with NF-kB p50, the compact α-helical insert region element is rotated 
away from the core of the N-terminal domain, opening up a mainly polar cleft. The insert 
region presents potential interaction surfaces to other proteins. The high resolution of the 
structure reveals many water molecules which mediate interactions in the protein–DNA 
interface. Additional complexity in Rel protein–DNA interaction comes from an 
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extended interfacial water cavity that connects residues at the edge of the dimer interface 
to the central DNA bases. The observed water network might account for differences in 
binding specificity between NF-kB p52 and NF-kB p50 homodimers (Fig. 2.28). 
 
 
Figure 2.28. Schematic diagram of polar interactions between the homodimer p52/p52 and DNA. Contacts 
to DNA bases (yellow boxes), to the DNA backbone (red boxes) and water-mediated contacts (green 
boxes) in both half sites are shown. Water molecules are depicted as green spheres. [177] 
 
 
The structure of the p65 RHD bound to DNA has also been solved [178]. Although the 
overall architecture of the complex is quite similar to that of p50, the p65-DNA complex 
reveals a few novel features. Unlike the p50 homodimer, p65 subunits are not 
symmetrically arranged on the DNA target. While one of the subunits binds a four base-
pair DNA half site with sequence specificity, the other subunit displays a remarkably 
different mode of DNA recognition, retaining only partial specificity for the other half 
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site (Fig. 2.29). This novel model of DNA recognition exhibited by p65 probably helps to 
explain the wide range of DNA sequences recognised by NF-kB. 
 
 
Figure 2.29. The DNA contacts the p50/p65 NF-kB heterodimer. Blue and green distinguish the 
p65 and the p50 subunits, respectively. Arrows denote hydrogen bonds; brown ovals indicate van 
der Waals contacts. The p50 subunit binds to the 5' five-base-pair subsite; the p65 subunit binds 
to the 3' four-base-pair sub site [178]. 
 
The mRNA retrieved from the cloning of p50, surprisingly, was found to encode for a 
much larger protein of approximately 105 kDa. Likewise, the mRNA for p52 also 
encodes a protein of 100 kDa. The N-terminal regions of p105 and p100 are identical to 
the p50 and p52 proteins, respectively. Inspection of the C-terminal portion of these 
molecules revealed several ankyrin repeats (tandemly repeated molecules of about 33 
amino acids, it is one of the most common protein-protein interaction motifs in nature), 
reminiscent of the ankyrin repeats found in the NF-kB inhibitor molecule, IkB.  
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Later it was demonstrated that p100 and p105 are post-translationally cleaved to produce 
the smaller p50 and p52 products [179]. 
This processing is ATP-dependent and requires phosphorylation, polyubiquitination and 
proteasomic degradation. Probably it represents a further level of control of the activation 
of NF-kB, in fact the longer p105 and p100 proteins are exclusively cytosolic because of 
the masking of the nuclear localisation signals on p50 and p52 by the C-terminal ankyrin 
repeat region. Stimulation of cells with agents that activate NF-kB causes an increase in 
the rate of degradation of the C-terminal region of these proteins, and consequently 
increased amounts of p50 and p52, complexed with p65, are produced [181, 182].  
In Figure 2.30 members of the NF-kB/rel and IkB families of proteins are shown. 
The activation of NF-kB is also regulated by its cytoplasmic inhibitor, IkB. It binds NF-
kB and masks its nuclear localisation signal, thus retaining it in the cytoplasm [169].  
Like NF-kB, IkB is a member of a larger family of inhibitory molecules that includes 
IkBα, IkBβ, IkBε, IkBγ, and Bcl-3 (Fig. 2.30).  
 
 
 
Figure 2.30. The Rel/NF-kB/IkB family of protein [180]. The number of amino acids in each protein is 
shown on the right. The arrows point to the endoproteolytic cleavage sites of p100/p52 and p105/p50, LZ is 
the leucine zipper domain of rel-B; GRR is the glycine-rich region, ΙκΒα, IkBβ and IkBε contain an amino-
terminal regulatory domain, within which there are two conserved serines (SS). 
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All of these inhibitors contain multiple regions of homology known as the ankyrin-repeat 
motifs. The ankyrin repeats are regions of protein/protein interaction, and the specific 
interaction between ankyrin repeats and rel-homology domains appears to be a crucial, 
evolutionarily conserved feature of the regulation of NF-kB proteins. Each IkB differs in 
the number of ankyrin repeats, and this number appears to influence the specificity with 
which IkB pairs with a rel dimer. As mentioned above, p100 and p105 also contain 
ankyrin repeats and are sometimes included in the IkB family. 
The best characterised IkB protein is IkBα, a 37 kDa unit that has a tripartite organisation 
also seen in IkBβ: 1) an N-terminal domain that is phosphorylated in response to signals, 
2) a central ankyrin repeat domain, and 3) a C-terminal domain that is involved in the 
basal turnover of the protein [170].  
In order to clarify the structural basis for inhibition of both nuclear entry and DNA 
binding of NF-kB by IkBα, some authors [183, 171] have determined the crystal 
structure of the NF-kB p50/p65 heterodimer in complex with IkBα. 
The crystal structure demonstrates how IkBα/NF-kB interactions promote cytoplasmic 
retention and transcriptional inactivation of NF-kB. Amino acid residues vicinal to both 
the p50 and p65 NLSs are tethered to the first two ankyrin repeats of IkBα, suggesting a 
mechanism for cytoplasmic retention of NF-kB. In the presence of IkBα, the p65 subunit 
of NF-kB undergoes a profound conformation change. Adoption of this closed 
conformation by NF-kB impedes DNA binding through the occlusion of basic DNA-
contacting surfaces. 
Physiologically the defining characteristic of IkBα is its ability to regulate rapid but 
transient induction of NF-kB activity, owing to the participation of IkBα in an 
autoregulatory feedback loop; that is, the activation of NF-kB causes the upregulation of 
transcription of IkBα, which serves to shut off the signal. There is some evidence that 
IkBα, which is very rapidly resynthesized after degradation, can enter the nucleus and 
remove NF-kB from DNA. The inactive NF-kB/IkB complex is then transported back 
into the cytoplasm thereby completing a cycle of activation and inactivation of NF-kB 
[184]. The continuing presence of certain inducing agents, for example 
Lypopolysaccharide (LPS), however causes NF-kB to be maintained in the nucleus 
despite the upregulation of IkBα mRNA synthesis, and this persistent activation of NF-
kB is regulated by IkBβ [185]. 
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IkBβ is a 45 kDa molecule that was cloned later and hence is less well characterised than 
IkBα [71]. Surprisingly, IkBβ binds the same rel subunits as IkBα, the divergence 
appears to be at the level of the incoming signal and at the timing of the onset and 
duration of the response. Both IkBα and IkBβ are rapidly degraded after cells are treated 
with the inducing agents Interleukin-1 (IL-1) and LPS; however, IkBα is re-transcribed 
as a result of NF-kB activation, whereas IkBβ is not. Thus, IkBβ levels remain low until 
the NF-kB activating signal is attenuated. 
The most recent member of the IkB family to be described is IkBε. The characterisation 
of the protein revealed that it was unable to interact with either p50 or p52; instead it 
appeared to be a specific inhibitor of p65 and c-Rel complexes. IkBε can be degraded 
with slow kinetics upon stimulation of cells with the majority of inducers of NF-kB, and 
as with the other IkBs, this degradation requires two N-terminal serine residues (see NF-
kB pathway). At present it seems that IkBε acts as a specific inhibitor of a subset of Rel 
complexes, and it therefore probably regulates the expression of specific genes, e.g. IL-8, 
whose promoters bind preferentially to p65 and c-Rel complexes. 
Bcl-3 is the most unusual member of the IkB family. Structurally, Bcl-3 is very much like 
the other IkB family members in that its predicted protein structure contains 7 ankyrin 
repeats. However, unlike IkBα and IkBβ which are located in the cytoplasm, Bcl-3 
appears to be located in the nucleus and has a binding specificity for p50 and p52 
homodimers [186, 187]. Bcl-3 acts like other IkB proteins forming an inactive complex 
with NF-kB, unable to bind the double stranded DNA. Since the p50/p50 and p52/p52 
homodimers are transcriptionally repressive, Bcl-3 may function as a transactivator by 
removing these inhibitory NF-kB complexes from kB sites. The complex p52/Bcl-3 can 
also directly bind to kB sites and activate the transcription [188]. Thus, Bcl-3 is 
apparently unique among the IkB proteins in that its binding to rel proteins leads to 
transcriptional activation rather than repression. 
Finally, very little is known about the IkB family member IkBγ, which is a 70-kDa 
molecule detected only in lymphoid cells. Its sequence is identical to the IkB-like C-
terminal region of p105, and indeed IkB is the product of an alternate promoter usage that 
produces an mRNA encoding the C-terminal portion of p105. Although the initial report 
of IkB suggested that it functioned as a trans-inhibitor of Rel-proteins, similar to the 
other IkB proteins, subsequent studies have suggested that IkB probably plays a more 
limited role, probably inhibiting only p50 or p52 homodimers [189]. 
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2.4.3 Signalling pathway of the Nuclear Factor kB 
 
As mentioned above, the activation of NF-kB is achieved primarily through the 
degradation of IkB proteins. 
This process, which is mediated by the 26S proteasome [190], depends on the 
phosphorylation of two conserved serines (ser-32 and ser-36 in human IkBα) in the N-
terminal regulatory domain of IkBs. Once phosphorylated, the IkBs, still bound to NF-
kB, almost immediately undergo a second post-translational modification, a 
polyubiquitination. The major ubiquitin acceptor sites in human IkBα are lysines 21 and 
22. 
The enzymes that catalyze the ubiquitination of phospho-IkB are constitutively active. 
Hence, the only regulated step that dictates the fate of IkB and NF-kB is in most cases the 
phosphorylation of the two N-terminal serines in the IkB molecule. There are only two 
exceptions to this universal pathway for NF-kB activation. The first is the activation of 
NF-kB in response to UV radiation, which although dependent on IkB degradation does 
not involve N-terminal IkB phosphorylation. The second exception is anoxia, which 
stimulate phosphorylation of IkBα at tyrosine 42. 
The control of IkB phosphorylation in response to all other NF-kB activating stimuli is 
dependent on the IkB kinase (IKK) complex, a large (700 to 900 kDa) multisubunit 
cytoplasmic complex [191]. 
By means of protein purification, microsequencing, and molecular cloning, three 
components of IKK were unambiguously identified. IKKα and IKKβ (also referred to as 
IKK1 and IKK2) are 85- and 87- kDa proteins, respectively. IKKα and IKKβ are highly 
homologous proteins and contain N-terminal protein kinase domains as well as leucine 
zipper (LZ) and helix-loop-helix (HLH) motifs. IKKα and IKKβ serve as the catalytic 
subunits of the IKK complex. 
The third component of IKK is a 48-kDa regulatory subunit named IKKγ, or  NF-kB 
essential modulator (NEMO), or IKK-associated protein 1 (IKKAP1), or 14.7 interacting 
protein (FIP-3) [192].  
Secondary-structure prediction algorithms indicate that IKKγ is predominantly helical 
with large stretches of coiled-coil structure, including an LZ motif near the C terminal. 
Extensive research over the last few years indicates that NF-kB activation is highly 
complex and may involve as many as 20 different protein kinases. These kinases may 
form a cascade, and different cascades may be formed depending on the NF-kB activator. 
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For instance, IKK can undergo phosphorylation by NIK (NF-kB inducing kinase), 
MEKK (mitogen activated protein kinase kinase) or AKT (protein kinase Bα). Although 
several signalling proteins and protein kinases have been recently identified that mediate 
IKK activation, the exact role of these kinases and their placement within the activation 
cascade is controversial. The activation of some of these kinases may be specific for cell 
type and to the stimulus employed to activate NF-kB. For instance, NIK, while found to 
be critical for NF-kB activation by LT and CD40L (receptor ligands), was found to have 
no role in TNF-induced NF-kB activation [193]. 
In the IKK complex the kinase activity of IKKα and IKKβ and their abilities to be 
activated depend on their LZ-mediated dimerisation, and LZ mutations, that interfere 
with this process, abolish IkB kinase activity. IKKα and IKKβ activity is also abolished 
by mutations within the HLH motif. The HLH mutations, however, do not interfere with 
dimerisation or binding to IKKγ. IKK activation is also dependent on the presence of an 
intact IKKγ subunit. Several authors [194, 195] provide proof for the importance of IKK 
in the NF-kB activation and suggest that the C-terminal region of the IKKγ is necessary 
for recruitment for upstream activators. In addition, overexpression of IKKγ can inhibit 
IKK activation due to titration of limiting IKK activators. 
Activation of IKK depends on phosphorylation of its IKKβ subunit. Although IKKα 
phosphorylation is concurrent with that of IKKβ, it is not essential for stimulation of IkB 
kinase activity. These activators are recruited to the complex via the IKKγ subunit, most 
likely through interaction with its C-terminal domain. Phosphorylation can also result in 
negative regulation of IKK activity. In addition to its activation loop, IKKβ is extensively 
phosphorylated within a region located between its HLH motif and the C-terminus, which 
contains multiple serines. Phosphorylation of these serines depends on autokinase activity 
and presumably occurs subsequent to phosphorylation of the activation loop. 
Mutagenesis experiments indicate that the C-terminal autophosphorylation sites are 
involved in downregulation of kinase activity [196]. Initially, the inactive IKK complex 
is not phosphorylated. In response to upstream stimuli IKK kinases are activated and 
recruited to the IKK complex via the IKKγ subunit. It results in phosphorylation of the 
IKKβ activation loop and consequently in activation of IKK. Through trans-
autophosphorylation the activated IKKβ subunit can phosphorylate an adjacent subunit, 
which can be either IKKα or IKKβ as well as other inactive IKK complexes through an 
intermolecular reaction. The activated IKK complexes then phosphorylate IkB subunits 
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in NF-kB/IkB complexes, triggering their ubiquitin-dependent degradation, and the 
activation of NF-kB. Concurrently and maybe due to the decrease of IkB abundance, the 
activated IKKβ subunits (and presumably the IKKα subunit as well) undergo C-terminal 
autophosphorylation. This reaction, which could be regulated by the level of IkB, 
operates as a timing device so that when at least 9 of the C-terminal serines are 
phosphorylated, the enzyme reaches a low activity state. Once in this state, IKK become 
sensitive to inactivation by phosphatases. As the C-terminal autophosphorylation sites are 
adjacent to the HLH motif they may exert their negative effect on kinase activity by 
changing the conformation of this intrinsic kinase activator domain and affecting its 
interaction with the catalytic domain.  
A model representing the regulation of IKK is shown in figure 2.31. 
 
 
 
Figure 2.31 A model for IKK activity regulation by phosphorylation. The two catalytic subunit of IKK are 
associated in a heterodimer via their leucine zippers. In non-stimulated cells, the activation loop within the 
kinase domain is not phosphorylated and the helix-loop-helix (HLH) motif contacts the kinase domain. 
Upon cell stimulation the activation loop of IKKβ is phosphorylated and through trans-autophosphorylation 
of the second subunit IKK is activated. Once activated, in addition to phosphorylation of IkBs, IKK 
undergoes progressive autophosphorylation at its C-terminal serine cluster. When at least nine of the C-
terminal serines are phosphorylated, electrostatic repulsion alters the interaction between the activating 
HLH motif and the kinase domain such that the kinase reaches a low activity state. In this situation the IKK 
activity decreases [196]. 
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Due to the ability of IKKβ to propagate its active state via autophosphorylation it is 
important to have a mechanism for decreasing its kinase activity thus rendering it 
sensitive to inactivation by phosphatase. Without negative autoregulation, a single bolus 
of a proinflammatory cytokine could result in prolonged IKK activation leading to 
prolonged NF-kB activation followed by increased production of both primary and 
secondary inflammatory mediators. As these mediators can cause further NF-kB 
activation, there is a risk that in the absence of efficient negative feedback mechanisms 
even a minor proinflammatory insult would result in a major catastrophe, such as septic 
shock [197]. 
One of the most interesting aspects of NF-kB is the variety and the nature of the inducers 
that lead to its activation. A summary of all stimuli that are known to activate NF-kB are 
shown online (http://www.nf-kb.org). 
Many different inducers initiate their pathways through distinct receptors and all of these 
different responses result in the activation of NF-kB. Depending on the stimulus, the 
mechanism of activation involves overlapping and non-overlapping steps.  
Though a wide variety of stimuli can activate NF-kB, among the most potent inducers are 
gram-negative endotoxin or lipopolysaccharide (LPS), TNF-α, and IL-1β which activate 
NF-kB via receptor-dependent signal transduction that involves specific intracellular 
protein-protein interaction. A wide array of receptor-independent stimuli, including UV 
radiation, physical stress or deformation, ischemia-reperfusion, and exposure to H2O2, are 
capable of activating NF-kB but the mechanism is unknown [198].  
A simplified version of the key events that link these kinds of stimuli to NF-kB activation 
is shown in figure 2.32. 
TNF-α binds to the type 1 TNF receptor (TNFR1), which results in an association with 
TNFR1 associated death domain protein (TRADD), the receptor-interacting protein 
(RIP), and the TNF receptor-associated factor-2 (TRAF-2). These cytoplasmic proteins 
form an active signaling complex that interacts with NF-kB-inducing kinase (NIK). 
Activation of NIK results in phosphorylation of IKK, which cause phosphorylation IkB. 
Phosphorylated IkB is targeted for destruction by the ubiquination/proteosome 
degradation pathway, allowing the translocation of NF-kB to the nucleus [199]. 
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Figure 2.32. A schematic view of different stimuli that activate NF-kB towards the production of 
inflammatory proteins [199]. 
 
 
IL-1 binds to the type 1 IL-1 receptor (IL-1R1) and the IL-1 receptor accessory protein 
(IL-1RAcP) which facilitates an interaction between IL-1 receptor-associated kinase 
(IRAK) and TNR receptor-associated factor-6 (TRAF-6). The interaction between IRAK 
and TRAF-6 can also be triggered by endotoxin, as LPS (Lipopolysaccharide).  
LPS binds with high affinity to CD-14 (the LPS receptor), and to Toll-like Receptor 2 
(TLR2). These proteins form an active signally complex that also result in activation of 
NIK and IKK leading to the sequence of events that results in activation of NF-kB. 
Activation of NF-kB results in expression of mRNA of a variety of pro-inflammatory 
mediators which are involved in the inflammatory process. IkB is also induced by NF-kB 
activation and contributes to the down-regulation of this intracellular signaling cascade 
[85]. Also depicted are the potential points in this intracellular cascade where reactive 
oxygen species (ROS) modulate the activation process. Any process that increases 
intracellular ROS, like TNF, IL-1 or H2O2, might influence the activity of NIK or the 
IKK signalsome. An interrupted line links ROS, NIK, and IKK because this point of 
interaction has not been proven. Modulation of the sulfhydryl (SH) group in the 
conserved Cys62 in RelA and p50 by cellular redox can dramatically alter DNA binding, 
oxidation (-S-SR) decreases binding affinity while a reductive process (-SH) is critical for 
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strong NF-kB binding to DNA. This sulfhydryl group is shown in the cytoplasm in the 
oxidised state (-S-SR) and in the nucleus in the reduced state (SH) to correspond with 
effects on binding activity [198]. 
Reactive oxygen species (ROS), including hydrogen peroxide, superoxide anion and the 
hydroxyl radical have been implicated in the pathogenesis of most inflammatory diseases 
including cerebral vascular disease. Since pro-inflammatory molecules are involved in 
the pathogenesis of these inflammatory diseases, interactions between ROS and NF-kB 
might be a component of the intracellular signalling process that leads to activation. Four 
areas of evidence indicate that NF-kB activation is linked to the generation of ROS. First, 
treatment with hydrogen peroxide directly activates NF-kB in some cells [200].  
In addition, overexpression of superoxide dismutase (SOD), the enzyme that converts 
superoxide anion to hydrogen peroxide, enhances the TNFα-induced activation of NF-
kB. Second, most of the known stimuli for NF-kB activation, including LPS, TNFα, and 
IL-1β, produce oxidative stress in cells [201].  
Third, treatment with N-acetylcysteine (NAC), α-lipoic acid, membrane permeable 
hydroxyl scavengers, metallothionein and the iron chelator, PDTC, blocks NF-kB 
activation that is induced by a wide variety of stimuli. These antioxidants are also 
effective in attenuating inflammation in rodent models of neutrophilic lung and cerebral 
inflammation. Fourth, overexpression of catalase, an enzyme that scavenges hydrogen 
peroxide, as well as overexpression of glutathione (GSH) peroxidase, an enzyme that 
scavenges hydrogen peroxide as well as organic peroxides using GSH as the electron 
donor, inhibits the cytokine-induced activation of NF-kB. Moreover, over-expression of 
γ-glutamylcysteine synthetase, the rate-limiting enzyme for GSH synthesis attenuates 
TNFα-induced NF-kB activation [202]. 
These observations suggest that ROS act as a common second messenger following 
cellular exposure to agents that induce NF-kB activation [203]. However, the main site of 
the interaction between ROS on the NF-kB activation pathway has not been completely 
defined. The most likely scenario is that ROS promote the activation pathway by 
activating a critical redox-sensitive kinase, probably NIK or the IKK signalsome since 
these molecules lead to phosphorylation of critical serine residues in IkB, resulting in 
liberation of cytoplasmic RelA/p50 heterodimers. However, the exact biochemical nature 
of the interaction between ROS and kinase activity of IKKα, IKKβ, or NIK has not yet 
been delineated. A recent study demonstrates that the IKK activity is blocked by 
apocynin (400 µM), a specific NADPH oxidase inhibitor, and diphenyleneiodonium 
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chloride (DPI; 10 µM), an inhibitor of flavin-containing oxidases like NADPH oxidases. 
Determination of ROS also demonstrated an increased generation in low shear stress that 
could be blocked by DPI. These results suggest that the source of ROS generation in 
endothelial cells in response to low shear stress is NADPH oxidase. The DPI-inhibitable 
component of ROS is the primary regulator of specific upstream kinases that determine 
the persistent NF- B activation selectively in low shear-induced endothelial cells [204].  
It is also possible, though not proven, that the redox state of critical cysteine residues 
could reversibly modulate kinase activity and regulates NF-kB activation [198].  
Besides NIK and IKK signalsome, a second potential point of interaction of ROS on the 
NF-kB activation pathway has been suggested using cell-free in vitro systems. These 
studies have shown that redox changes can have a direct effect on DNA binding activity. 
The N-terminal region of NF-kB/Rel proteins, including p50 and RelA, contain a cysteine 
residue at position 62 (Cys62) which is critical for DNA binding activity but is not 
essential for dimerisation or interaction with IkB family members. While mutation of 
Cys62 to Serine does not affect DNA-binding activity, mutation to Asparagine markedly 
impairs DNA binding activity in response to redox changes. This implies that the 
conserved Cys62 in the N-terminal region of the Rel homology domain is susceptible to 
redox changes that govern binding activity to DNA. Modulation of the sulfhydryl (SH) 
group in Cys62 by cellular redox can dramatically alter DNA binding. 
Oxidation (-S-SR) decreases binding affinity while a reductive process (-SH) is critical 
for strong NF-kB binding to its cognate DNA sequence.  
These observations suggest that cellular oxidative stress has a paradoxical action on NF-
kB by facilitating activation yet inhibiting DNA binding activity. Under conditions of 
oxidative stress, the sulfhydryl group of Cys62 should be in the oxidised state in the 
cytoplasm, but conversion to the reduced state must occur in the nucleus in order for 
strong DNA binding to occur. 
As mentioned above, once activated, in the nucleus, NF-kB dimers bind to target DNA 
elements and activate transcription of genes which encode for proteins involved with 
immune or inflammation responses and with cell growth control. 
A complete list of the target genes, inducers and inhibitors of NF-kB is available online at: 
http://people.bu.edu/gilmore/nf-kb/
Because of its direct role in regulating responses to inflammatory cytokines and 
endotoxin, the activation of NF-kB may play a role in the development of chronic 
diseases such as rheumatoid arthritis or in acute situations such as septic shock.  
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Support for a critical role for NF-kB activation in arthritis comes from two observations: 
NF-kB is activated in the arthritic synovium and therapies that are used for treatment, 
such as prednisone and gold compounds [205], are now known to block NF-kB. 
Septic shock is a systemic inflammatory response that develops when LPS or other 
microbial products stimulate expression of various inflammatory cytokines. The massive 
production of these proteins ultimately leads to reduction in blood pressure and to general 
organ failure. It has recently been proposed that the production of nitric oxide in response 
to LPS regulates important aspects of septic shock [206]. These experiments showed that 
iNOS-deficient mice were protected from septic shock. Since NF-kB activates 
transcription of the iNOS gene, activation of NF-kB by LPS may play a role in the 
development of septic shock. Other activators of NF-kB, such as TNFα, may also 
mediate septic shock [207]. Autoimmune diseases such as systemic lupus erythromatus 
(SLE) may involve activation of NF-kB as well. Additionally, Alzheimer’s disease may 
also involve activation of NF-kB in a chronic setting, since the amyloid β peptide causes 
production of ROS and activates gene expression through kB sites [208].  
Moreover, NF-kB plays an important role in the activation of HIV gene expression. The 
influenza virus protein hemagglutinin activates NF-kB, and this activation may contribute 
to viral induction of cytokines and to some of the symptoms associated with flu [209]. 
Products of the genes that are regulated by NF-kB also cause the activation of NF-kB. 
The proinflammatory cytokines IL-1β and TNF-α both activate and are activated by NF-
kB. This type of positive regulatory loop may amplify and perpetuate local inflammatory 
response [210].  
NF-kB may also play a role in the development of atherosclerosis by transducing 
pathogenic stimulation to expression of genes that promote recruitment and activation of 
inflammatory cells in the plaque.  
The NF-kB-regulated inflammatory mediators such as cytokines, inducible NO synthase 
and leukocyte adhesion molecules have been detected in atheroscleroris lesions. 
Activated NF-kB has been identified in macrophages, smooth muscle cells and 
endothelial cells in human atherosclerotic plaques but not in healthy vessels [211, 212]. 
As mentioned above, NF-kB has a fundamental role also in the regulation of cellular 
growth and it might have both pro-apoptotic and anti-apoptotic effects. TNFα, for 
example, is a proinflammatory cytokine that is produced by cytokine and other activators, 
such as LPS and viruses. It has several functions, including roles in inflammation, 
immunoregulation, proliferation, and anti-viral response [213].  
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The diverse actions of TNFα are mediated by two receptors, TNF-R1 (p60) and TNF-R2 
(p80). TNFα binding to TNF-R1 leads to activation of NF-kB and AP-1, which 
culminates in a proinflammatory and immunomodulatory response [214]. However, in 
certain cell types and under certain conditions, TNFα can induce apoptosis [215]. The 
duality of TNF-R1 signalling became clear through the identification of two distinct 
TNF-R1 intracellular pathways: a pro-apoptotic pathway, which is mediated by FADD, 
and an anti-apoptotic pathway, which is mediated by TRAF2 [216] and, in some cell 
types, by the Akt kinase [217], that leads to activation of NF-kB. 
Several studies have also shown that NF-kB has a pro-apoptotic and an anti-apoptotic 
role on nervous system. For example, treatment of rat primary neuronal cultures and 
hippocampal slices with the neurotoxin glutamate induces NF-kB activity and apoptosis, 
and activation of NF-kB in these cells can be inhibited by some common anti-
inflammatory drugs, as aspirin and salicylates [218]. On the other side, the β-amyloid 
peptide associated with Alzheimer’s disease my cause its neurodegenerative effects by 
down regulating NF-kB activity [219].  
The protective role of NF-kB in Alzheimer’s disease was also reported [220], 
demonstrating that the neuroprotective form of soluble β-amyloid peptide precursor 
protein can activate NF-kB and prevent apoptosis induced by the β-amyloid peptide. 
Moreover, NF-kB may have a pro-apoptotic or an anti-apoptotic role in response to a 
viral infection. For example, NF-kB can protect HIV-1-infected myeloid cells from 
apoptosis [221]; however, HIV-1 may also induce apoptosis through NF-kB in some 
situations: the HIV-1 encoded transcriptional transactivator TAT has been shown to 
render cells sensitive to apoptosis by inducing NF-kB [222]. 
An emerging picture is that, depending on a variety of circumstances, including the cell 
type and the inducing agent, NF-kB can have pro- or anti-apoptotic effects. These effects 
are likely carried out by the activation of target genes that lead to different outcomes. 
As a consequence of which types of genes are expressed after NF-kB activation, it seems 
that the pro- or anti-apoptotic effects of NF-kB may be part of a more complex process, 
namely the development of cancer. Cancer is a hyperproliferative disorder that involves 
transformation, initiation, promotion, angiogenesis, invasion, and metastasis. NF-kB 
activation participates at multiple steps in this pathway not only because it blocks 
apoptosis and promotes cell proliferation [223-225] but also because:  
1) NF-kB mediates the expression of genes that are involved in tumour promotion, 
angiogenesis, and metastasis [226]. For example, NF-kB may regulate the production of 
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prostaglandins via the proinflammatory gene cyclooxygenase-2 (COX2), which has been 
shown to be overexpressed in a variety of cancers including colorectal cancer and 
mesothelioma [227]. Moreover, Tumour cells, just like normal cells, need oxygen to 
survive and this can be a limiting factor to progression of tumours. Vascularisation of 
tumours requires the release of angiogenic growth factors (e.g. VEGF, MCP-1) from 
tumour cells and/or inflammatory cells such as macrophages and neutrophils or in 
response to pro-inflammatory cytokines (e.g. TNF). NF-kB regulates the expression of 
such growth factors and cytokines (VEGF, TNF, MCP-1) necessary for angiogenesis 
[228, 229, 230]. And also, the metastasis of cancer requires the migration of cancerous 
cells both into and out of the vessel walls that transport them to other parts of the body. 
The ability to cross vessel walls is mediated by specific molecules that are expressed in 
response to a number of signals from inflammatory cells, tumour cells, etc. Among those 
special molecules are ICAM-1, ELAM-1, and VCAM-1, all of which have been shown to 
be expressed in response to NF-kB activation [231, 232]. 
2) It has been shown that NF-kB is activated by hypoxia and acidic pH, both indigenous 
to the tumour microenvironment [233]. The stress of fluctuation in blood flow in the 
microenvironment of solid tumours and the resultant intermittent hypoxia has been 
shown to activate NF-kB [234, 235]. Since oxygen is needed for a tumour to grow, the 
tumour must secrete chemotactic signals such as growth factors and cytokines in order to 
induce neovascularisation. Many of these growth factors and necessary signals for 
tumour progression are target genes of NF-kB and utilize its activation for their 
transcription. 
3) Several tumour types show a persistent constitutive nuclear activation of NF-kB [236-
241]. 
4) NF-kB activation has been shown to induce resistance to various chemotherapeutic 
agents [242]. Likewise, the precise mechanism for NF-kB’s involvement in 
chemotherapeutic efficacy is not clear, but its enhanced activity has been shown to be 
linked to decreased apoptosis via expression of the anti-apoptotic gene A1/Bfl-1 and 
enhanced expression of the multiple-drug resistance gene product or MDR gene (prevents 
the intracellular accumulation of toxic drugs such as those used in chemotherapy), both 
likely factors in the progression of tumours [243, 244]. 
5) NF-kB gene products can be oncogenic when aberrantly expressed and are implicated 
in a number of tumour types. While the expression of a large number of genes involved 
in the development of cancer are regulated by NF-kB, the genes that code for individual 
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NF-kB proteins themselves have also been implicated in the development of several types 
of cancers, both hematopoietic and solid tumours. These genes are expressed aberrantly, 
i.e. amplification of gene on chromosome, rearrangement, overexpression, substitution, 
mutation, truncation, etc. [245, 246]. 
Because of the multitude of cellular and organism processes affected by NF-kB signaling, 
there has been great interest in modulators of this pathway and, for this reason, specific 
and efficient inhibitors of NF-kB have been sought. Due to the large number of inducers 
of NF-kB and the various levels of the regulation of this pathway, inhibitors also include 
a large variety of molecules that act at multiple levels. 
 
 
2.4.4 NF-kB: a target for therapeutic agents 
 
As mentioned above, NF-kB regulates the transcription of an exceptionally large number 
of genes [247], particularly those involved in immune and inflammatory responses (248, 
249, 210]. NF-kB activation also plays an important role in the antiviral response through 
interferon gene induction [250, 251]. Yet, through adaptation, many viruses, including 
human immunodeficiency virus type 1 (HIV-1) [252] and human T-lymphotrophic virus 
type 1 (HTLV-1) [253], which do not cause interferon induction, exploit NF-kB to 
activate their own genes and to stimulate the survival and proliferation of lymphoid cells 
in which they replicate. In most cells, NF-kB activation protects from apoptosis, through 
induction of survival genes, although under certain conditions and in certain cell types it 
may also induce apoptosis [254, 255]. Inappropriate regulation of NF-kB is directly 
involved in a wide range of human disorders, including a variety of cancers [256], 
neurodegenerative diseases [257], arthritis [258], asthma [259], inflammatory bowel 
disease [260], and numerous other inflammatory conditions. 
Because of the multitude of cellular and organism processes affected by NF-kB 
signalling, there has been great interest in modulators of this pathway.  
Intense efforts are currently made to develop novel drugs that specifically block NF-kB 
activating pathways. Due to the large number of inducers of NF-kB and the various levels 
of regulation of this pathway, inhibitors also include a large variety of molecules that act 
at multiple levels. 
The cascade of NF-kB signalling events provide several key steps for specific inhibition 
of NF-kB activity that could be classified as follow: 
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1) blocking the incoming stimulating signal at an early stage and thus blocking its general 
effect; 2) interfering with any step in the NF-kB activation pathway by blocking a 
specific member of the cascade; 3) blocking NF-kB nuclear activity, that is, inhibiting its 
translocation to the nucleus, its binding to DNA or its interactions with the basal 
transcription machinery. Each of these three major steps would not be susceptible to the 
same types of inhibitors. The following Tables give examples of a NF-kB-inhibitors 
classification. In a great number of cell types, NF-kB can be activated by oxidants and its 
induced activity can be inhibited by anti-oxidants. 
A list of anti-oxidants that have been shown to inhibit activation of NF-kB is available 
online on the website: http://people.bu.edu/gilmore/nf-kb/inhibitors/index.html 
The last common step before NF-kB is freed from the cytoplasm is the degradation of 
ubiquitinated IkB by the 26S proteasome [190, 261].  
Thus, inhibitors of the ubiquitin-proteasome pathway suppress activation of NF-kB by 
stabilizing IkB. The inhibitors described below can all penetrate cells and inhibit NF-kB 
activation in a dose-dependent manner by blocking proteasome-mediated degradation of 
IkB (but not its phosphorylation). 
A list of proteasome and proteases inhibitors that inhibit NF-kB is available online on the 
website: http://people.bu.edu/gilmore/nf-kb/inhibitors/index.html
In addition to the proteasome inhibitors, several other molecules inhibit NF-kB by 
maintaining a high level of IkB proteins in the cytoplasm and thereby preventing NF-kB 
nuclear translocation. Among these molecules, some inhibit IkBα phosphorylation and its 
subsequent ubiquitination, while others block IkBα degradation. Those molecules can be 
grouped into two classes: (1) natural molecules, that is, molecules produced by cells 
under specific condition or synthesized by diverse organisms (plants or micro-
organisms), and (2) artificial compounds, designed and produced by chemical, 
pharmacological or molecular biological processes. 
A list of IkBα phosphorylation and/or degradation inhibitors is available online on the 
website: http://people.bu.edu/gilmore/nf-kb/inhibitors/index.html 
Direct inhibition of NF-kB-specific trans-activation could involve several other 
molecules with different mechanisms of action blocking either nuclear translocation, 
DNA binding, or transactivation by NF-kB dimers.  
Because many of NF-kB target genes are involved in the acute phase or inflammatory 
response, inhibition of NF-kB has been used to minimise the pathologic effects induced 
by the immune system misregulation. As such, several of the most commonly used drugs 
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can inhibit NF-kB activity. An example of that are the anti-inflammatory drugs (aspirin, 
sodium salycilate, glucocorticoids, etc.) and the immunosuppressive agents (Cyclosporin 
A, FK506, PG490, etc.).  
Another general strategy for inhibiting NF-kB activity is to develop genetically-
engineered proteins that block specific steps in the activation process.  
It has been possible to block the activation of NF-kB by manipulating the genes that 
encode proteins (eg TRAF2, TRAF6, I-TRAF, NIK, MEKK1, and IKK) found directly in 
the known activation pathways [262].  
TRAF2 (TNF receptor-associated factor) and TRAF6 interact with TNF receptors and 
serve as adapters for the activation of NF-kB.  
Dominant negative mutants of TRAF2 and TRAF6 have been shown to repress NF-kB 
activity in response to TNFα and IL-1, respectively [216].  
I-TRAF interacts with TRAF2, and its overexpression inhibits TRAF2 activation of NF-
kB [263]. NIK (NF-kB-inducing kinase) is induced by several proteins in the activation 
pathway, including TRAF-2 and TRAF-6, and activates IKK (as does MEKK1).  
Therefore it has been shown that a dominant-negative mutant of NIK (and MEKK1) 
represses NF-kB activation [264-266].  
The IKKs (IkB kinases, alpha and beta) phosphorylate IkBα to subsequently cause its 
ubiquitination and ultimate degradation.  
Thus, alterations in the ATP-binding site of the IKK complex (IKKβ more so than IKKα) 
or its activation loop have been shown to block the activation of NF-kB as well (267-
272]. 
From the commonly-used aspirin to the IkBα super repressor, numerous inhibitors of the 
NF-kB activity have been described. Their mode of action is sometimes known, other 
times it has simply been noticed that such molecules inhibit NF-kB-induced DNA 
binding. Some NF-kB inhibitors are “broad-range” inhibitors, such as the many anti-
oxidants and proteasome inhibitors, which can block most NF-kB activating signals. 
Other inhibitors of NF-kB block activation when induced by only certain stimuli, for 
example by acting on a particular protein in the signalling cascade or by blocking specific 
NF-kB complexes. From the pharmacological point of view, it is moreover important, not 
only the transcription factor inhibition, but also its control, useful to evaluate the efficacy 
of the drug-therapy applied. This could be obtained quantifying the concentration 
decrease of the active factor, related to the dispensed drug. In order to have the possibility 
to detect the active NF-kB, several methods have been developed. 
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A list of miscellanous inhibitors of NF-kB is available online on the website: 
http://people.bu.edu/gilmore/nf-kb/inhibitors/index.html
 
2.4.5 Different methods for NF-kB detection 
 
NF-kB is involved in so many human diseases, including inflammation, asthma, 
atherosclerosis, AIDS, septic shock, arthritis, cancer.  
Several efforts for the development of a successful method, capable to detect the active 
form of the protein, have been done.  
Different methods have been proposed and successively used for the determination of the 
transcription factor, even if many of these are unable to discriminate the active form from 
the inactive one.  
Basic classical assays currently used for NF-kB detection include: Southwestern blotting 
[273, 274] enzyme-linked immunosorbent assay (ELISA) [275], electrophoresis mobility-
shift assay (EMSA) on gel [276], free solution capillary electrophoresis (FSCE) [277]. 
Moreover some modern techniques, often combining two different classical approaches 
in order to take advantage of the value of both, have been proposed and commercial kits 
have been developed. 
 
2.4.6 Detection kits commercially available 
 
The common aspect of simple and fast assay-kits for NF-kB detection commercially 
available is the research of a non-radioactive labelling method, in order to avoid the 
tedious and time consuming aspect of these assays. Furthermore, all of them are based on 
the antigen-antibody interaction.  
 
Different assay kits for detection of NF-kB, p50 are available on the market: 
ASSAY DESIGNS/STRESSGEN BIOREAGENTS Company produce an assay which uses 
streptavidin-coated plates with bound NFkappaB biotinylated-consensus sequence to 
capture only the active form of NFkappaB. The captured active NFkappaB is incubated 
with a specific NFkappaB p50 antibody which is subsequently detected using an HRP 
conjugated secondary antibody. The assay is developed with a chemiluminescent 
substrate and the signal is detected using a luminometer. 
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The CAYMAN CHEMICAL® Company provide a NF-kB (human p50) Transcription Factor 
Assay non-radioactive method for detecting specific transcription factor DNA binding 
activity in nuclear extracts and whole cell lysates. A 96 well enzyme-linked 
immunosorbent assay (ELISA) replaces the cumbersome radioactive electrophoretic 
mobility shift assay (EMSA). A specific double stranded DNA (dsDNA) sequence 
containing the NF-kB response element is immobilised onto the bottom of wells of a 96 
well plate. NF-kB contained in a nuclear extract, binds specifically to the NF-kB 
response element. NF-kB (p50) is detected by addition of specific primary antibody 
directed against NF-kB (p50). A secondary antibody conjugated to HRP is added to 
provide a sensitive colorimetric readout at 450 nm. The Cayman Chemical NF-kB 
(human p50) Transcription Factor Assay detects human NF-kB (p50) is specific and does 
not cross-react with NF-kB (p65). 
 
The CHEMICON® (MilliporeTM Corporation Company) sells non-radioactive NF-kB 
p50/p65 Transcription Factor Assay which provides a method to detect specific DNA 
binding activity for transcription factor in nuclear extracts. This assay combines the 
principle of the EMSA with the 96-well based ELISA, enabling manual or high-
throughput sample analysis with significantly greater sensitivity than conventional 
EMSA assays. The entire assay takes less than 4 hours to complete with minimal hands-
on time. The versatile set up allows a flexible assay design and because the binding 
reaction occurs in solution, various parameters can be optimised such as probe titration, 
competitive oligonucleotide concentration, or treatment conditions. The system is similar 
to the one described before, actually the non-radioactive NF-kB p50/p65 Transcription 
Factor Assay kit is provided in a 96-well format. During the assay, the Capture Probe, a 
double stranded biotinylated oligonucleotide containing the consensus sequence for NF-
kB binding (5’-GGGACTTTCC-3’), is mixed with cellular (nuclear) extract in the 
Transcription Factor Assay Buffer provided. When incubated together, the active form of 
NF-kB contained in the nuclear extract binds to its consensus sequence. After incubation, 
the extract/probe/buffer mixture is then directly transferred to the streptavidin coated 
plate. The biotinylated double stranded oligonucleotide bound by active NF-kB protein is 
immobilised and any inactive, unbound material is washed away. The bound NF-kB 
transcription factor subunits, p50 and p65, are detected with specific primary antibodies, 
a Rabbit anti-NF-kB p50 (active form) and a Rabbit anti-NF-kB p65. An HRP-
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conjugated secondary antibody is then used for detection and provides sensitive 
colorimetric detection that can be read in a spectrophotometric plate reader.  
 
NOVAGEN® Company proposes an identification of DNA binding protein using the 
NoShiftTM Transcription Factor Assay Kit. The NoShift™ assay is a microassay plate–
based test to identify proteins that bind to a specific DNA sequence. One advantage of 
this plate-based assay over traditional gel shift assays is the remarkable specificity of the 
test. The shift in mobility of a DNA probe in an EMSA indicates that some protein in a 
crude extract binds, but the identity of the protein is unknown unless a supershift is 
performed with a protein-specific antibody. The NoShift assay has dual specificity: that 
of the protein for the DNA probe and of the antibody for the interacting protein. The 
convenient 96-well format of the NoShift assay permits screening for multiple DNA 
binding proteins in the same plate. The basic NoShift kit consists of a streptavidin-coated 
microassay plate. A NF-kB reagent kit contains biotinylated oligonucleotides that include 
a consensus recognition sequence, specific and non-specific competitors, a transcription 
factor–specific antibody, secondary antibody conjugated to HRP, and positive control 
nuclear extract. The NoShift assay kits, as the others described before, offers a fast, 
sensitive, non-radioactive alternative to gel shift assays. 
 
These interesting kits solved the problem of an unspecific active-inactive NF-kB bound 
by means of a DNA consensus sequence in the ELISA assay. In spite of that, it seems a 
laborious approach that takes several hours before the sandwich antigen-antibody was 
ready to be measured.  
 
2.4.7 In vivo imaging of NF-kB activity 
 
An original contribution for the control of NF-kB activity has been recently given [278]. 
As NF-kB is involved in a number of diseases, their model offers a tool for studying NF-
kB regulation in condition were NF-kB is a key player. Their goal is to define 
mechanisms through which NF-kB leads to the development of disease, for that they have 
developed transgenic mice that express a luciferase reporter whose transcription is 
dependent upon NF-kB. The relative amount of luminescence can be assayed 
uninvasively by real-time imaging. 
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Reporter gene expression in vivo has previously been assessed using optical techniques 
such as microscopy of green fluorescent protein [279] or near-infrared fluorescence 
[280], both of which have limited depth penetration. Nuclear imaging techniques using 
gamma cameras [281], positron emission tomography [282], or single-photon emission 
computed tomography [283] have satisfactory depth penetration, but they have a lower 
spatial resolution. Magnetic resonance imaging techniques [284] provide excellent spatial 
resolutions, but the temporal resolution is limited, and the technique is several orders of 
magnitude less sensitive than optical and nuclear techniques. Their detection system was 
adapted from one described by Contag and colleagues [285]. In their study of mice 
infected with recombinant bacteria containing the luciferase gene, the displayed 
luminescence was sufficiently intense to be detected externally. The transgenic mice 
expressing luciferase prepared by Carlsen and co-workers gives the possibility to monitor 
changes in NF-kB activity in living animals as a function of cytokines, endotoxin, 
physical agent, and state of disease. In other words, it is an interesting model to observe 
exogenous factors, such as nutrients, pharmaceuticals, and pollutants, for modulation of 
gene expression related to NF-kB, but it is not able to quantify the active protein that is 
increased after an external stimulus and decreased after the appropriate drug therapy. 
 
2.4.8 dsDNA microarrays for DNA/protein interactions studying 
 
An array of dsDNA specific for transcription factor was recently realized by Wang and 
co-workers [286]. They proposed as an alternative to the classical techniques, the 
immobilization on a glass surface of dsDNA interacting specifically with a fluorescent 
labelled protein. The oligonucleotide chain was covalently immobilised on a glass slide, 
consequently the p50 subunit of NF-kB was labelled with the fluorescent dye Cy3 and the 
interaction with the DNA fragment was performed. The construction of an array carrying 
different DNA sequences could be potentially used to study: screening sequence-specific 
DNA-binding proteins; predicting new DNA-binding sites of transcription factors in 
genome; assessing importance of nucleotides in DNA-binding sites for DNA/protein 
interactions; monitoring the expression of drug-induced DNA-binding proteins; and 
screening sequence-specific DNA-binding drugs.Taking advantage of this biosensing 
method described for the NF-kB detection, during this work an optical sensor-model for 
active NF-kB quantification was proposed. The reliability of a reusable biosensor, 
important for the construction of a cheap device, was also demonstrated. 
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 2.4.9 Idea of biosensor for NF-kB  
 
Standard techniques to quantify the protein NF-kB (e.g. ELISA) are not able to 
discriminate the active structure from the inactive one, and other methods (such as 
electrophoresis mobility shift assay, EMSA) are laborious and time consuming. The 
critical need for a simple and direct method to evaluate the quantity of a transcription 
factor in a biological sample can be addressed using a suitable, renewable biosensor, 
consisting of two basic elements: the biological recognition system which interacts 
selectively with the analyte of interest, and the transduction process, able to convert the 
molecular recognition into a detectable optical signal.  
In particular, an optical detection method based on fluorescence has been considered, in 
which the active form of NF-kB is detected by its binding to a specific DNA sequence. 
An optical biosensor for the NF-kB based on fluorescence resonance energy transfer 
(FRET) is reported in literature [168]. The principle of operation of the biosensor is based 
on the DNA binding activity of NF-kB, which relies on its ability to bind to one particular 
sequence of DNA.  
The device described in this thesis was constructed using a bioreceptor made of a 
synthetic double filament (dsDNA) that represents the site of binding (kB site) of the 
transcription activator NF-kB1 (p50/p50).  
The biosensor, therefore, is required to transduce the binding event with an unknown 
quantity of the factor to a measurable and quantifiable physical phenomenon (a variation 
in fluorescence) induced from the formation of the complex DNA/protein [175, 176].  
The achievement of direct and quantitative detection of activated NF-kB would be far 
preferable to the traditional assay methods (EMSA, western blot, immunoprecipitation) 
that are extremely laborious, have insufficient reproducibility and are only capable of 
providing semi-quantitative results.  
The optical biosensor developed here and suitable for the specific measurements of the 
levels of factor NF-kB in biological samples is based on a sandwich assay.  
The first step was the immobilisation of an oligonucleotidic probe (which mimics the 
DNA sequence kB) on the internal wall of a flow channel. Then, in a second step, a 
protein (p50) was inserted in the channel interacting with the DNA probe. Cy5-labeled 
antibodies specific for the interaction with p50 were then inserted, as a third step, and the 
intensity of fluorescence, which was proportional to the concentration of p50, was 
measured (Fig. 2.33).   
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Figure 2.33 A diagrammatic representation of the two step operation idea for the optical biosensor for NF-
kB. Top: dsDNA is immobilised on the wall of the flow channel; binding between protein p50/p50 and 
DNA takes place. Bottom: the protein p50/p50, bound to dsDNA, is measured by means of a labelled (Cy5) 
antibody specific for p50, causing a variation in the fluorescence signal. 
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 2.5    MGMT  
 
MGMT (O6-Methylguanine-DNA methyltransferase) is a ubiquitous DNA repair protein 
that removes O6-alkyl-guanine lesions, primarily O6-methyl-guanine from damaged 
DNA. It is a major contributor to cellular protection from the mutagenic, carcinogenic, 
and cytotoxic effects of DNA alkylation [287]. Recent studies define the role of MGMT 
in protecting from alkylating agent-induced toxicity and mutations in mammals [288]. 
The alkylation of DNA occurs in the O6 position of the guanine and the MGMT protein 
is able to remove these residual agents that constitute a condition of mutagenic lesion of 
the DNA. In fact the presence of O6-methylguanine during the replication of the DNA 
can cause a mutation from cytosine into thymine; in O6-Metilguanina, thymine is the 
favoured complementary partner rather than cytosine, the correct complementary base of 
guanine. [289]. A brief representation of the chemical reactions in play is shown in fig. 
2.34. DNA mutation caused by a methyl group in position O6 can be favoured 
considering the rearrangement of electrons if a methyl group reacts in the oxygen 
position number 6. This fact can cause a modification of guanine into O6-methylguanine 
[290]. The part highlighted in red in O6-methylguanine (Fig. 2.34) looks chemically 
similar to the same part of adenine molecule. Consequently during the transcription from 
DNA into RNA, RNA recognises the O6-methylguanine as if it is an adenine base, with 
the consequent conversion of O6-methylguanine into a thymine instead of cytosine.   
 
Figure 2.34 The normal complementary pairs of DNA bases are shown on the left. On the right (top) the 
modification due to alkylating agents (in this case a methyl group) is shown. On the right (bottom) the 
DNA wrong transcription due to O6-methylguanine is represented. I personally depicted this image.   
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 In recent years, it was plenty demonstrated that MGMT protein is able to play a 
fundamental role in the cellular defence against the alkylating agents, especially in the 
case of undesirable methylation of guanine base [291-309]. 
All these works about MGMT protein reveal the potentiality that SH group, belonging to 
cysteine, possess in prevention of mutagenicity. In fact, the evolution of mutagenic 
nucleotides can cause an unnatural cellular revolution caused by low levels of MGMT. 
On the contrary, high level of this parameter tends to preserve the DNA replication 
process [291, 293]. 
In particular, Glioblastoma multiform (GBM) is the most common and aggressive type of 
primary brain tumour. Treatment can involve chemotherapy, radiotherapy and surgery. 
The use of temolozide (Temodar ©) alongside radiotherapy has shown survival benefit 
and is currently considered the standard of care by the National Cancer Institute [294-
298]. In particular, the gene silencing of MGMT can help temolozide drug activation in 
radiotherapy in glioblastomas brain tumour. mRNA silencing is usually performed using 
a promoter of methylation (methylation-specific polymerase-chain-reaction) preventing 
its DNA repair function when temolozide is involved as specific drug in brain cellular 
processes [299-301].  
In low-grade diffuse astrocytomas, promoter hypermethylation of MGMT has been 
shown to predict an increased sensitivity to alkylating chemotherapeutic agents; earlier 
chemotherapy could serve to improve an unfavorable natural history in tumors with 
MGMT methylation [291].  
The DNA-repair enzyme MGMT inhibits the killing of tumor cells by alkylating agents. 
MGMT activity is controlled by a promoter; methylation of the promoter silences the 
gene in cancer, and the cells no longer produce MGMT. Methylation of the MGMT 
promoter is related to the responsiveness of the gliomas (primary central nervous system 
tumour) to alkylating agents; research studies were conducted on clinical patients with 
gliomas treated with carmustine (1,3-bis(2-chloroethyl)-1-nitrosourea, or BCNU).  
The MGMT promoter was methylated in gliomas from 19 of 47 patients (40 percent). 
This finding was associated with regression of the tumor and prolonged overall and 
disease-free survival. It was an independent and stronger prognostic factor than age, 
stage, tumor grade, or performance status. Hence, methylation of the MGMT promoter in 
gliomas is a useful predictor of the responsiveness of the tumors to alkylating agents 
[292]. 
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Methylation of the promoter region of the O(6)-methylguanine-DNA methyltransferase 
(MGMT) gene is known to be predictive of response to temozolomide treatment in 
patients with glioblastoma [294]. Little is known about variations in the methylation 
status of the MGMT promoter after temozolomide treatment or across different regions of 
the same tumor. A study about the variation in the methylation status of the MGMT 
promoter after this treatment or across different regions of the same tumor suggests that 
variation in MGMT promoter methylation can occur within the same tumor, necessitating 
caution in clinical decision-making based on this analysis [294].  
A study conducted in these days relates on MGMT activity in primary and recurrent 
glioblastomas of patients who received radiation therapy (RT) or RT plus chemotherapy 
with alkylating agents (temozolomide, chloroethylnitrosoureas). The data revealed a 
threshold of MGMT expression below which patients respond better to alkylating agents. 
Therefore, determination of MGMT activity in the primary tumor appears to be useful in 
predicting the outcome of glioblastoma therapy [295]. Other investigations revealed that 
MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide 
therapy [296].  
In general, the use of triazene compounds for clinical approaches (i.e. dacarbazine and 
temozolomide) and their mechanism of action related to DNA repair systems were 
recently well described in literature [298]. Triazene compounds have excellent 
pharmacokinetic properties and limited toxicity. Dacarbazine requires hepatic activation 
whereas temozolomide is spontaneously converted into active metabolite in aqueous 
solution at physiological pH. Moreover, temozolomide is fully active when administrated 
orally (100% bioavailability) [298]. 
Recent published articles conclude that MGMT is widely expressed in primary 
neuroblastoma tumors, and is a relevant therapeutic target in neuroblastoma. Both in vitro 
and in vivo studies suggest inactivation of MGMT with O(6)-benzylguanine may 
increase the activity of temozolomide against neuroblastoma [299]. 
Epigenetic silencing of the MGMT by promoter methylation compromises DNA repair 
and has been associated with longer survival in patients with glioblastoma who receive 
alkylating agents. Patients (206 cases) with glioblastoma containing a methylated MGMT 
promoter benefited from temozolomide, whereas those who did not have a methylated 
MGMT promoter did not have such a benefit [300-301].  
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The above citations reveal the potentiality which could possess a biosensor able to 
measure variations of MGMT in glioblastoma samples, representing a key factor in 
temozolomide treatment. 
 
MGMT activity is also involved in positive studies on the treatment of lung cancer as a 
DNA repair gene [302], and in vitro studies on promoted methylation during Human 
Papilloma Virus (HPV-16, HPV-18) induced by cervical carcinogenesis [303, 304]. 
MGMT activity is also frequent in human oral cancer cells [305].  
A recent clinical study, reported among Singapore Chinese, investigated the role in 
colorectal cancer, due to mutations in the colorectal lumen caused by smoking and 
alcohol drinking, of single-nucleotide polymorphisms in MGMT (Leu (84) Phe). This 
research conducted on 310 cases (180 colon, 130 rectum cancer) revealed, in the case of 
colon cancer a positive association of PARP (codon 940 Lys/Arg and Arg/Arg genotypes 
and colorectal cancer risk, and an inverse association between the MGMT codon 84 
Leu/Phe or Phe/Phe genotypes and colon cancer risk, but not rectal cancer [293]. 
On the other side, on a population based San Francisco Adult Glioma study, associations 
between XRCC1 Arg399Gln, MGMT Leu(84)Phe, and MGMT Ile(143)Val 
polymorphisms with glioma risk was evaluated. No evidence of an association between 
XRCC1 genotypes and glioma was found. Instead, a weak positive association for the 
MGMT Leu(84)Phe polymorphism (Leu or Phe/Phe versus Leu/Leu) and the MGMT 
Ile143Val polymorphism (Ile or Val/Val versus Ile/Ile) was found [297]. 
In general MGMT expression has been found to be drastically inferior in carcinogenic 
tissue compared to normal values measured on healthy tissue on pateints [310, 311].  
It is now evident that the realisation of a device able to estimate in cellular extracts the 
concentration of mRNA sequence that codifies for MGMT is of a primary importance.  
 
2.5.1 Three dimensional structure of MGMT protein 
 
Human O(6)-alkylguanine-DNA alkyltransferase (AGT), which directly reverses 
endogenous alkylation at the O(6)-position of guanine, confers resistance to alkylation 
chemotherapies and is therefore an active anticancer drug target [312]. 
Crystal structures of active human AGT and its biologically and therapeutically relevant 
methylated and benzylated product complexes reveal an unexpected zinc-stabilised 
helical bridge joining a two-domain alpha/beta structure. An asparagine hinge couples the 
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active site motif to a helix-turn-helix (HTH) motif implicated in DNA binding. The 
reactive cysteine environment, its position within a groove adjacent to the alkyl-binding 
cavity and mutational analyses characterize DNA-damage recognition and inhibitor 
specificity, support a structure-based dealkylation mechanism and suggest a molecular 
basis for destabilization of the alkylated protein. These results support damaged 
nucleotide flipping facilitated by an arginine finger within the HTH motif to stabilize the 
extrahelical O(6)-alkylguanine without the protein conformational change originally 
proposed from the empty Ada structure. Cysteine alkylation sterically shifts the HTH 
recognition helix to evidently mechanistically couple release of repaired DNA to an 
opening of the protein fold to promote the biological turnover of the alkylated protein 
(Fig. 2.35). 
 
Figure 2.35 Human O6-alkylguanine methyltransferase (left), methylated human O6-alkylguanine-DNA 
alkyltransferase (middle) and benzylated human O6-alkylguanine-DNA alkyltransferase structures 
determined by X-ray diffraction (Daniels, Tainer et al.). Image source is Protein Data Bank.  
 
 
In 2004, a study evidence of DNA binding and nucleotide flipping by the human repair 
protein MGMT was determined by X-ray diffraction (Fig. 2.36, left). 
As mentioned above, O(6)-alkylguanine-DNA alkyltransferase (AGT), or O(6)-
methylguanine-DNA methyltransferase (MGMT), prevents mutations and apoptosis 
resulting from alkylation damage to guanines. AGT irreversibly transfers the alkyl lesion 
to an active site cysteine in a stoichiometric, direct damage reversal pathway. AGT 
expression therefore elicits tumour resistance to alkylating chemotherapies, and AGT 
inhibitors are in clinical trials. The structures of human AGT in complex with double-
stranded DNA containing the biological substrate O(6)-methylguanine or crosslinked to 
the mechanistic inhibitor N(1),O(6)-ethanoxanthosine is reported in literature.  
The prototypical DNA major groove-binding helix-turn-helix (HTH) motif mediates 
unprecedented minor groove DNA binding. This binding architecture has advantages for 
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DNA repair and nucleotide flipping, and provides a paradigm for HTH interactions in 
sequence-independent DNA-binding proteins like RecQ and BRCA2. Structural and 
biochemical results further support an unpredicted role for Tyr114 in nucleotide flipping 
through phosphate rotation and an efficient kinetic mechanism for locating alkylated 
bases [200].     
 
 
Figure 2.36 Left: Human O6-alkylguanine-DNA alkyltransferase bound to DNA containing O6-
methylguanine. Right: Crystal structure of O6-methylguanine-DNA methyltransferase from 
hyperthermophilic archaeon Pyrococcus Kodakaraensis strains KOD1 (Pk -MGMT).  
 
Another published work is in literature about crystal structure of MGMT and it was 
accomplished on Archaea, a group of prokaryotic and single celled microorganisms. 
Archaea are similar to bacteria but these two groups evolved differently, and are 
classified as different domains in the three-domain system.  A single individual or species 
from this domain is called archaeon, while the adjective is archaeal or archaean. The 
etymology is greek meaning “ancient things”.  
In particular, the crystal structure (Fig. 2.36, right) of O6-methylguanine-DNA 
methyltransferase of hyperthermophilic archaeon Pyrococcus Kodakaraensis strain 
KOD1 (Pk -MGMT) was determined by single isomorphous replacement method with 
anomalous scattering (SIRAS) [201].  
The archaeal protein is extremely thermostable and repairs alkylated DNA by suicidal 
alkyl transfer from guanine O6 to its own cysteine residue. Archaea constitute the third 
primary kingdom of living organisms, sharing characteristics with procaryotic and 
eucaryotic cells. They live in various extreme environments and are thought, as 
previously mentioned, to include the most ancient organisms on the earth. Structural 
studies on hyperthermophilic archaeal proteins reveal the structural features essential for 
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stability under the extreme environments in which these organisms live, and will provide 
the structural basis required for stabilizing various mesophilic proteins for industrial 
applications. The crystal structure of Pk-MGMT and structural comparison of Pk-MGMT 
and methyltransferase homologue from Escherichia coli (AdaC, C-terminal fragment of 
Ada protein) was reported. Analyses of solvent-accessible surface area (SASA) reveals a 
large discrepancy between Pk-MGMT and AdaC with respect to the property of the ASA. 
In the Pk-MGMT structure, the intra-helix ion-pairs contribute to reinforce stability of 
alpha-helices. The inter-helix ion-pairs exist in the interior of Pk-MGMT and stabilize 
internal packing of tertiary structure. Furthermore, structural features of helix cappings, 
intra and inter-helix ion-pairs are found around the active-site structure in Pk-MGMT 
[201]. Therefore, archaeal protein is a suicidal enzyme able to remove O6-guanine 
repairing DNA and transferring the alkyl group from DNA to its cysteine. 
 
 
2.5.2 Idea of a device able to quantify mRNA for MGMT   
 
Research to obtain an optical biosensor for MGMT derives from this overall idea.  
RNA interference (RNAi) by double strand formation (RNA/RNA) of molecules of 
approximately 25-30 nucleotides, represent a modern solution to regulate the expression 
of a protein. This mechanism is called the short interfering method (siRNAs) and is a 
powerful way of preventing the expression of a particular gene [306]. This means that the 
specific base-pairing of ribonucleic acids can be usefully adopted for RNA biosensing. 
Hence, the idea of the synthesis of RNA probes by virtue of their more stable pairing to 
target (RNA/RNA duplexes) rather than DNA probes (DNA/RNA duplexes) was 
planned. In particular, for the design of oligonucleotidic bioreceptor probes, the stability 
of the duplex, the conformational accessibility (favourable for probe binding), and the 
absence of any recurrence in other known transcribed sequences (uniqueness) must be 
considered. As previously mentioned, sequences of mRNA encoding for human MGMT 
were chosen.  
With the aim to assemble a RNA biosensor for MGMT, particular attention was focused 
on the bioreceptor and on its integration with the surface of the transducer. Starting from 
a computational selection of targets, complementary probe sequences were derived and 
synthesised. During the automated synthesis, some chemical modifications were 
introduced in order to confer resistance against RNA-ase to probes, increased binding 
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strength and anchoring ability, useful for conjugation to the sensing surface for the 
realisation of the optical mRNA biosensor. In addition, to overcome the extreme 
sensitivity of native RNA oligonucleotides to chemical and enzymatic hydrolyses, 2’-O-
methyl modified RNA monomers were used. In fact, they had been previously recognised 
to produce 2’-O-methyl RNA able to survive ribonucleases and alkali attack [307, 308]. 
Syntheses were performed on a DNA synthesiser and in order to evaluate the resistance 
of the probes to nucleases, different tests were conducted in serum, and then compared 
with experiments using unmodified RNA oligonucleotide. They were finally analysed for 
integrity by acrylamide gel electrophoresis (SDS-PAGE) as reported in literature [309]. 
The results of these experiments demonstrated good stability of the modified RNA 
compared with the unmodified one.  
The modified RNA was suitable and stable and could be immobilised and used as  
bioreceptor.  
 
 
2.5.3 The selection of RNA probes and targets 
 
The priorities in probe preparation were high selectivity and good affinity for the desired 
target, in order to make a stable duplex without interference and spurious hybridisation 
with non-target nucleic acid sequences. In order to prepare such probes, a study of 
folding of the target mRNA molecule was necessary. More generally, the folding of RNA 
is an unimolecular process occurring spontaneously in the cell and depends on the 
thermodynamics of pairing between complementary stretches of different regions of the 
RNA sequence and produces a number of secondary structures [315, 316]. 
There are computer algorithms, based on energy minimisation, able to predict secondary 
structures of RNA sequences and their sources of thermodynamic parameters are 
continuously improving [317]. A recent study [318] describes an “in silico” strategy to 
detect suitable targets within a given mRNA sequence to be used for hammerhead 
ribozyme design [319]. Such a computational method was exploited for selecting 
accessible regions in the human MGMT transcript and planning our probes. The program 
analyses the score of pairing events among the different structures nucleotide by 
nucleotide (the freedom of each nucleotide), considering the probability of existence of 
each structure. On these bases, for each sequence of desired length, an algorithm gives 
the accessibility score (AS) which was a basic parameter for selecting our target strings 
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[318]. All sequences of the MGMT transcript were classified [320] in four accessibility 
classes according to their accessibility score (see Table 2.4). 
 
 
 
Table 2.4 Main features of a set of potential probes for MGMT mRNA. All these putative probes are 
complementary to accessible regions of target mRNA (accessibility > 60%). For each probe six 
characteristics are shown: length, position of the complementary sequence in the mRNA sequence, 
accessibility, Gibbs energy of the self-structuring of probe, melting temperature (Tm) of the target-probe 
duplex and difference between the Tm of the correct duplex and the Tm of the most stable incorrect one. The 
most favourable ones are highlighted in bold. [320] 
 
 
The sequences were then evaluated for their pairing energy ∆G° using the Nearest 
Neighbour Nucleotide algorithm at standard conditions (25°C, 1 atm). Once the most 
accessible target sequences and their pairing energy suitable for probe binding were 
evaluated, the uniqueness of each target among the entire human known trascriptome was 
checked. Partial homologies between the target sequence and other unwanted mRNA 
sequences were searched. A homology threshold value of 70% was imposed and the 
partially homologous sequences which passed the limit were evaluated for their affinity 
towards the selected probes. The melting temperature (Tm) of these mismatched duplexes 
was then calculated and compared with the Tm of the correct duplex. The resulting ∆Tm 
expresses the difference in melting temperature between the correct duplex and the most 
stable of the incorrect ones. The higher ∆Tm corresponds to the most selective binding 
between the probe and its target. Probe sequences displaying a ∆Tm for mismatched 
duplexes under a threshold of 10°C were discarded. This gap in temperature can be 
exploited to reach stringent conditions. Increasing the temperature above the Tm of the 
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incorrect duplex but below the denaturing temperature of the right hybrid causes a 
selective detachment of unwanted sequences [320].  
Finally the evaluation of the thermodynamic properties of each selected probe was also 
performed in order to evaluate the tendency of the probes to intra-molecular pairing.  
For each potential probe the ∆G° of self-structuring was calculated and probes with high 
negative values were discarded. In Table 2.3 a set of potentially active probes 
(accessibility of the target sequence ≥ 60%) is reported and each probe is described by an 
identification number, by the position of its complementary sequence in the MGMT 
transcript and by a set of values corresponding to different criteria of the selection 
method. The probes selected according to this computing method, synthesised and 
employed in these experiments [320]. 
The final choice of these probes was done by in collaboration with the group Pisa based 
on a compromise between different criteria. For probes 7 and 64 uniqueness and absence 
of self-structuring were preferred, while in choosing probe 46 and 41, accessibility was 
the leading criterion and ∆G°, Tm and ∆Tm the auxiliary ones.  
In particular, in this thesis an experimental study on a new optical platform of 
hybridisation interactions between probe 7 and probe 46 (bioreceptor) with their 
respective complementary RNA sequences was investigated.  
 
 
2.5.4 Biosensor for mRNA 
 
The plan was to realise an assay for the development of a RNA biosensor able to detect 
hybridisation between RNA probes (25 nucleotides) and RNA complementary targets. 
For this purpose, a sequence of oligonucleotide that mimics the complementary sequence 
of mRNA for the protein MGMT was selected to be used. Hence, the bioreceptor will be 
a probe for RNA, complementary to the mRNA sequence, which was opportunely 
realised by means of DNA synthesiser and chromatography purification.  
For the measurements, a flow channel was designed and prepared containing the chain of 
synthetic RNA complementary to the target RNA by which measurements could be 
carried out to establish the RNA/RNA interactions.  
When hybridisation occurs and an opportune detection of the target is realised, a further 
step based on RNA/RNA duplex interaction can be performed. In the first step the 
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bioreceptor (probe) is covalently attached to the internal wall of a transparent flow 
channel (Fig 2.37, top).  
In the second step the RNA target is inserted in the flow channel and the RNA/RNA 
hybridisation takes place (Fig. 2.37, middle).  
In the third step (Fig. 2.37, bottom) an oligo probe opportunely planned and synthesised 
flows into the channel to obtain a second hybridisation with the accessible free parts of 
the mRNA previously linked to the bioreceptor. The second oligo probe, labelled with a 
fluorophore, is then introduced at known concentration, so that a fluorescence signal is 
observed which is dependent on the mRNA present. 
 
 
 
Figure 2.20 Three-step operation for the optical biosensor for mRNA. Top: RNA is immobilised on the 
wall of the flow channel; middle: RNA/RNA duplex hybridization takes place. Bottom: a second probe of 
Cy5-labeled RNA, complementary to a second target of mRNA, hybridizes the free part of mRNA 
enhancing the fluorescence signal.  
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2.5.5 Commercial kits available for MGMT 
 
Only one type of detection kits able to determine MGMT protein is available on the 
market and is sold by Sigma-Aldrich TM. Sigma's MGMT assay kit is based on the 
formation of a new restriction site in a 23-mer 32P labeled ds-oligonucleotide after 
removal of the O6-methyl-guanine lesion. Cleavage of the new restriction site results in 
two smaller oligonucleotides that can be resolved on a denaturing SDS-PAGE gel. 
This assay is based on a radioactivity method that utilizes 32P, an isotope of phosphorus, 
beta-emitter, primarily used to produce radiolabeled DNA or RNA probes for use in 
Northern or Southern Blot. Because the high energy beta particles produced by penetrate 
skin and corneas, and because any 32P ingested, inhaled, or absorbed is readily 
incorporated into bone and nucleic acids, Occupational Safety and Health Administration 
requires that a lab coat, disposable gloves, and safety glasses or goggles be worn when 
working with 32P, and that working directly over an open container be avoided in order to 
protect the eyes. Monitoring personal, clothing, and surface contamination is also 
required. In addition, due to the high energy of the beta particles, shielding this radiation 
with the normally used dense materials (e.g. lead), gives rise to secondary emission of X-
rays via a process known as Bremsstrahlung, meaning braking radiation. Therefore 
shielding must be accomplished with low density materials, e.g. Plexiglas, Lucite, plastic, 
wood, or water (http://www.oseh.umich.edu/TrainP32.pdf). 
All these precautions represent an awful, tedious limit for MGMT detection; moreover 
this dangerous labour requires specialised human handling.  
The research to obtain a novel clean and economic method based on fluorescence for 
sensing mRNA codifying in MGMT protein represents a challenge for the actual standard 
of measurements.  
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3. AIMS & OBJECTIVES   
 
This thesis consists in the realisation of optical affinity biosensors based considering all 
the scientific aspects mentioned in the Introduction-part of this thesis.  
The aim is the obtainment of an optical biochip able to detect several biological 
parameters in a multianalyte optical setup.   
In the multidisciplinary path of this work the aim is the design, hence the realization of 
a modern device, the fluorescence enhanced optimization of its performances and the 
miniaturised setup which will combines optics and microfluidics based on it.  
Optical sensors able to detect pH and antigen-antibody affinities have to be obtained in 
order to investigate the better performances gathered from the results changing 
chemical reactants and optical properties.  
This experimental knowledge will be directly applied into the biochip system.  
After that, it will be possible to start investigations on the immobilization of short 
sequences of DNA and RNA to the substrate.  
When those will be properly reached the DNA and RNA bioreceptors will be able to 
detect rispectively:  
• The transcription factor (NF-kB) by DNA/NF-kB binding. 
• The mRNA sequence that codify in MGMT protein by RNA/mRNA binding. 
 
Several chemical treatments of the surfaces have to be properly investigated in order to 
obtain the most effective chemical deposition of an hydrophilic substrate which will 
represent the “floor” for the attachement of proteins, DNA and RNA.  
A key objective is to find the appropriate polymer to obtain a reproducible surface 
enhanced for the fluorescence measurements. 
Several steps are considered in the obtainment of the biochip;  
as first, a sensor for pH made by immobilizing pH fluorescent dyes on a receptor 
channel will be considered and an optimisation of the maximum fluorescence intensity 
will be set up. 
Secondarily, an immunoassay for immunoglobulins Ig will be investigated contributing 
useful informations on the best chemical-physical conditions which will determine a 
proper coverage of bioreceptors on the transduction surface area.  
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This represents in fact a critical issue. An objective is the improvement in the 
sensitivity of the system until a linear range from 1 ng/ml to 1mg/ml covering with IgG 
the bioreceptor channel and measuring the anti-IgG diluted in buffered solutions.  
Further chemical treatments must be considered and the deposition of the polymers 
selected has to be compared to detect the most effective one.    
The deposition method of the polymer should be well considered because is crucial for 
reproducible sensing. The concentration of the chosen polymer in its solvent must keep 
integral the optical transparency. The polymer must possess chemical ON/OFF 
properties in the sense that activation of chemical groups on the surface (ON) and 
inactivation of these groups on the surface (OFF) can be selected. 
Finally, the chemical nature of the polymer have to combine transparency, dissolution 
in a low temperature solvent, low cost, reproducibility, reliability. 
Reuse of the biosensor or reuse of the substrate will depend on the configuration 
adopted and will be extremely useful to provide an easy-handling solution for the user.  
The reuse of the biosensor will imply that the substrate has to be sterilised properly 
without the need of a heating procedure. This, in fact, could be detrimental for the 
biosensing activity and for the optical transparency.   
On the other side, the reuse of the substrate will depend on the total remove of the 
bioreceptors immobilised and consequently on its sterilisation. If the substrate is not 
more usable because, for example, it lost its optical properties, it becomes waste 
material. Fortunately, transparent substrates are made of recyclable materials such as 
plastic or glass.  
The measurement of the affinity biosensors, the identification of the protocol bioassays 
and the design and characterisation of the optical platform was mainly held in the 
Institute of Applied Physics at National Research Council (IFAC-CNR), Firenze, Italy. 
The biochemical aspects devoted to the design and synthesis of the chemical 
components for the realisation of affinity biosensors able to detect and quantify 
antigens, transcription factors and RNA sequences is carried out in collaboration with 
the Institute of Clinical Physiology at the National Research Council (IFC-CNR), in 
Pisa, Italy.  
AFM Imaging and deposition studies of the surfaces were experimentally carried out in 
the Biomedical Department in Cranfield Health, Cranfield University, Silsoe, UK.   
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 4. MATERIALS AND METHODS 
 
4.1 pH sensing of fluorescein solutions in glass capillary 
 
Optical setup: 
A silica glass capillary was firstly used as flow chamber to detect a fluorescence signal of 
dyes dissolved in buffer pH solutions. Dimensions of the capillary are: 127 mm in length, 
1 mm in external diameter and 500 µm in internal diameter. Inner volume is 10 µl. Bare 
capillaries were purchased from Drummond Scientific Company, Broomall, PA, U.S.A. 
Multimode optical fibres (200 µm glass core diameter) were purchased from Polymicro 
Technologies, Phoenix, Arizona, United States. These fibres were used to transport the 
optical signal from the excitation source to the biosensing layer and the fluorescent signal 
from the biosensing layer to a detector. SMA connectors were used for the optical 
coupling. The method consisted in to couple the capillary with a system of optical fibres 
able to interrogate the sensing layer in absorbance and fluorescence modes (Figure 4.1).     
A tungsten white lamp was used as source in the absorbance mode to detect absorption of 
immobilised dyes. A blue LED with a 490 nm peak was employed as a source in the 
fluorescence mode, and was firstly coupled at the input with low pass (LP) filters 480 nm 
or with one band-pass (BP) filter at 488 nm, set between the source and the sensing layer.  
Output filter BP at 525 nm and a high-pass HP filter at 546 nm were considered too.  
A led source was preferred to an Argon laser because it provided a miniaturized and 
cheap solution for prototype engineering. A fibre optic spectrometer (S2000) with a 
wavelength range of 300-900 nm was used as detector and it was purchased from Ocean 
Optics Inc., Dunedin, FL, United States. 
 
Figure 4.1 Detail of the interface between the capillary and the optical fibres. 
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 Chemical protocols: 
Six buffers at different pH were prepared mixing, pure water, citric acid (C6H8O7), 
disodium hydrogen phosphate (Na2HPO4), and potassium chloride (KCl) following 
McIlvaine protocol. Solvents and salts were purchased by Sigma, St. Louis, MO, U.S.  
  McIlvaine pH buffers were prepared at 1 M of ionic strength in accord with Table 4.1. 
 
pH        g / liter         g / liter 
Buffer 
system 
KCl added g / liter of solution to 
produce IS of: 
T= 25°C Na2HPO4-12H20 H3C6H5O7-H20 
Ionic 
strength(IS)          1 M                      0.5 M 
4.6 33.4 11.2 0.2100 58.9 21.6 
5.4 40 9.29 0.3020 52.1 14.8 
6.0 45.2 7.74 0.3440 48.9 11.6 
6.6 52.1 5.72 0.3850 45.8 8.5 
7.2 62.3 2.74 0.4570 40.4 3.1 
8.0 69.6 0.59 0.5590 32.9 0.0 
 
Table 4.1. McIlvaine protocol for buffers at different pH.   
 
Fluorescein sodium salt was dissolved in the buffers in a range between 10-4-10-9 M to set 
a preliminary session of pH measurements.  
Fluorescein sodium salt was dissolved in a buffer pH 8 to set the measurement for 
calibration curves.  
Fluorescein sodium salt was purchased from Sigma-Aldrich, Riedel de Haen.  
For all the experiments a peristaltic pump model Minipuls 3, with a four channel pump 
head, was used and purchased from Gilson, Middletown, WI, United States.  
Tygon tubes, with an internal diameter of 1.02 mm, were purchased from Saint Gobain. 
Flow speed used in these experiments was 10 µl/min. 
 
 
4.2 pH sensor in glass capillary 
 
First optical setup: 
Silica glass capillary was used as substrate for the immobilisation of fluorescent dyes and 
as flow chamber to detect a fluorescence signal of dyes dissolved in buffer pH solutions. 
A tungsten white lamp, coupled via SMA connector with an optical fibre multimode, was 
used as source in the absorbance mode to detect absorption of immobilised dyes. For 
fluorescein derivatives a blue LED at 490 nm was employed as a source in the 
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fluorescence mode. This light source was coupled to a band-pass (BP) filter at 488 nm, 
set in entrance (source-sensing layer), and a BP filter at 525 nm, set in output (sensing 
layer-detector). These filters were purchased from Andover Corporation, Salem, NH, 
U.S. For cyanine derivatives a red LD at 635 nm, 3 mW output power (Hitachi-
HL6314MG) was the main source employed in IgG/anti-IgG biosensing. 
BP filter, at 635 nm was set in entrance (source-sensing layer) and a high-pass (HP) filter, 
cut-on at 650 nm was set in output (sensing layer-detector).  
These filters were purchased from Thorlabs, Munich, Germany. 
 
Second optical setup: 
A second optical system configuration was studied to improve signal to noise ratio.  
This was based on a glass capillary coupled with a second fused silica capillary 450 µm 
fixed using epoxy glue. A PVC sleeve allowed two optical fibres, 200 µm in core 
diameter, to be located facing the capillary section. The two fibres were interfaced to a 
double detector system. (Figure 4.2) 
As detectors, a fibre optic spectrometer (S2000) with a wavelength range of 300-900 nm 
(Ocean Optics) and a photomultiplier tube (PMT) connected to a frequency photon 
counter (PicoQuant 2006) were used. 
Transversal excitation with a blue light emitting diode (490 nm) and a filter BP-488 was 
employed for fluorescein derivatives, whereas a red diode laser source (635 nm) was used 
for cyanine derivatives.  
 
 
 
Figure 4.2. Second configuration used to improve the optical efficiency of the system. The dye was 
immobilised inside a capillary which was used as waveguide to capture the fluorescence signal by coupling 
with two optical fibres on a photomultiplier tube and on a spectrophotometer.   
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 Chemical protocol: 
Activation of the glass surface of capillaries was obtained with sulphuric acid (H2SO4), 
and hydrogen peroxide (H2O2, 3:1 v/v). After 1 hour the capillary was rinsed with water.  
Modification of the internal wall of the capillary was achieved by filling the capillary 
with APTES in EtOH (30:70 v/v).  
The capillary was kept overnight in the oven at 80°C.  
Basilar chemical protocols were considered changing the concentrations of silanes in 
EtOH (pure, 10%, 20%, 30%), the types of silanes (APTMS, APTES), the solvents 
(ethanol or methanol) and the temperature environment (25-100°C) for silanisation.  
Silanes were purchased from ABCR GmbH, Karlsruhe, Germany; the solvents were 
purchased from Sigma, St. Louis, MO, U.S.  
On exposed amino pendants, fluorescent dyes with reactive functional groups were 
attached by covalent bonding on the glass (Figure 4.3): fluorescein isothiocyanate 
(FITC), was dissolved in EtOH in a concentration of 1 mM and succinimidyl derivatives 
(FAM-X-SE and Cy5) were dissolved in dimethylformamide (DMF) in a concentration 
of 1 mM and then were inserted filling the entire capillary.  
 
   
Figure 4.3 Three step reaction for the covalent binding of fluorescent dyes to the glass surface inside a 
capillary. In the first step the oxidation was performed using the so-called Piranha solution. In the second 
step silanisation of the substrate was done to obtain exposed amino groups. In the third step the 
fluorophores were covalently bound to the surface by condensation and peptide bond formation.  
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 Dyes: 
• Fluorescein isothiocyanate  (FITC) was purchased from Sigma-Aldrich.         
• 6-(Fluorescein-5-carboxamido) hexanoic acid, succinimidyl ester (5-FAM-X, SE) 
was purchased from Fluka.   
• N-hydroxysuccinimidyl cyanine or Cy5 was purchased from Amersham 
Bioscience, GE Healthcare, England, UK.  
These type of dye molecules possess functional groups reactive to attach primary amino 
groups (Figure 4.4). In the case of 5-FAM-X, SE the spacer of six atoms of carbons helps 
the succinimidyl group to be sterically more reactive to primary amino groups. 
 
 
Figure 4.4 From left to right: organic structures of  Fluorescein-5-(and-6)-carboxamido) hexanoic acid, 
succinimidyl ester 5-FAM-X, SE; Fluorescein isothiocyanate (FITC); Cyanine 5-N-pentil-succinimidyl 
ester  (Cy5).  
 
Optical spectra of fluorescein and cyanine derivatives were obtained from literature 
[332]. Optical behaviour of the fluorophores involved in the experiments are summarized 
in Figure 4.5 where normalized absorption and fluorescence are reported.  
 
 
 
Figure 4.5 Absorbance and emission spectra of fluorescein and cyanine derivatives from literature [332]. 
In the case of fluorescein it is possible to note a fluorescent pH dependence.   
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 4.3 pH sensor in PMMA chip 
 
Optical setup: 
A second transparent substrate, the PMMA biochip, was obtained from a 3 mm-thick 
planar slide by mechanical processing. The chip consisted of four channels, obtained by 
combining two pieces: the lower part, which included the four micro-channels and the 
inlet and outlet for the fluidics (Figure 4.6a), and the upper part, on which the sensing 
layer was immobilised (Figure 4.6b). The dimensions of a single flow-channel were: 0.5 
mm wide, 0.4 mm high and 18 mm long. The model engineering of this innovative 
prototype for an optical multichannel chip made in PMMA was carried out at IFAC-
CNR, Firenze, Italy, and realised in collaboration with DATAMED S.r.l., Milan, Italy. 
 
        
 
Figure 4.6 a) Top view of PMMA multi-channel chip. b) Bottom view where is shown a single channel 
surface in which a bioreceptor is immobilised. 
 
The dimensions of a single flow channel were: 0.5 mm wide, 0.4 mm high and 18 mm 
long. The longitudinal cross section of the flow cell is clearly illustrated in Figure 4.7.  
A fraction of the fluorescence emitted by the layer is guided at the end of the cover where 
it is collected by means of a 200 µm optical fibre. The signal was analysed using an 
Ocean Optics S2000 spectrometer.  
The particular profile of the cover with the air gaps allowed a physical separation of the 
fluorescence signal coming from the different channels and each channel was optically 
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separated from the others. The presence of the inlet and outlet for the fluidics on the 
bottom of the structure facilitated the monitoring of the fluorescence which travelled 
inside the plastic cap along the same direction as the flow.  
 
 
Figure 4.7 Lateral section of the PMMA chip. The cover and the flow cell, both made with PMMA, are 
complementary shaped. The fluorescence is guided along the PMMA cover and is collected by an optical 
fibre.     
 
The realisation of the first prototype is shown in Figure 4.8a. Another image of the 
prototype under working conditions is shown in Figure 4.8b. 
            a)                                      b) 
                     
 
Figure 4.8 a) Image of the initial prototype biochip. b) Optical angular coupling of the LED 490 nm on a 
channel with a filter BP-488 with the optical fibre and GRIN lens coupled with a side face of the channel 
cover at an angular position of 50°.   
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Chemical protocol: 
A copolymer of PMMA (Eudragit RL100, MW= 150000) 
was dissolved in EtOH at 0.1 mM concentration. Eudragit 
RL100 was purchased from Degussa Röhm Pharma 
Polymers, Essen, Germany.  
This solution was mixed 1:1 with a solution of FITC in 
EtOH (1 mM). Few drops of the cocktail were dropped on 
the PMMA channel of the biochip.  
Total evaporation of the solvent occurred at room temperature after few minutes.  
The sensing surface was then rinsed abundantly with pure water.  
The fluorescent layer, containing fluorescein and Eudragit RL100 was excited by led at 
490 nm, with a BP filter at 488 nm.  
Buffers at different pH were prepared mixing, pure water, citric acid (C6H8O7), disodium 
hydrogen phosphate (Na2HPO4), and potassium chloride (KCl) following McIlvaine 
protocol. Solvents and salts were purchased by Sigma, St. Louis, MO, U.S.  
  McIlvaine pH buffers were prepared at 1 M of ionic strength in accord with Table 4.1. 
The pH value was increased starting from pH 4.6 to pH 8.0 in six different intermediary 
steps and the maximum peak of fluorescence was recorded at 539 nm for more than 3 
hours and changing pH concentrations every 12 minutes. Flow speed was set at 10 µl/min.  
 
 
4.4 Antigen sensor in PMMA planar squares 
 
Optical setup: 
The potentiality of the PMMA chip, its ease of use and its convenient geometrical 
configuration for a simple replacement encouraged in-depth examination.  
For this reason, a cheaper and easier preliminary substrate was thought and realised and 
inexpensive proteins such as IgG and anti-IgG-Cy5 were purchased and investigated.            
Small squares of PMMA were used as substrates in order to identify a proper 
immobilisation procedure of the bioreceptor.  
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The research implied to find the best arrangement for an immunosensor based on 
interactions between IgG immobilised on the substrate and anti-IgG-Cy5 flowing in 
solution.  
The optical setup shown in figure 4.9 was used because the results in the anisotropic 
angle for Cy5 were in agreement with the ones for fluorescein.  
As source it was used a red DL at 635 nm, 3 mW output power (Hitachi-HL6314MG). 
Filters were not added for these preliminary experiments (Fig. 4.9).   
Fibre optic spectrometer (S2000) with a wavelength range of 300-900 nm was used and 
purchased from Ocean Optics Inc., Dunedin, FL, United States.  
 
 
 
Figure 4.9 The source, a diode laser He/Ne at 635 nm, is perpendicularly directed on a PMMA square 
surface on which a mixture of Eudragit RL100 and cy5 was deposited. The fluorescence is guided through 
the channel and collected using an optical fibre.  
 
Chemical protocol: 
Large transparent plates of PMMA were cut using a CO2 laser (2 kW) for industrial 
applications.  
Thousands of single planar squares of size 10 mm x 10 mm x 1.5 mm were thus obtained.  
These squares where used as a planar configuration of the PMMA chip in order to 
determine the best operating conditions in the chemical treatments and to improve the 
optical properties.  
Polymethylmetacrylate (PMMA) was purchased from RS Components, Milan, Italy.  
Two different polymers were deposited on the surface:  
 
• poly L-lactic acid (PLLA) is currently used in a number of biomedical 
applications, such as sutures, stents, dialysis media and drug delivery devices, but 
it has also been evaluated as a material for tissue engineering [336]. PLLA was 
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dissolved in CHCl3 and then activated into a carboxyl surface by strong basic 
solutions (e.g. NaOH 2M). Figure 4.10 shows that PLLA is the product resulting 
from polymerisation of L,L-lactide (also known as L-lactide). The polymer blend 
dissolved in CHCl3 is perfectly transparent. PLLA was purchased from DURECT 
Corporation, Cupertino, CA, U.S.  
Figure 4.10 Ring opening polymerisation of lactide into polylactide.  
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• Copolymer of PMMA (Eudragit L100) deriving from polymethylmethacrylate, 
possess methacrylic acid groups in their chemical structure (Figure 4.11). 
Eudragit L100 was dissolved in EtOH. EudragitL100 was purchased from 
Degussa Röhm Pharma Polymers, Essen, Germany.   
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Figure 4.11 Chemical structure of Eudragit L100. 
The deposition of these two polymers was compared to two direct chemical modifications 
of PMMA substrate, considering the idea to convert methyl esters groups of PMMA into 
carboxylic groups using a strong basic solution or mixtures of pyridine and water. 
In summary, the PMMA surface was treated by following several protocols in order to 
covalently immobilise mouse-IgG through the interaction of their amino groups with 
carboxylic groups present on the solid support.  
The carboxylic groups were obtained (Figure 4.12) by several treatments listed below: 
1) Direct surface treatment with NaOH 2M in pure H2O and in a mixture of 
H2O/DMSO (1:1) for 1 hour, and then washing with deionised H2O;  
2) Direct surface treatment with pyridin/water (95:5 and 50:50 v/v) dropping the 
solutions on the surface for 10, 20 and 30 minutes and then rinsing with deionised water;   
3) Deposition of Eudragit L100 in EtOH at different concentrations (0.001-100 
mM) until the solvent had evaporated and then washing with deionised water; 
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4) Deposition of PLLA in CHCl3 at different concentrations (0.01-10 mM) until 
the solvent had evaporated; then after washing with deionised water, treatment with 2 M 
NaOH and then further washing with deionised water. 
 
 
Figure 4.12 Chemical modifications of PMMA to obtain carboxylic groups. Two polymer depositions were 
compared to two direct surface treatments.   
 
EDC and s-NHS were used to convert surface carboxylic groups into amino reactive 
NHS esters. This was accomplished by mixing s-NHS with a dehydrating agent such as 
the carbodiimmide EDC (Figure 4.13). EDC and NHS were dissolved in 2-
morpholinoethanesulfonic acid (MES) buffer 0.1 M at pH 6.2 and dropped for 30 minutes 
on the carboxylic surface following protocols from Pierce. After EDC/NHS procedure, 
unreacted semi-stable succinimydil esters were inactivated by tris-(hydroxymethyl)-
aminomethane (TRIS) buffer pH 7.4, and then washed with a phosphate buffer solution 
PBS (NaCl 137 mM, Na2HPO410 mM,  KCl 2.7 mM, pH 7.4). A solution of mouse IgG 
in PBS (50µl, 1.25 mg/ml) was then dropped on the small squares for 1 hour and the 
squares were washed with PBS.  
  
 
Figure 4.13 Mechanism of catalysis of EDC /s-NHS for amino covalent bonding of a protein on a 
carboxylic surface. 
 
 108
The immobilisation was then followed by incubation with antiIgG-Cy5 (1 mg/ml) for 1 
hour and finally rinsing with PBS buffer to remove unreacted anti-IgG. 
Mouse-IgG and goat-antimouse-IgG labeled Cy5 were purchased from Zymed 
Laboratories, Invitrogen Corporation, Carlsbad, CA, U.S. 
The results obtained from these preliminary experiments on planar PMMA squares were 
applied on the four micro-channel PMMA chip.  
 
 
4.5 Antigen sensor in PMMA chip 
 
Optical setup: 
The PMMA chip was modified cutting the PMMA cover channel with an angle of 30° in 
order to obtain a perpendicular output area of the guided fluorescence (Figure 4.14a).      
Hemi cylindrical lenses made of PMMA were developed in the laboratory and positioned 
on the top of every single channel to improve the excitation focus in the channel thus 
increasing the signal (Figure 4.14b).  
Graded index (GRIN) lenses, ¼ pitch, 1.8 mm diameter, were used to increase the 
collection area of the emitted signal and were purchased from SELFOC MicroLens, NSG 
Europe, Temse, Belgium.  
A red DL at 635 nm, 3 mW output power (Hitachi-HL6314MG), was used as source.  
The laser diode combo controller ITC 510 was purchased from THORLABS.  
This instrument provides a current controller and a temperature controller in one unit. 
The source requires an external cooling system which was built in our labs around the 
diode laser and included a Peltier cell coupled with a heat sink.  
A filter BP at 635 nm was set between the diode laser and the flow channel.  
A second high-pass filter (> 650 nm) was set on the top of the optical fibre at the output. 
A more sensitive fibre optic spectrometer (SWNIR CCD, purchased from Hamamatsu 
Photonics) with a wavelength range of 500-1100 nm was employed for these 
measurements.  
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   a)      b) 
 
Figure 4.14 Lateral section (a) and cross section (b) of the optical chip for the interrogation in flow of 
antigen labelled Cy5. On the left is shown the lateral section of the PMMA chip. The fluorescence is 
guided along the PMMA cover, filtered with a HP > 650 nm, and collected by an optical fibre coupled with 
a GRIN lens. An hemicylindrical lens was added on the top of the channel in order to increase the focus of 
the source thus emproving the sensitivity.        
 
Chemical protocol: 
After deposition of Eudragit L100 in EtOH and EDC/NHS activation, as described above, 
the pmma cover part was ready to be inserted on its complementary flow cell part.  
In the case of PMMA chip, the IgG immobilisation and the assay were carried out in flow 
conditions. The PMMA chip was connected to a peristaltic pump by means of the PVC 
tubing. The flow rate used for IgG immobilisation was 1 µl/min, whereas the speed for 
assay experiments was 10 µl/min. 
Different concentrations of mouse IgG (0.5, 0.05, 0.005 mg/ml) were inserted in the 
channels for 30 minutes, and sensing efficiency was compared to understand the more 
convenient concentration of IgG to be deposited for one single channel.   
Three different treatments of the surface to obtain carboxylic groups were executed with 
Eudragit L100/EtOH (0.01 mM); PLLA/CHCl3 (0.01 mM) + NaOH 2M; NaOH/dmso 
(1:1). These treatments were compared in biosensing efficiency and a final microfluidic 
assay protocol for antiIgG detection was implemented as follow: 
 
1) A mouse IgG solution in PBS (0.05 mg/ml was chosen) in flow for 30 minutes was 
inserted on a single channel at speed of 1 µl/ml to obtain a reproducible coverage of the 
substrate previously modified with Eudragit L100 (0.01 mM) and EDC/NHS method.  
2) TRIS buffer pH 7,4 in flow for 5 minutes with a speed of 1 µl/min was used to 
deactivate the surface.  
3) PBS in flow for 5 minutes with a speed of 10 µl/min was used to wash unbound IgG.  
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4) AntiIgG-Cy5 was diluted in PBS in a range between 1 ng/ml - 1 mg/ml.  
5) AntiIgG-Cy5 in flow for 15 minutes spaced out by washing steps of PBS for 5 minutes 
for every concentration measured.  
6) Measurements were performed starting from the more diluted (1 ng/ml) to the more 
concentrated (1 mg/ml) solutions of antiIgG-Cy5 after PBS wash. 
7) The DL (635 nm, 3 mW) was switched on and 10 measurements of the optical spectra 
were captured with an integration time of 10 sec for a total time of 100 sec.  
8) The DL was switched off and an average spectrum of the measurements was collected 
by the Hamamatsu spectrophotometer.  
 
 
4.6 mRNA (MGMT) biosensor in PMMA planar squares: 
 
Optical setup: 
A led at 490 nm coupled with an optical filter BP at 488 nm was used as excitation source 
(Figure 4.15). The collection of fluorescence signal was carried out using an optical fibre 
at 50° angle. Graded index (GRIN) lenses, ¼ pitch, 1.8 mm diameter, were used to 
increase the collection area of the emitted signal. GRIN lenses were purchased from 
SELFOC MicroLens, NSG Europe, Temse, Belgium.  
 
 
 
Figure 4.15. A blue led source filtered at 488 nm is perpendicular to the transparent pmma square where 
the fluorescent layer is deposited. The guided fluorescent signal is captured with a graded index lens 
coupled with an optical fibre.    
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 Chemical protocols: 
A solution of Eudragit L100/EtOH (0.01mM) was prepared and dropped on a small planar 
square to obtain a surface covered with carboxyl groups.  
To obtain a surface with exposed amino groups, hexamethylendiammina (HMDA) was 
then dropped.  
HMDA amino groups react covalently with the carboxyl groups forming peptidic bond and 
water.  
Hexamethylendiammina (HMDA) was diluted in 100 mM borate buffer at pH 9, as 
reported in literature [5], and dropped on the surface to obtain primary amino groups 
exposed on the surface (Figure 4.16).  
Hexamethylendiammina (HMDA) was purchased from Fluka, Riedel de Haen, Germany. 
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Figure 4.16 HMDA binding to a carboxylate surface.  
 
 
Surface treatments to activate the PMMA with amino groups were considered and several 
experiments were conducted to find the better solution in terms of quantity of amino 
groups present on the surface.  
Planar square of PMMA were used as substrate for preliminary studies of the surface 
chemistry. Amino groups were obtained by means of pre-treatment of the surface with 
Eudragit L100 and consequently EDC/NHS treatment followed by HMDA treatment. 
The same reaction was also carried out directly with pure HMDA.  
In particular, the following pre-treatments before HMDA treatment were compared:  
 
a) surface deposition of Eudragit L100;  
b,c,d) acid hydrolysis of ester groups on PMMA (H2SO4 3M; H2SO4 1M; HCl 1M)  
e,f) alkaline hydrolysis of ester groups (NaOH 4M; NaOH 1M) with PMMA planar 
square immersed in the solution for 3 h.  
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g) PMMA chip immersed in HMDA 1M in DMSO;  
h) Drop deposition of HMDA 1M in DMSO.  
A quantitative measurement of amino groups generated on the surface was achieved with 
sulfosuccinimidyl-4-O-(4,4-dimethoxytrityl) butyrate (s-SDTB), a molecule that reacts 
with an amino group releasing a dye (λmax Abs = 498 nm) as by-product of reaction  
(Figure 4.17) [352]. 
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Figure 4.17 Quantification of amino groups with s-SDTB. The quantity of amino groups present on a 
surface is proportional to the quantity of dye released in solution.  
 
A 0.1 mM solution of sulfosuccinimidyl s-SDTB was prepared by first dissolving it in 
acetonitrile: sodium bicarbonate (1:50) buffer at pH 8.5. 
The s-SDTB solution was dropped for 30 minutes on the planar squares of PMMA 
pretreated with HMDA.  
The samples were then washed abundantly with pure water and placed in vials with  
perchloric acid (30%).  
The absorbance signal was recorded at 498 nm by spectrophotometer and amino groups 
were quantified.  
The reaction between pmma planar square amino modified and thiolated RNA was 
obtained using an etero-bifunctional cross-linker: sulfo-succinimidyl 4-(N-
maleimidomethyl) cicloesan-1-carboxylate (SMCC) was purchased from Pierce, 
Rockford, IL, United States (Figure 4.18). 
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Figure 4.18 Reaction of peptidic bond formation between amino groups and SMCC. 
 
The protocol of SMCC, able to react in an etero-bifunctional manner [337-340] with 
amine groups and with thiol-modified 2’OMe-RNA (Figure 4.19), was performed 
following the protocol from Pierce. 
 
     
 
Figure 4.19 Left: Cross-linking reaction of SMCC between an amino carrier and a thiol carrier. Right: 
2’OMe-RNA sequence thiol-modified is covalently bound to the PMMA surface The overall structure is 
about 10 nm in length.    
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The sequences of RNA synthesised in Dept. of Clinical Physiology, at IFC-CNR, in Pisa, 
Italy, were chosen in accord with previous experiments carried out and reported in 
literature [318]. The sequences of RNA were modified with methoxyl group at 2’ carbon 
atom (2’OMe-RNA) to protect RNA from RNAses enzymes.     
RNA sequences and concentrations were: 
          
  Probe 7:              5’-GUGCGUUUCAUUUCACAAUCCUUGU-3’ 
         Characteristics:   2’-OMe, SH or NH2 at 3’, conc. 234.4 mM. 
Probe 46:            5’-CCUCGGGCUGGUGGAAAUAGGCAUU- 3’ 
Characteristics:   2’-OMe, NH2 at 3’, conc. 246.9 mM. 
Probe 7 mism.:   5’-GUGCGUAUCAUUGCACAAGCCUUGU-3’ 
Characteristics:   2’-OMe, SH at 3’, conc. 234.4 mM.  
Target 7*: 3’-CACGCAAAGUAAAGUGUUAGGAACA-5’ 
Characteristics:   2’-OMe, FITC or Cy5 labelled, conc. 100.0 mM. 
 
The RNA probes were dissolved in pure water whereas, the RNA targets were dissolved 
in an hybridisation buffer (2X) made of 5 ml of formamide (50%), 5 ml of SSC (10X), 
0.2 ml of  SDS (10%). SSC (20X) buffer was prepared adding NaCl 3 M, sodium citrate 
0.3 M, EDTA 1 mM.    
 
 
4.7 mRNA (MGMT) biosensor in PMMA chip: 
 
Calibration curve regarding the sensitivity for RNA/RNA hybridisation between probe 7 
and target 7* was recorded using the PMMA multi-channel chip.  
In this case the RNA probe was modified with an amino group instead of a thiol group, in 
order to simplify the chemical protocol for the self-assembling of the bioreceptor.  
The target 7* was labelled with Cy5 instead of FITC to match the source characteristics.    
A solution of Eudragit L100/EtOH (0.01 mM) was prepared and 50 µl were dropped on a 
bare single channel of a PMMA chip.  
After solvent evaporation, a solution of EDC/NHS in MES buffer 0.1 M, pH 6.2 was 
dropped on the surface for 30 minutes. 
The PMMA cover part was then ready to be inserted on its complementary flow cell part. 
Bioreceptor immobilisation (probe 7) was executed in flow for 30 minutes at 1 µl/min.  
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TRIS buffer in flow for 5 minutes at 1 µl/min was used to deactivate the surface.  
After a washing step of 5 minutes with buffer, the RNA target 7* solution, dissolved in 
hybridisation buffer at different concentrations was inserted at 10 µl/min speed for 15 
minutes.  
After a washing step for 5 minutes with pure buffer, the red diode laser was turned on and 
ten measurements were captured with an integration time of 10 seconds.  
After 100 seconds the diode laser was turned off and an average spectrum was saved.  
The integral fluorescence area in a range between 650-750 nm was calculated and a 
calibration curve was plotted for different concentrations of the target 7*.       
 
 
4.8 NF-kB sensor in PMMA chip: 
 
The DNA sequence for the capture of NF-kB was invented and realised in the laboratory 
of the institute of Clinical Physiology (IFC-CNR) in Pisa by means of DNA synthesizer.   
The specific sequence for NF-kB protein detection was a single chain of 30 nucleotides 
opportunely synthesised to auto-hybridize folding on itself and leaving a closed loop of 
four bases.  
This specific sequence of DNA binds to NF-kB protein and is known as a NF-kB decoy 
[168].  
The synthesis of the bioreceptor should include primary amino groups (Figure 4.20) on 
the loop side for further attachment onto an activated surface.  
The DNA was dissolved in pure deionised water in a concentration of 0.1 µM and 
inserted inside a PMMA channel previously treated with Eudragit L100/EtOH (0.01mM) 
and activated by EDC/NHS method. The PMMA cover part was then ready to be inserted 
on its complementary flow cell part. 
 
 
Figure 4.20 The DNA decoy for NF-kB is constituted by the 20 bases surrounded by the dotted line and 
functional amino groups on the loop side.  
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The immobilisation of NF-kB decoy was carried out for 30 minutes at a flow speed of 10 
µl/min. 
Ethanolamine, TRIS or bovine serum albumin (BSA) deactivation treatments were 
compared and the last one was the most effective one.  
After a washing step of 5 minutes with buffer solution, the p50 solution was dissolved in 
binding buffer (10mM HEPES pH=7.9, 50 mM KCl, 0.1M EDTA, 2.5 mM DTT, 10% 
glycerol and 0.05% NP-40) in a concentration of 0.1 µM and inserted in flow for 30 
minutes at speed of 10 µl/min.  
The protein p50/p50 was purchased from Promega, Madison, WI, United States.  
After a washing step for 5 minutes with pure buffer, the red diode laser was turned on and 
ten measurements were captured with an integration time of 10 seconds.  
After 100 seconds the diode laser was turned off and an average spectrum was saved.  
The integral fluorescence area in a range between 650-750 nm was calculated and this 
value represents the background signal due to PMMA autofluorescence.  
Then, an antibody (clone 19) able to bind to p50, was firstly labelled with Cy5, and then 
was inserted at different concentrations in the channel at 10 µl/min for 15 minutes plus 5 
minutes of washing steps with pure buffer.  
After every washing step the measurement was caught integrating the fluorescence area 
between 650-750 nm.    
 
To detect how many sites are available to interact with the heterodimer protein p50/p65 it 
was necessary to quantify the quantity of p50 bound to the DNA decoy. 
Unfortunately the heterodimer protein p50/p65 (our target) is not actually present on the 
biotechnology market so the experiment was performed using the most similar dimer 
protein (p50/p50).  
 
The antibody able to interact with p50 is the clone 19 (C-19), an affinity purified 
polyclonal antibody raised against a peptide mapping at the C-terminus of NF-kB p50 of 
human origin, and was purchased from Santa Cruz Biotechnology, CA, U.S.  
Clone 19 was previously labelled with Cy5 fluorophore in order to match the 
characteristics of the optical system.   
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 4.9 Atomic Force Microscope 
 
The AFM is an extremely accurate technique for measuring and analysing films.  
It uses a very sharp tip attached to a triangle cantilever of 0.2 mm with a laser beam 
positioned on it, so the cantilever reflects the light of the laser which is detected by a 
photo-detector. The tip scans the surface of the sample to be analysed. The interaction 
forces occurring between the tip and the atoms of the scanned sample surface, of the 
order of nano-newtons (nN), promote a deflection of the cantilever where the tip is 
mounted. When there is a change in the surface topography, a change in the cantilever 
deflection is detected by the position of a laser beam. From a scan over the sample 
surface, a bi-dimensional and tri-dimensional image can be obtained (see Figure 4.21).  
 
         
 
 
Figure 4.21 Atomic Force Microscopy. The tip scans the surface of interest and cantilever reflects back the 
laser beam on a photo-detector. All data are collected by computer and converted into an image. 
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 4.10 Langmuir-Blodgett deposition method 
 
Film transfer involves the vertical movement of a solid substrate through the 
monolayer/air interface with the simultaneous control of the surface pressure (Π) that is 
determined by measuring the surface tension with the Wilhelm plate method:                 
Π = γwater - γmonolayer where γwater is the surface tension in absence of a monolayer and 
γmonolayer is the surface tension with the monolayer present (Figure 4.22). 
 
 
 
 
Figure 4.22. The Langmuir-Blodgett method is constituted by a trough and a barrier, made in PTFE 
(Teflon); in the trough the sub-phase is ultra-pure water Milli-Q. The polymer is spread on the water-air 
interface and its surface pressure is controlled by Wilhelm plate. In the interface between air and water the 
polymer molecules orient themselves following hydrophobic and hydrophilic interactions. The up or down 
process is selected depending on hydrophobic or hydrophilic desired modification of the substrate.   
 
 
The surface pressure of the monolayer is controlled by a computer program connected to 
the Wilhelm plate. The instrument pushes the barrier until the desired surface pressure is 
obtained and keeps the surface pressure constant by moving the barrier during the 
deposition process [341].  
For a surface hydrophobic interaction, the deposition of the polymer on the substrate is 
conducted by immersing the chip in the sub-phase. The monolayer attaches to the 
PMMA and is transferred with different surface pressure [342].  
The driving force for rearrangement of molecules on the sub-phase is given by the 
interactions between the hydrophobic chains of Eudragit L100 and PLLA and the 
hydrophilic substrate of PMMA with the formation of hydrogen bonds between them. 
The single most important indicator of the monolayer properties of a material is given by 
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a plot of surface pressure as a function of the area of water surface available to each 
molecule. The isotherm calculated is important to determine the right surface pressure to 
have the layer of molecules in a condensed phase.  
Furthermore with a large surface area the surfactant molecules are widely separated and 
are considered to lie quite flat on the surface [342].  
The interactions between the molecules are small and as a result the monolayer has 
relatively little effect on the sub-phase surface tension. In this position the monolayer can 
be considered as a two dimensional “gas”.  
On compression of the gas state the pressure rises until a two dimensional liquid begins 
to form. The liquid state is often distinguished in a liquid expanded (LE) and a liquid 
condensed (LC) state. In the liquid expanded state the hydrophobic portions are assumed 
to have a more or less random orientation (Figure 4.23).  
In the LC state the monolayer molecules are more closely packed. Further compression 
produces a closely-packed solid (S) or condensed film which is highly incompressible. 
Attempts to compress the solid film further will lead to film collapse: molecules are 
forced out of the monolayer to form agglomerates called micelles [342].  
The highest pressure to which a monolayer can be compressed is called the collapse 
pressure. When this is exceeded, micelles start to form.  
 
 
 
Figure 4.23 Schematic representation of the molecular arrangement in: a) gaseous; b) liquid-expanded LE; 
c) liquid condensed LC; d) solid condensed state. Image source is [342]. 
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5. RESULTS AND DISCUSSION  
 
5.1 pH fluorescence sensing on glass capillary and on PMMA  
 
A suitable transparent substrate was required for the development of the optical sensors.  
A silica glass capillary was firstly used as flow chamber to detect the fluorescence signal 
of dyes dissolved in buffer pH solutions.  
After calibration of the system, the interrogation of fluorescent signals of biological 
solutions was performed using silanisation as immobilisation procedure.  
A disposable chemical compound such as APTES was able to covalent bind the substrate 
on the glass and a pH-sensitive fluorescent molecule on the other side.  
The concentration of the silane was a basilar starting point from an optical and 
mechanical point of view to test the resistance to the continuous flow of buffers, thus 
ensuring a stable and durable signal.  
Different percentages of polymer/solvent content can in fact generate different 
thicknesses of the material deposited on the substrate affecting the intensity of the 
recorded optical signal.  
More generally, the study of several chemical treatments of the substrate and of different 
types of polymer is an essential issue in biosensor chemistry.  
An optimal concentration of the right polymer, a proper deposition of it on the substrate 
and a reproducible method were researched.   
Attachment of fluorescent chemical compounds, such as fluorescein and cyanine 
derivative dyes onto the substrate enabled a direct control of the fluorescence optical 
signal providing information on the stability and reproducibility of the modified layer. 
The fluidic apparatus, consisting in a peristaltic pump with tygon tubes, was interfaced 
with the optical system,  
The optical device enabled the interrogation of a glass capillary through which the 
sample is flowing (Figure 5.1). 
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Figure 5.1 The optical system for the collection of absorbance and fluorescence spectrum. The samples 
flow inside the sensor capillary and are interrogated by means of optical fibres positioned perpendicularly 
to the capillary. Optical data are collected by a spectrophotometer and a photomultiplier tube.     
 
The fluorescein molecule was chosen to test the optical system with a fluorescent dye 
that had been studied already [321-323] and the optical coupling between the capillary 
and the optical fibres was optimised.  
The main objectives were a good separation of the optical signal between the excitation 
and the emission light and a high fluorescence signal. Ideally, the immobilised 
fluorescent layer should be resistant to water flow for several hours giving a constant 
fluorescence signal and avoiding a loss of dye.  
Light scattering and multiple reflections of the excitation radiation, due to the geometry 
of the capillary, can increase significantly the background signal at the photodetector.  
All these issues were considered in the optimisation of the chemical protocols of the 
bioassays and in the integration of the optical setup.   
Another fluorescent dye, a cyanine derivative named Cy5, was used for the experiments. 
The usefulness of long wavelength fluorophores has been shown in numerous 
applications [324-326], mainly in biological analysis, because degradation is 
considerably reduced at higher wavelength and fluorescence of the sample matrix (i.e. 
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intrinsic fluorescence of PMMA) in the visible region is a source of interference. 
Cyanine reagents have been shown to be useful as fluorescent labels for biological 
compounds [326-331]. These dyes are intensively fluorescent and water soluble, 
providing significant advantages over other existing fluorophores. Cy5 dye produces an 
intense signal in the far-red region of the spectrum. Although not recommended for 
visual applications, this dye is ideally suited for detection using CCD cameras, PMT, or 
red-sensitive films [326-331].  
  To test the efficiency of the optical system, fluorescein or cyanine derivatives were 
immobilised on the internal wall of the capillary and the intensity was recorded to 
monitor the resistance of a sensing layer in flow conditions.  
Fluorescence and absorbance spectra were recorded using a spectrophotometer when 
optical fibres were used or by using a photomultiplier tube. Data were recorded by 
Hamamatsu spectrophotometer and analysed with Excel and Origin software’s.  
A Gilson peristaltic pump generated a controlled and stable flow of the samples under 
test. The plastic tubes were made of tygon which is highly inert, extremely flexible and 
commonly used in industrial applications.  
In summary, a double detector system was set up in order to capture both absorption and 
fluorescence signals at the same time. An optical interferential filter was positioned 
between the capillary and the PMT reducing the scattering noise due to the excitation 
source.  
  
 
5.1.2 pH sensing of fluorescein solutions in glass capillary 
 
The light source was a blue led at 490 nm coupled with a BP filter 488 nm. 
The choice of the best arrangement was carried out by performing measurements of 
sodium salt fluorescein dissolved in solvent solutions.  
Different concentrations of fluorescein were dissolved in McIlvaine buffer solution, pH 
8.0 in a range between 10-4 - 10-9 M and measurements in fluorescence were performed 
by means of photomultiplier tube (PMT) connected to a frequency photon counter.  
 
5.1.3 Input filtering  
 
Three different calibration curves were obtained with one low-pass (LP) filter at 480 nm, 
and with two or three of these types of filter in a cascade configuration (Figure 5.2). The 
log of the concentrations of fluorescein are shown on the x axis, while on the y axis are 
 123
shown the log of counts in Hz measured by the frequency counter connected to the PMT. 
The use of three filters resulted in a lower detection limit as aspected; the emission tail, 
due to the light emitting diode source, and the scattering light were almost denied at λ > 
500 nm. The enhancement is more evident in the nanomolar region. 
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Figure 5.2 Comparison between calibration curves using input low pass filters at 480 nm in cascade at the 
input and no filtering in output was applied.   
 
5.1.4 Output filtering 
 
Two different output filters were compared, one high pass (HP) at 546 nm and one band 
pass (BP) at 525 nm. Calibration curves of the fluorescence signal of sodium salt 
fluorescein dissolved in different pH buffers were compared. The difference between the 
red and blue lines is not appreciable, but in order to be sure that interfering light was not 
captured at longer wavelengths, the BP filter 525 nm configuration was selected because 
a lower background noise due to the source was observed (Figure 5.3). 
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Figure 5.3 Comparison between output filters, a high-pass filter at 546 nm (blue) and a band pass filter at 
525 nm (red). These calibration curves were obtained using one entrance filter LP at 480 nm.  
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 5.1.5 Calibration curve  
 
The calibration curve shown in figure 5.4 was obtained in accord with the instrumental 
setup described in Figure 5.1 and with the results in Figure 5.2 and 5.3, adding three input 
low pass (LP) filters in cascade at 480 nm and one output band pass (BP) filter at 525 nm.  
The linear range was considered satisfactory for concentrations between 10-4-10-7 M.  
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Figure 5.4 Calibration curve was obtained with solutions of fluorescein flowing inside a bare glass 
capillary adding three low pass filters (480 nm) at the input and one band pass filter (525 nm) at the output. 
 
This calibration curve represented just the starting point for the sensitivity of the optical 
system and will be subjected to an enhanced improvement through research conducted in 
this thesis.  
 
 
5.2 pH sensor glass capillary 
 
5.2.1 Development of a first optical system for the glass capillary 
 
The silanisation is a chemical procedure well known in sensor chemistry [321-323, 333-
335]. A particular attention was focussed on the covalent attachment of fluorophores 
inside the capillary. The internal surface of the capillary was oxidised by a mixture of 
H2SO4/H2O2. After preliminary trials which took in consideration the type of silane 
(APTMS, APTES), the concentration of the silanes and the temperature of evaporation of 
the solvent, an appropriate silanisation protocol was selected.  
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A solution made of APTES at 30% in EtOH was inserted to fill the entire capillary and 
was dried in oven overnight at 80°C. A solution 10-3 M of the dye dissolved in solvent 
was then inserted in the silanised capillary (Figure 5.5) and was dried overnight at 80°C.  
 
 
Figure 5.5 This image was captured on an optical microscope by digital camera. Left: a bare empty 
capillary as reference (Ø external=1 mm; Ø internal=0.5 mm. Centre: a second empty capillary after 
silanisation overnight in the oven at 80°C. Right: a third empty capillary after the total evaporation of EtOH 
in which fluorescein dye was dissolved.  
 
The light source was a white tungsten lamp coupled with an optical fibre. As previously 
described, the white light was applied perpendicular to the capillary.  
To obtain the absorption measurement, the signal was transported by a second optical 
fibre, in axis with the first one, and signal was collected by a spectrophotometer.  
A third optical fibre, disposed perpendicularly to the capillary and to the other two optical 
fibres, collected the fluorescence signal into a photomultiplier tube.  
 
 
Figure 5.6 Absorbance spectra of the fluorophores FITC (left), FAM-X SE (center), and Cy5 (right) 
molecules immobilized on the internal wall of the capillary. In the case of FITC, the white light was turned 
on and the absorption spectra was collected again after 24 hours of flow, revealing that the loss of dye was 
almost insignificant. Numbers on the plots refers to pH values. 
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 In figure 5.6 absorbance spectras of three different fluorophore dyes (FITC, 5-FAM-X-
SE and Cy5) immobilised in the glass capillary are shown during flow of pH buffers 
using the capillary fibre system.  
To speed up the process, APTES and FITC were then mixed together and few drops of 
the cocktail were deposited by a siringe in the central part of the capillary to localise the 
silanisation. (Figure 5.7) 
 
 
Figure 5.7 Image at the microscope of a controlled silanisation of the substrate using the cocktail made 
with APTES 30% in EtOH and FITC 10-3 M. 
 
The sensor was then inserted and interrogated with the capillary fibre system. The results 
shown in Figure 5.8 were recorded during flow of pH buffers at 10 µl/min demonstrating 
to be in good accord with theory [332]. 
The three LP filters at 480 nm were substituted, in this case, with one BP filter (505 nm). 
The signal output was not filtered to observe the separation between the led peak and the 
fluorescence signal.  
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Figure 5.8 Right: Optical spectra of the sensing layer immobilised on the capillary wall during the flow of 
buffers at 4 different pH values . 
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The contribution of scattered light coming from the source and amplified by the rounded 
geometry of the capillary was studied registering the signal in the case of a bare capillary 
and in the case of a modified fluorescent capillary. (Figure 5.9)     
   
The measurement confirmed that the loss of the dye and the photobleaching effects are 
really limited in a 3 hour experiment, thanks to a good silanisation procedure and to the 
implicit low power light typical for a led source.  
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Figure 5.9 On-line measurement of the light signal of the capillary functionalised with FITC compared to a 
bare one during the flow of buffer pH 8.0. The fluorescence signal contribution is much higher than 
scattering signal deriving from the light source. Loss of dye and photobleaching effect can be considered  
almost irrelevant.  
 
 
The result demonstrated that the contribution deriving from scattered light is about 6%  of 
of the fluorescence one (60 Hz vs 1000 Hz) and represented a significant background 
which could be avoided if a better geometrical separation is engineered. 
 
The contribution of the scattering light can represent an undesired background value, 
especially if low concentrations of fluorescence detection have to be reached. 
  
So, a new optical system was ideated to enhance signal avoiding the contribution derived 
from scattered light.  
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5.2.2 Development of a second optical system for the glass capillary 
 
A second setup for the optical recording of a fluorescence signal is shown in Figure 5.10 
and was developed to improve the optical efficiency by collecting a higher proportion of 
the signal [343]. The idea consisted in to use a capillary as waveguide to collect the 
fluorescence signal separated from the source signal. The setup was studied in order to 
obtain a better geometrical separation between the signal of emission and excitation.  
                
 
Figure 5.10 Left: a blue LED enlighten the capillary with fluorescein immobilized inside. The optical 
system was studied to collect the fluorescence signal geometrically separated from the LED source.  
Right: source-capillary optical setup and guided fluorescence collected by two optical fibres connected to a 
photomultiplier tube and a spectrophotometer.   
 
 
Two fibres were used for the collection of the fluorescence emitted by the immobilised 
layer (Fig. 5.11), using the capillary as waveguide and coupling it with a 
spectrophotometer and a photomultiplier tube simultaneously.  
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Figure 5.11 Left: a photo image in true colour of lateral section of the capillary with fluorescein silanised 
when a buffer pH 8 is flowing inside. Right: 3D-image of the technical particular of the coupling between 
capillary and optical fibres. 
 
 
Tests on the efficiency of the system were carried out with fluorophores (FITC and Cy5) 
covalently immobilised directly on the internal wall of the glass capillary using the 
silanisation process.  
Figure 5.12 shows the results obtained with fluorescein: high intensity fluorescence 
signal was collected during pH buffers flow. The result is impressive in the increase of 
the fluorescence signal and also in the decrease of guided light coming from the source.  
 
 
Figure 5.12 Optical spectra collected with the Ocean Optics spectrometer in the case of fluorescein (FITC) 
immobilised in the glass capillary. The two spectra correspond to buffer at different pH values (4.6 and 8) 
flowing inside the capillary.  
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 Flow of buffer at pH 7.4 was monitored for 25 hours to gain information on the stability 
of the fluorescent layer at physiological pH ranges.  
 
 
Figure 5.13 Optical spectra collected with the Ocean Optics spectrometer in the case of Cy5 immobilised 
in the glass capillary. After 5 hours of buffer flow in the capillary it was possible to observe a decrease of 
the signal of fluorescence due to the loss of not covalently bound Cy5. 
 
After 5 hours, the signal almost stopped to decrease confirming that a deep washing 
procedure was necessary to delete the adsorbed dye rather than the covalently bound. 
In general, the results obtained with the glass capillary were quite good, but the 
reproducibility of the deposited layer in the internal wall was poor.  
This was mainly caused by the geometry of the capillary, in which the evaporation of the 
solvent is particularly difficult and maybe predictable only by complicate mathematical 
models.  
Experiments about the changes in the temperature of silanisation determined the quality 
of the layer: higher is the temperature (>100°C) and lower is the time for the silane to 
attach the glass oxidized surface, because ethanol evaporate too fast.  
On the other side, lower is the temperature (<100°C) and less strong is the covalent 
attachment of the silane in the internal wall of the capillary because evaporation of the 
water does not occur, and this fact cause not proper attachment of the silane.  
A compromise temperature was found keeping the capillary at 80° C for 24 hours; so, the 
silane had enough time to react and water had enough time to evaporate.  
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Anyway, the best solution was found avoiding the central part of the capillary as 
deposition location of the silane trying to cause the solvent evaporation on one exit side 
of the capillary.   
Eventually, an occluded part can form inside the capillary; this was handily broken 
leaving an integral side able to couple with the optical fibres for the detection of 
fluorescence [344].  
All these troubles suggested starting thinking about a different substrate, based on 
transparent PMMA, which was considered as an alternative to the glass capillary.  
 
5.3 Anisotropic emission on PMMA 
 
Experiments were carried out in order to study the anisotropy of the fluorescence emitted 
by an immobilised layer of dyes on the PMMA.  
The anisotropy of electric dipoles (excited fluorophores), when the distance from a 
dielectric interface is comparable with the emitted wavelength, is a well known 
phenomenon [345-347].  
Therefore, an analysis of the preferential directions of the emitted fluorescence was 
carried out, with a mixture of FITC/Eudragit RL 100 dropped on the PMMA cover, to 
study anisotropic emission on a PMMA-water interface (Figure 5.14) under flow at pH 8 
buffer.  
Both the fluorescence emitted light at 539 nm and the scattered signal at 488 nm, coming 
from the source, were measured by means of a collecting fibre positioned at different 
angles respect to the flow direction. 
 
 
Figure 5.14 The fluorescence emission is reported in Figure a), while the efficiency, i.e. the ratio of the 
fluorescence and the scattered signal, is reported in Figure b).  Optical optimisation of the setup for small 
planar squares is reported in Figure c). 
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Data were collected every 5 degree angle. From these results it was possible to optimize 
the detected signal by choosing a collection angle of 50°, as shown in Figure 5.17.  
It is important to note that the collection of the fluorescence at 50° angle implies an 
amplification of roughly one order of magnitude in the ratio between the fluorescence 
signal and the scattered light.  
  
 
5.4 pH sensor in PMMA chip 
 
An initial characterisation of the optical multi-channel chip was carried out by 
immobilising a pH sensing layer on the PMMA cover.  
Solutions of FITC/EtOH (1 mM) and Eudragit RL100/EtOH (0.1 mM) were mixed 1:1; 
few drops of the cocktail formed a stable fluorescent layer sensible to the change in pH of 
buffered solutions flowing inside (Figure 4.15).  
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Figure 5.15 Response of absorbance and fluorescence with time for a pH sensor based on Eudragit RL100 
and FITC immobilised on a microchannel of the PMMA chip under flow of buffers at different pH values. 
Both fluorescence signal at 525 nm (green line) and absorption signal at 488 nm (blue line) are shown.  
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The fluorescence signal and the source signal were monitored during a flow of pH buffer 
(Figure 5.15). The decrease in absorbance at 488 nm (in blue) reflects the increase of the 
fluorescence signal at 525 nm (in green) as expected from literature [348].  
The pH change depends from the characteristics of the fluorophore dye and this result 
reflects exactly what is known in literature about fluorescein [349].  
This result was really satisfactory because demonstrated clearly the capability of the 
optical chip in terms of sensitivity to the analyte in solution, good detection efficiency, 
fast response time, and honest reproducibility.  
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5.5 Development of a new optical biosensing platform for IgG/anti-IgG  
 
The potentiality of the PMMA chip, its ease of use and its convenient geometrical 
configuration for a simple replacement encouraged a depth examination.  
The validation of a prototype for affinity biosensors necessitated a study on how 
interactions between antigen and antibody are occurring on the PMMA substrate.  
For this purpose, inexpensive proteins (IgG and anti-IgG) were selected and purchased 
for a deep investigation.            
The research key step consisted in to find the best arrangement in terms of physics and 
chemistry, in order to obtain an immunosensor based on mouse IgG (bioreceptors) and 
goat antimouse IgG labelled Cy5 (analytes).  
The plan strategy involved the modification of PMMA surface in order to obtain the most 
effective deposition of carboxylic groups. This choice was preferred in order to obtain 
mainly the covalent bond between amino groups of the variable region of IgG 
bioreceptors [131]. This treatment was carried out to achieve an entrapment of 
fluorescent antigens close to the surface where the outcome of the fluorescent light is 
guided in a  more effective manner.   
Small squares of PMMA were used as planar substrates in order to identify the best 
immobilisation procedure. 
Polymer depositions of PLLA [336] or Eudragit L100 [362] were compared with surface 
treatments (NaOH in dmso/water or pyridine/water) to obtain exposed carboxyl groups.  
Immobilisation of an excess quantity of mouse-IgG (50 µl drop, 1 mg/ml) was carried out 
via EDC/NHS [Pierce], and its interaction with a concentrated solution of antimouse-
IgG-Cy5 in PBS buffer was analysed.  
An optical setup similar to the one shown in figure 5.14c was used.  
The result in the anisotropic angle using Cy5 was in agreement with the one using 
fluorescein so the optical fibre at the output was interfaced with one lateral side of the 
planar square with an angle of 50° (Figure 5.16). 
A diode laser at 635 nm was preferred to the led source and no filter was added between 
the source and the PMMA substrate.   
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Figure 5.16 The source, a diode laser He/Ne at 635 nm, is perpendicularly directed on a PMMA square 
surface on which mouse IgG were immobilised. Their interactions with a solution of antiIgG-Cy5 were 
considered and studied. The emission signal in fluorescence is guided through the channel and collected 
using an optical fibre and a spectrophotometer.  
 
The red laser diode source was driven by a current of 30 mA and the Ocean Optics 
spectrometer was adjusted with an integration time of 5000 msec.  
The choice of the source at 635 nm, where the excitation efficiency of Cy5 is roughly 
65%, follows the criterion of achieving a good separation between the excitation and 
emission wavelengths used. 
Figure 5.17 shows a typical optical spectrum of the PMMA small squares treated with a 
polymer such as PLLA, with a concentration that ranged from 0.01 mM to 10 mM. 
 
Figure 5.17 Optical spectra of the PMMA small squares treated with a PLLA concentration ranging from 
0.01 mM to 10 mM; then EDC/NHS in MES 0.1 M and 50 µl of IgG (1mg/ml) to immobilise the antibodies 
for antiIgG-Cy5 revelation in flow. PBS buffer was used to rinse step by step. The measurement was 
performed with the optical setup shown in Figure 4.16. The contributions coming directly from the source 
(centred at 640 nm) and from the sensing layer (λ>650 nm) are shown.  
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The results are summarised in the histogram shown in Figure 5.18, in which the columns 
were obtained by evaluating the integral of the fluorescence spectra between 650-750 nm. 
 
0
100000
200000
300000
400000
500000
600000
10 1 0,1 0,01
PLLA (mM)
Em
itt
ed
 fl
uo
re
sc
en
ce
 (a
.u
.)
 
Figure 5.18 Histogram of the emitted fluorescence of the small squares treated with PLLA at different 
concentrations (10-0.01 mM) evaluated by considering the area of the collected spectra shown in Figure 
4.17 between 650 nm and 750 nm. The error bar gives the standard deviation on three measurements 
performed on three different squares. 
 
The error bar was the standard deviation of three measurements made on three different 
squares. As can be seen from the histogram, the concentration of carboxylic groups on 
the PMMA surface was a critical value: the measured fluorescence increased with a 
decrease in the PLLA concentration, i.e. with a decrease in the COOH concentrations on 
the PMMA surface. This can be easily explained by the fact that an overly large 
concentration of exposed functional groups led to an excessive and disordered 
immobilisation of IgG molecules.  
The consequent steric hindrance and interaction among the IgG themselves implied a 
lower affinity toward the labelled anti-IgG. Moreover, a thick polymer substrate turn out 
to be non convenient, resulting in a wide separation between the sensing layer and the 
substrate resulting in a non appropriate optical coupling on a nano meter scale.      
On the other hand, it was reasonable to wait for a decrease of fluorescence if the COOH 
concentration decreased too much.  
This was observed in the case of the treatment of the PMMA surface with Eudragit L100. 
Figure 5.19 shows the histogram for six different concentrations of Eudragit L100. The 
trend was the same as the one observed for PLLA: by decreasing the concentration of 
Eudragit, an increase of the detected fluorescence was observed. However, a further 
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decrease beyond 0.01 mM implied a decrease in the detected signal, showing that the 
optimum concentration of Eudragit L100 on the PMMA surface was 0.01 mM.  
0
50000
100000
150000
200000
250000
300000
350000
400000
100 10 1 0,1 0,01 0,001
Eudragit L100 (mM)
Em
itt
ed
 fl
uo
re
sc
en
ce
 (a
.u
.)
 
Figure 5.19 Histogram of the emitted fluorescence of the small squares treated with Eudragit L100 at 
different concentrations (100-0.001 mM), evaluated by considering the area of the collected spectra 
between 650 nm and 750 nm. The error bar gives the standard deviation of three measurements performed 
on three different squares. 
 
The results obtained with NaOH are summarised in Figure 5.20. The treatment with 
NaOH in pure water was not very effective. Better results were obtained with NaOH 
dissolved in a 1:1 mixture of water and DMSO since this increased the wetting ability of 
the PMMA and implies a better interaction of the solution with surface. 
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Figure 5.20 Histogram of the emitted fluorescence of the small squares treated with NaOH 2M in H2O and 
with NaOH 2M in a 1:1 mixture of water and DMSO, evaluated by considering the area of the collected 
spectra between 650 nm and 750 nm. The error bars give the standard deviation of three measurements 
performed on three different squares. 
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The results obtained with pyridin/H20 treatment at different ratio (1:1 and 95:5) and for 
different minutes (5, 20, 30 minutes) of drop deposition are summarized in Figure 5.21. 
The best chemical treatment in this case was found to be a mixture 1:1 for 30 minutes of 
deposition. However, the treated surface showed a lost in transparency and the formation 
of a thin white layer on the top of the surface, probably due to the aggressive action of 
pyridine. This was sufficient to enhance the scattering signal causing a large decrease in 
the signal to noise ratio. For this main reason the pyridine/water treatment was excluded 
from further analysis.   
 
Figure 5.21 Histogram of the emitted fluorescence of the small squares treated with NaOH 2M in H2O and 
with NaOH 2M in a 1:1 mixture of water and DMSO, evaluated by considering the area of the collected 
spectra between 650 nm and 750 nm. The error bars give the standard deviation of three measurements 
performed on three different squares. 
 
The non-specific binding of labelled anti-IgG on the treated PMMA was tested by 
carrying out a one-hour incubation with the labelled anti-IgG on small squares with the 
immobilised IgG (specific binding) and on small squares with only activated carboxylic 
groups without immobilised IgG (non specific binding). In this second case, the 
unreacted carboxyl groups were treated with tris-HCl 0.2 M, pH 7.5 in order to block the 
activated surface for covalent immobilisation. After the incubation, the small squares 
were rinsed abundantly with PBS and the fluorescence spectra were collected. These tests 
were performed on small squares treated with Eudragit L100 (0.01 mM), PLLA (0.01 
mM) and NaOH 2M (in 1:1 water/DMSO mixture) and the resulting fluorescence spectra 
are shown in Figure 5.22 a) b) and c), respectively. In all the cases, the non-specific 
binding was negligible, with the best performance exhibited by the surface treated with 
Eudragit L100. In these experiments, the contribution coming from the source was 
filtered using the HP filter (cut-on at 650 nm) with the consequent almost total removal 
of the source peak. 
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Fig. 5.22 Fluorescence spectra of the PMMA small squares treated with: a) Eudragit L100 0.01 mM, b) 
PLLA 0.01 mM, c) NaOH 2M (in 1:1 H2O/DMSO mixture), and with (black spectrum) and without (grey 
spectrum) immobilised IgG, after 1-hour incubation with the labelled antiIgG-Cy5. Measurements were 
carried out with the optical set up shown in Figure 4.16 with the addiction of an HP filter cut on at 650 nm 
which decrease almost totally the source peak at 640 nm.   
 
 
5.6 IgG/anti-IgG sensor in PMMA biochip  
 
The sensitivity of the PMMA multiarray biochip was tested for a IgG/anti-IgG 
immunoassay with an optical system (Figure 5.23) built around the chip as first 
prototype. 
 
Figure 5.23 Optical setup for the PMMA multi-channel biochip. Top right is shown the detail of the 
coupling between the biochip, the diode laser and the optical fibre.  
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From the previous results, Eudragit L100 0.01 mM demonstrated to be the optimal 
concentration of polymer for IgG immobilisation.   
In order to identify the optimal concentration of IgG for the sensing layer on the PMMA 
chip, three different IgG concentrations (0.005-0.05-0.5 mg/ml) were deposited on the 
chip. After one-hour incubation with 0.1 mg/ml of labelled anti-mouse-IgG, the chip was 
interrogated with the optical configuration shown in Figure 5.23, without the cylindrical 
lens and the input BP filter at 635 nm. The results obtained are shown in Figure 5.24. The 
fluorescence signal was centred at 670 nm, whereas the peak was around 655 nm due to 
the contribution coming directly from the source as a result of scattering. 
 
 
 
Figure 5.24. Optical intensity detected with the PMMA chip in the case of three different mouse IgG 
concentrations used for the formation of the sensing layer. The signal was recorded after 1-hour incubation 
with 0.1 mg/ml of labelled anti-IgG. 
 
Although the signal levels and the efficiency of the fluorescence collection are low, the 
results shown in Figure 5.24 give a clear indication that 0.05 mg/ml was the optimal 
concentration of IgG to cover the PMMA surface. The reason for the low signal levels 
obtained with the PMMA chip compared with the small squares, is due to two main 
factors: 
1)  The different dimension of the luminous spot used to produce fluorescence; in the 
case of the small squares, the surface carrying the labelled anti-IgG was almost the whole 
surface of the square (1 cm2) whereas in the case of the channel in the PMMA chip this 
surface was limited by the dimension of the flow channel. Since the lateral dimension of 
the flow channel was 0.5 mm, the illuminated surface usefully producing fluorescence 
can be estimated to be in the range of 0.05 cm2.  
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2) The labelled anti-IgG concentration used in the experiments shown in Figure 5.24 was 
0.1 mg/ml, ten times smaller than the concentration used in the chip experiments (Figure 
5.17-5.22).  
 
The optical efficiency of the system was improved by positioning a cylindrical lens on 
the top of the PMMA chip in correspondence with the sensing layer, which allowed the 
LD beam to be focussed on the immobilised sensing layer. Also the contribution from the 
scattered light coming from the source, represented by the peak at 655 nm, was 
noticeably reduced by placing the BP filter at 635 nm in front of the source. A further 
improvement in sensitivity was obtained by replacing the Ocean Optics spectrometer 
(based on CMOS technology) with an Hamamatsu spectrometer integrated with back-
thinned type CCD image sensor.  
The response of both the spectrometers to the optical signal coming from the same chip is 
reported in Figure 5.25, demonstrating a signal to noise ratio (SNR) improvement of 
about two orders of magnitude (difference in sensitivity between CMOS and CCD). 
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Figure 5.25 Response to the same optical signal of the Ocean Optics (left) based on CMOS technology, 
and the Hamamatsu (right) spectrometer based on CCD technology. The Hamamatsu SNR is about two 
orders of magnitude better. 
 
On the basis of the results shown in Figure 5.24, the IgG/anti-IgG assay was then carried 
out by immobilising IgG 0.05 mg/ml on the PMMA chip, previously treated with either 
Eudragit L100 0.01 mM or PLLA 0.01 mM or NaOH 2M in DMSO/H2O. The level of 
the improvement in the optical efficiency can be appreciated in Figure 5.26, which shows 
the fluorescence spectra in the case of treatment with Eudragit L100, for different 
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concentration of labelled anti-IgG (the spectra should be compared with those shown in 
Figure 5.24).  
 
 
Figure 5.26 Optical spectra coming from the PMMA chip in the case of treatment with Eudragit L100, for 
different concentration of antiIgG-Cy5 The flow chamber is one channel of the PMMA biochip. The source 
is red diode laser. One filter at the input (BP-640) and a second filter at the output (HP >650) were applied 
to the optical system. The incubation time for each measurement was 15 minutes. The measurement was 
collected after 5 minutes more of buffer flow to exclude the presence of any aspecific interaction between 
antiIgG and the surface rich in IgG receptors. Every measurement is the average of ten spectra captured in a 
session of two minutes. 
 
The measurements were carried out under flowing conditions at 10 µl/min. It is also 
important to stress the fact that in this case the incubation time (flow of anti-IgG) was 
reduced to 15 minutes. This is a very important parameter in the design and development 
of clinical assays, especially those for point-of-care applications, where reduction of the 
duration of the assay is an essential requirement. The spectra were recorded after washing 
for 5 minutes with PBS. Each spectrum is the average of ten spectra acquired with an 
integration time of 10 sec. It is important to observe the presence of a fluorescence signal 
also in the case of PBS buffer alone, without any labelled molecules bound to the IgG 
layer. The spectrum in this case overlaps with the 0.001 µg/ml spectrum, shown in Figure 
5.26, and this spectrum represents the zero for this series of measurements. This effect is 
due to the autofluorescence of PMMA, which implies the presence of an intrinsic 
background in the detected signals. It is important to stress the fact that the PMMA, if 
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produced by injection moulding, is characterised by low autofluorescence, when excited 
in the red region [350]. In our case the provider of PMMA was unable to give this 
information. Figure 5.27 shows the calibration curves for IgG/anti-IgG assay in the three 
different cases: PMMA treatment with NaOH, Eudragit L100 and PLLA.  
The fitting of the experimental points with a sigmoid curve is also shown. The 
contribution of the PMMA autofluorescence to the fluorescence signal was ignored, 
considering that the value obtained using pure PBS sample was equal to zero. 
 
 
Fig. 5.27 Calibration curves of the IgG/anti-IgG assay for the three different treatments of the PMMA 
surface. The horizontal lines represent three times (dashed line) and ten times (solid line) the highest value 
of the standard deviation calculated for the different points for the curve related to Eudragit L100.  
 
The integral between 650 and 750 nm of each spectra was evaluated and each point of the 
graph was obtained by calculating the average value of a total of ten recorded spectra. 
The standard deviation for each point is also shown and is in the range of the dimension 
of the points. The best performance was obtained with Eudragit L100. In this case the 
limit of detection and the limit of quantification were evaluated: the horizontal lines 
shown in Figure 5.27 represent three times (dashed line) and ten times (solid line) the 
highest value of the standard deviation calculated for the different points for the curve 
related to Eudragit L100.  
The intercept of the calibration curve gives the limit of detection, 0.05 µg/ml, and the 
limit of quantification was 0.2 µg/ml for the IgG/anti-IgG assay. 
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5.6.1 Potential improvements in the optical efficiency of the PMMA biochip 
 
Further improvements could be obtained by minimisation of the background noise of 
PMMA due to autofluorescence. Two different types of transparent PMMA derivatives 
(Topas and Zeonex) were compared to the one used above. The results shown in Figure 
5.28 demonstrated that Zeonex is the minor autofluorescent material and should be used 
to fabricate the chip. 
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Figure 5.28 Excitation source is 635 nm. Comparison between optical spectra for three different type of 
transparent PMMA polymers.  
 
Another potential improvement could be obtained by using chemical vapour deposition 
of aluminium and silver on one of the two angular sides of the PMMA biochip. The result 
for a bare mirror channel was compared to a normal chip channel (in water) is shown in 
Figure 5.29. The experiment demonstrated that more fluorescence signal (in this case the 
autofluorescence of PMMA) could be collected to improve the optical efficiency.  
 
 
Figure 5.29 Comparison between a normal PMMA cover and a mirror PMMA cover. Excitation source 
was at 635 nm. The autofluorescence of PMMA (λ >650 nm) increases evidently with the addition of a 
micromirror on the second side of the channel. This micromirror was obtained by chemical vapour 
deposition of several layers made of aluminium and silver. 
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5.7 A biosensor for NF-kB1: A study of interactions by means of fluorescence 
between DNA kB site, p50 homodimer and antibody C19-Cy5 in a sandwich assay  
 
 
An exhaustive introduction about the importance to detect NF-kB in nuclear cell extracts 
is fully explained in the Introduction of this thesis. 
The optical system used for these experiments regarded the one used for PMMA multi-
channel biochip shown in Figure 5.23.  
The DNA sequence (kB site) specific for NF-kB detection possess amino group on its 
loop as shown in Figure 5.30 and it was synthesized in the laboratories of IFC-CNR in 
Pisa.  
 
   
Fig. 5.30 NF-kB decoy, the DNA sequence able to capture the target protein. A specific ssDNA sequence 
was synthesised with a loop part modified with primary amino groups. In the complementary part the DNA 
bend on itself in a dsDNA configuration. 
  
 
The DNA was dissolved in pure deionised water in a concentration of 0.1µM and then 
inserted into a PMMA channel previously treated with Eudragit L100/EtOH (0.01mM) 
and activated with EDC/NHS activation. The immobilisation of NF-kB decoy was carried 
out at a constant flow speed of 10 µl/min for 30 minutes. Ethanolamine was used, after 
DNA, to deactivate the surface and to avoid further undesirable covalent binding.  
The unreacted ethanolamine was removed by washing for five minutes with the binding 
buffer for p50 (binding buffer: 10mM HEPES pH=7.9, 50 mM KCl, 0.1M EDTA, 2.5 
mM DTT, 10% glycerol and 0.05% NP-40).  
The p50 solution was dissolved in binding buffer in a concentration of 0.1 µM and was 
inserted for 30 minutes in the channel where interaction between DNA and p50 was 
expected. PBS was used to wash out in flow for 5 minutes the unreacted p50, then the 
signal was recorded (PMMA autofluorescence signal).  
A specific antibody for p50 detection, called clone 19 (C19), was labelled with Cy5, and 
then was inserted in flow in the channel in a concentration of 0.1 µM for 15 minutes at 10 
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µl/min; then the channel was washed for 5 minutes with PBS and the signal was recorded 
(Figure 5.31). 
 
     
Figure 5.31 Left: optical spectra. Right: fluorescence area in the range 650-750 nm. The autofluorescence 
of PMMA is represented with light blue colour. The interaction between the p50 bound to DNA and the 
antibody specific for p50 is represented with red colour.  
 
A control experiment was carried out to ensure the antibody C19-Cy5 is binding only at 
p50 sites and is not adsorbed (aspecific binding) to the surface. A channel was prepared 
with the same procedure but, after DNA immobilisation, the p50 protein was not added. 
Then the C19-Cy5 was added to determine if it binds to the surface where DNA is 
immobilised. The result obtained (Figure 5.32) was not satisfactory because in this case 
p50 is not inside the channel, so C19-Cy5 must not bind to anything.   
 
  
Figure 5.32 Left: Optical spectra. Right: fluorescence area is in the range 650-750 nm. The 
autofluorescence of PMMA is represented with light blue colour. The interaction between the surface (with 
DNA immobilised) and the antibody specific for p50 is represented with red colour. The difference 
between these two areas had to be zero to ensure that C19-Cy5 interact just with p50 and not with the 
surface. This is not the case. This result demonstrate that C19-Cy5 interact with the surface and means that 
something wrong is occurring inside the channel.  
 
This result means that antibody C19-Cy5 binds not only to p50 but also non specifically, 
in part or totally, to the free sites of the PMMA.    
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To avoid aspecific binding of the fluorescent antibody (C19-Cy5) on the PMMA surface, 
the use of bovine serum albumin (BSA), reported in the literature [353], was considered. 
 A solution of BSA in PBS at 10% (w/v) was prepared to cover all the free sites of the 
channel and to avoid aspecific binding of proteins to the surface.  
The same protocol described before was repeated and besides ethanolamine, BSA was 
used. The result obtained for BSA treatment was satisfactory (Figure 5.33).   
BSA protein inactivate all the free sites present on the PMMA surface and avoid  
aspecific binding of C19-Cy5 antibody to the surface. 
        
 
Figure 5.33 Left: Optical spectra. Right: fluorescence area in the range 650-750 nm. The autofluorescence 
of PMMA is represented with light blue colour. The interaction between the surface and the antibody 
specific for p50 is represented with red colour. The difference between these two areas had to be zero to 
ensure that C19-Cy5 interact just with p50. This is the right case. Aspecific binding of C19-Cy5 was 
avoided using BSA besides ethanolamine in the pre-treatment inactivation of the surface. 
 
Inactivation of the surface with BSA 10% (w/v) in PBS was carried out and the first 
experiment using p50 was repeated. The signal of C19-Cy5 resulted now specific for p50 
detection bound to the DNA decoy and the experiment result shown in Figure 5.34 was 
considered successful.  
 
Figure 5.34. Left: Optical spectra. Right: fluorescence area in the range 650-750 nm. The autofluorescence 
of PMMA is represented with light blue colour. The interaction between the sensing surface and the 
antibody specific for p50 is represented with red colour. The difference between these two areas is 
proportional to the quantity of p50 present inside the channel. 
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 5.7.1 Regeneration by SDS 
 
Regeneration of the sensing surface is highly desirable for a biosensor system.  
This was achieved by flowing SDS 10% for 20 minutes. The complex DNA/p50 + C19-
Cy5 was washed with SDS and the signal decreased because all the proteins were washed 
out (p50 and C19-Cy5). SDS tightly binds to proteins and washes those, but not DNA 
which is imperturbable by SDS treatment [354]; the decoy for NF-kB was regenerated by 
this method and the measurement with p50 and C19-Cy5 was repeated again (Fig. 5.35). 
 
Figure 5.35 Regeneration of the biosensor with SDS (10%). Left: Optical spectra. Right: fluorescence area 
in the range 650-750 nm. The autofluorescence of PMMA is represented with light blue colour. The 
interaction between the sensing surface and the antibody specific for p50 is represented with red colour. 
The difference between these two areas is proportional to the quantity of p50 and C19-Cy5 washed inside 
the channel. 
 
The regenerated biosensor was used a second time to reveal different quantities of p50; 
two treatments with different concentrations of p50 (0.01 µM and 0.1 µM) were tested.  
The concentration of C19-Cy5 in this case was kept constant (0.1 µM).  
 
Fig. 5.36 Detection of two different concentrations of p50 (0.01 µM, 0.1 µM) using C19-Cy5 (antibody 
specific for p50). Left: Optical spectra. Right: fluorescence area in the range 650-750 nm. The 
autofluorescence of PMMA is represented with light blue colour. The interaction between the sensing 
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surface and the antibody specific for p50 at different concentrations is represented with red colour. The 
difference between these two areas is proportional to the quantity of p50 present inside the channel. 
 
The results shown in Figure 5.36 reveal that for more concentrated solution the 
fluorescence increased as expected, because C19-Cy5 bind to more accessible p50  bound 
to the DNA decoy.  
The interaction between DNA and NF-kB p50/p50 is reported in literature [175, 176] and 
is considered biologically as the precursor step for NF-kB p50/p65 revelation.  
As it was plenty described in the introduction, although most of the NF-kB proteins are 
transcriptionally active, some combinations are thought to act as inactive complexes.  
P50/p65, p50/c-Rel, p65/p65, and p65/c-Rel are all transcriptionally active, whereas p50 
homodimer (the one used in these experiments) and p52 homodimer repress transcription 
[174]. It is important to notice also that stimulation of cells with agents that activate NF-
kB causes an increase in the p50/p65 content [181]. 
It is also known from theory that p50/p65 binds more tightly to DNA decoy replacing 
p50/p50 [173, 176]. 
So a future plan for the research to obtain a NF-kB biosensor is to insert in the channel 
with DNA decoy immobilised, the active heterodimer p50/p65, and calibrate the system 
with it using C19-Cy5 antibody which demonstrated to be trusty and reliable for the 
detection of p50. 
Another future plan in the research to obtain a NF-kB biosensor is to insert p50/p65 in the 
channel with DNA immobilised and with p50/p50 bound to it, in order to determine the 
replacement of p50/p50 by p50/p65. This shift could be measured using C19-Cy5, 
pointing out that the fluorescence signal should decrease of half in the case of p50/p65 
compared to p50/p50, just because this heterodimer contains half quantity of p50.  
Unfortunately the heterodimer protein p50/p65 is not freely available in the market, so it 
will be necessary to synthesise or to extract it biologically in order to perform a 
calibration curve for this protein.  
In literature is present only one work about detection by fluorescence of p50 homodimer 
bound to DNA [168], and in that case FRET (Forster Resonance Energy Transfer) 
method was employed, using a fluorescent compound for DNA labelling and a quencher 
(that absorbs the emission at the same wavelength) compound for p50 labelling.  
Anyway, also in this case, was not possible to detect the p50/p65, but only p50/p50 for 
the same reason explained before (unavailability of p50/p65 on the market).  
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5.8 Biosensor for MGMT: A study of interactions by means of fluorescence between 
target RNA and synthetic 2’OMe-RNA probes covalently bound on PMMA 
 
In order to attach thiol-modified 2’OMe-RNA probes using the SMCC cross-linker, it 
was necessary to obtain amino groups on the PMMA surface. 
Quantification of amino groups obtained by several chemical treatments on the surface 
was performed using a sulfo-SDTB [351-352] which reacts with amino groups releasing, 
in perchloric acid, the dimethoxytrityl dye molecule (absorbance at 498 nm).  
The different treatments considered are reported as follows: 
b) Drop deposition of Eudragit L100 (x2);  
b,c,d) acid hydrolysis of ester groups on PMMA (H2SO4 3M; H2SO4 1M; HCl 1M)  
e,f) alkaline hydrolysis of ester groups (NaOH 4M; NaOH 1M) with PMMA planar 
square immersed in the solution for 3 h.  
g) PMMA chip immersed in HMDA 1M in DMSO;  
h) Drop deposition of HMDA 1M in DMSO (x2).  
i) bare PMMA; 
In Figure 5.37 is shown the calibration curve obtained with s-SDTB.  
 
 
Figure 5.37 s-SDTB calibration curve was obtained measuring absorbance at 498 nm for different 
concentrations of the released dye after perchloric acid treatment. 
 
In Figure 5.38 the results in the surface density of amino groups, obtained measuring the 
absorbance spectra at this wavelength with a spectrophotometer, was reported: a) and h) 
were the most efficient treatments, and the drop method was preferred to the immersion 
method. In particular, the treatment with Eudragit L100 was chosen for the 
immobilisation of the RNA oligonucleotide by means of SMCC cross-linking.  
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Figure 5.38 Surface density (in nmol/cm2) of amino groups bound to the surface. The drop method offered 
better performance compared to the immersion method. In the case of the drop method the area considered 
was one face of the PMMA chip. In the case of immersed method the total surface area of the volumetric 
PMMA chip was considered. Buffer for SDTB was NaHCO3 at pH 8.5. 
 
 
A further control experiment was performed to be sure of no interaction between Cy5 and 
bare PMMA and to understand the entity of the fluorescence signal in the case of HMDA 
treatment of the surface. In this case HMDA acts as a crosslinker between bare PMMA 
and Cy5 dye. Two different planar squares were prepared with a solution of Eudragit 
L100/EtOH (0.01 mM); 50 µl of this solution was dropped on the surface and let dry at 
25°C.  In the first planar square a solution of HMDA 100 mM in DMSO was dropped to 
the surface. After 1 hour this was washed with pure water and a solution of Cy5 in DMF 
(0.1 mM) was dropped on the surface, reacted for 30 minutes and then washed with 
water. In the second planar square (control with no HMDA) a solution of Cy5 0.1 mM 
was dropped directly on the surface treated with Eudragit L100 and washed with pure 
water after 30 minutes. The results in Figure 5.39 demonstrated that if HMDA was 
deposited, Cy5 reacted with it; if amino groups were not present (no HMDA), Cy5 did 
not bind to the surface. The result was clearly evident without filtering of the source. 
 
Figure 5.39 Signal of fluorescence of Cy5 covalently bound to exposed amino groups of the PMMA chip.   
The excitation source was a red diode laser at 635 nm. 
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 5.8.1 MGMT: Results for Target 7/Probe 7 RNA/RNA duplex  
 
The next step aimed to immobilise a thiol-modified RNA, by means of SMCC cross-
linking action. The immobilized bioreceptor RNA probes were as follows:  
         Probe 7: 5’-GUGCGUUUCAUUUCACAAUCCUUGU-3’ 
         Characteristics:  2’OMe, SH at 3’, conc. 0.1mM. 
Probe 7’ mismatched:  5’-GUGCGUAUCAUUGCACAAGCCUUGU-3’ 
Characteristics: 2’OMe, SH at 3’, conc. 0.1mM. 
The RNA target 7 is complementary to probe 7:  
Target 7 (7*):  3’-CACGCAAAGUAAAGUGUUAGGAACA-5’ 
 Characteristics: 2’OMe, FITC-labelled, conc. 0.1mM. 
2’-O-methyl-RNA probes (7 and 7’) were spotted on two PMMA planar squares of 1 cm2 
pre-treated with Eudragit L100/EtOH, HDMA/DMSO, SMCC and washed step by step 
with PBS buffer.  
The immobilised bioreceptors were the probe 7, a sequence complementary to the target 
7*, and the probe 7’, a mismatched sequence with three nucleotides of difference to the 
probe 7 (evidenced in bold). Target 7* was labelled with FITC fluorophore (Figure 5.40).  
The RNA probes were dissolved in pure water, whereas the RNA targets were dissolved 
in an hybridisation buffer (2X) made of 5 ml of formamide (50%), 5 ml of SSC (10X), 
0.2 ml of  SDS (10%). SSC (20X) buffer was prepared adding NaCl 3 M, sodium citrate 
0.3 M and EDTA 1 mM.    
 
 
Figure 5.40 Procedure to test the detection and the specificity of target 7*. Two probes (7, 7’) were 
immobilised on the planar surface and let react with a solution of target 7*. After hybridisation occurred, 
the planar square were washed accurately with an SDS solution in order to take out the not hybridised 
oligos. The ideal case is shown on the right, where the complementary is attached to the probe whereas the 
non complementary is washed out.  The differences in the bases between the two probes are highlighted on 
the top; anyway both 2’OMe-RNA were modified with a thiol group as functional group for immobilisation 
on the surface.  
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 The led source (490 nm) was not filtered at the input and output, and the signal for 
2’OMe-RNA/RNA duplex (Figure 5.41) was collected.  
Letter “A” represent the interaction between the complementary RNA strands probe 7 
and target 7*, while letter “B” represent the interaction between a mismatched probe 7’ 
and target 7* as it was  reported previously, in Figure 5.40. 
 
 
Figure 5.41 Optical spectra signal for two different planar square on which probe 7 and probe 7’ were 
immobilised. A blue LED 488 nm is the source. Not filters were applied at the input and output. The letter 
A represent the hybridisation for probe 7 and target 7*, whereas the letter B represent the hybridisation (not 
occurring)  for probe 7’ and target 7*. This experiment confirm the proper specificity of probe 7 to target 7. 
 
 
5.8.2 Specificity of the probe 7 to the T7* in a T7*/T46 solution  
 
Further experiments on the specificity of probe 7 were executed by immobilising probes 
7 and probe 46 and observing the interaction with a mixture 1:1 of targets (T7* and T46).  
This experiment was accomplished in order to obtain a sandwich system (probe 7- 
mRNA-probe 46) as it was described in the introduction part.  
Figure 5.42 shows optical spectra obtained for this experiment which was performed to 
understand if the probe 7, in a T7*/T46 solution, interact only with T7* and not with the 
T46. The specificity of the probe 7 to the T7* in a T7*/T46 solution is an essential 
requirement, in order to avoid unwanted cross reactions for the obtainment of a proper 
sandwich construct. Probe 7 represents, in fact, in the strategy plan thought, the first site 
of attachment for the mRNA target, whereas probe 46 represents the second site 
(sandwich locking up).   
Therefore, sixteen PMMA planar squares were investigated by means of fluorescence 
coming from hybridised target 7* using the optical setup shown in Figure 5.14c. Drops of 
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5 µl of three solutions were spread on the PMMA surface pre-treated with cross-linker 
SMCC. The three solutions were probe 7, probe 46, and a mix 1:1 of probe 7 and 46. 
Two kind of carboxylic polymers were compared (PLLA and Eudragit L100) and on all 
the planar squares two different solutions were deposited; 50 µl of T7* in annealing 
buffer solution (1:1) and 50 µl of T7* and T46 (1:1) were let react for two hours.  
The planar squares were then washed abundantly with buffer.  
The optical system was not filtered to understand any variation of the fluorescence signal. 
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Figure 5.42 Left: Optical spectra of the interactions between probe 7 or probe 46 with a mixture 1:1 of 
T7*/T46; Right: Optical spectra of the interactions between probe 7 or probe 46 with a solution 1:1 of 
T7*/buffer. 
 
The results, partially covered by a high signal of noise due to PMMA autofluorescence, 
can be simplified if considered from another perspective (Figure 5.43).  
 
Figure 5.43 Results in fluorescence for bioreceptor probes 7 and 46 immobilised on the PMMA planar 
squares. On the sensing surface two solutions were dropped: as first the target 7*, and as second a mixture 
solution of target 7* and 46 (1:1). Fluorescence area of probe 7 immobilised are shown in light blue colour 
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whereas area of probe 46 immobilised are shown in red colour. On the Y axis is shown the type of polymer 
employed (PLLA or Eudragit L100) and the type of solution adopted (T7/buffer, 1:1 and T7/T46, 1:1). On 
the X axis is shown the intensity of fluorescence due to PMMA and due to the occurred hybridisation.  
 
In particular, in red are shown the area of the fluorescence signals for the probe 7 
immobilised, whereas in light blue are shown the signals for probe 46 immobilised on the 
surface.  
It is important to stress the fact that for this experiment a concentration of T7* (and T46) 
ten times smaller than the previous experiment (Figure 5.41) was used and for this 
reason, the optical signals seems to be not “clean” as usual.  
In future plans will be important to repeat the same experiment filtering the input and 
output signals in order to collect a better spectral resolution.  
The fluorescence signal was calculated considering the area in the range between 515-
585 nm.  
In this area the autofluorescence of PMMA was quite high and so, to understand any 
variation of the fluorescence signal, a vertical line was drawn to separate at the left the 
PMMA autofluorescence contribution and at the right the fluorescence derived by T7* 
binding (Figure 5.46).  
A second horizontal line divides the signals obtained using a mixture of targets (T7 and 
T46) or  a single target (T7).  
Hybridization between probe 7 and T7* was detected in the case of a solution containing 
only T7*. This seems to be in accord with the result obtained in Fig. 5.44.  
In a mixture solution of both targets (T7* and T46) the hybridization between probe 7 
and T7* seems to be partially impeded or disturbed, in particular in the case of PLLA 
polymer. This effect is less relevant in the case of Eudragit L100. 
As described in the introduction part, the probes were chosen from a computational 
method described in literature [318, 320], which was exploited for selecting accessible 
regions of the probes in the human MGMT transcript.  
The program analyses the score of pairing events among the different structures 
nucleotide by nucleotide (the freedom of each nucleotide), considering the probability of 
existence of each structure.  
A set of potential probes for MGMT mRNA were considered and some of the most 
favourable ones were selected as probes for T7 and for T46 detection [320]. 
In a future plan research will be opportune to try the same experiment carried out on 
probe 46 using other kind of probes, such as probe 64 and probe 41.  
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The sequences can be found considering the article reported in literature [320]. 
Unfortunately, in this case, the literature is poor for this argument revealing a certain 
limitation in the comprehension of this argument.         
 
 
5.8.3 Calibration curve probe 7-target 7*  in PMMA chip: 
 
The detection of RNA target 7* was accomplished: so, a calibration curve (Figure 5.44) 
was obtained for the experiments carried out in flow conditions.  
The PMMA substrate of the multi-channel chip was previously modified with Eudragit 
L100/ EtOH (0.01 mM) and then activated with EDC/NHS treatment; 2’OMe-RNA 
(probe 7) was inserted in flow at 10 µl/min of speed for 30 minutes for immobilisation on 
the channel. In this case the immobilisation procedure was simplified using a 2’Ome-
RNA modified with amino groups (probe 7), and the complementary target 7* was 
labelled with Cy5, in order to match the optical characteristics for a red diode laser.   
The target solution was inserted in the channel at flow speed of 10 µl/min for 15 minutes, 
starting from the more diluted solution to the more concentrated one, with intermediate 
washing steps of 5 minutes with buffer. The signal was finally registered after every 
washing step in the spectral region between 650-750 nm.  
The collected spectra signals were recorded as the medium average of ten measurements 
using 10 sec of integration time in a total period of 100 seconds. The area of fluorescence 
was plotted (Figure 5.44) and standard deviations were reported for each point measured. 
 
Figure 5.44. Calibration curve for the detection of RNA target 7* for MGMT using as bioreceptor the 
probe 7. The sensing ability of the bioreceptor used and of the optical chip adopted reaches about 0.5µM as 
low detection limit. The standard deviation error bar is shown for each measurement.  
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5.9 Characterisation of IgG/anti-IgG interactions by means of AFM and anisotropic 
fluorescence using LB method to enhance the sensitivity of the optical biochip 
 
The final part of this thesis is divided in three parts and relates generally to the research 
for the obtainment of an optimised immobilisation of proteins on PMMA:  
- The first study describes the characterization of IgG and anti-IgG covalently bound on 
the PMMA surface by capturing images of the biosensor surface using atomic force 
microscopy (AFM). An implementation of the immobilisation procedure on the PMMA 
chip was obtained using Langmuir-Blodgett (LB) technique on planar surface of PMMA. 
The result obtained on the small square chips was then transferred, using the same 
deposition method, on the multi-channel PMMA chip and compared with the deposition 
method (by micropipette) of the polymer for the IgG/anti-IgG assay.  
- The second study relates to the immobilisation and characterisation of Photosystem II 
(PSII) proteins covalently bound on PMMA chip, using fluorescence measurements and 
AFM.  
- The third study relates to the possibility to scratch the PMMA surface to obtain wells 
with controlled dimensions on a micrometer scale.  
 
 
    5.9.1 AFM imaging for IgG/Anti-IgG immobilised on a PMMA chip  
 
 
Protein immobilisation is a common thread in the obtainment of a proper biosensing layer 
and requires reagents that can guarantee a covalent attachment of antibodies on the 
surface. This fact represents a key step to ensure enough reliability for a biosensor, 
ensuring enough resistance to the dynamic conditions involved in continuous flow 
measurements. For this reason the research pointed to capture images, as first, of 
antibodies immobilised to the PMMA surface and, as second, of antibodies-antigens 
complexes [361].    
The image in Fig. 5.45 shows a first approach to the PMMA surface, cleaned with Triton 
X surfactant (0.1%), composed by long woven filaments of 10 to 50 nm diameters.  
The surface seem to be a reticular net-like structure. This image was captured as control 
sample in order to recognize further biological compounds attached to the surface. 
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Figure 5.45 Bare PMMA. Topography and deflection images of  polymethylmethacrylate surface. AFM 
contact mode. Image size: 28x28 µm.  
 
Several methods for antibody immobilisation on PMMA surface are reported on literature 
including modifications of the substrate with carboxyl or amino groups [356], ultraviolet 
grafting of polymers [357], reactive ion etching by oxygen plasma treatment [358], 
periodate oxidation of PMMA microbeads through hydroxyl groups [359], and coatings 
of this material with gold nanoparticles functionalised with biocomposites [360].  
Here a direct treatment of the surface was carried out using a copolymer of PMMA 
avoiding instrumental techniques (UV, plasma) and expensive (gold nanobeads) or 
dangerous chemicals (oxidizers). Hence, Eudragit L100 was dissolved in ethanol, 0.01 
mM and the polymer was dropped directly onto the surface, waiting for EtOH 
evaporation, and rinsed after few minutes with ultra-pure H2O.  
The substrate was then treated with EDC/s-NHS in order to create stable succinimidyl 
ester groups on the surface.  
These functional groups reacted with primary amino groups to form a covalent bond 
between the surface and the proteins. The protein treatments of the surfaces were 
executed immobilising on two different chips, by drop deposition, mouse IgG (1 mg/ml) 
and mouse IgG/anti-mouse IgG (1 mg/ml), using an incubation time of one hour.  
These chips were washed accurately with PBS, dried with N2 and stored in a Petri dish.  
Captured images of these two chips are shown in Figure 5.46 and 5.47; the two upper 
images represent topography (top view) and deflection (of the cantilever axis) snapshots, 
whereas the lower images provide information on cut section and render a 3D picture of 
the surface. In both images are visible round particles of different diameter size (from 10 
to 100 nm). In Figure 5.46 a particular attention was focalised on a group of four 
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presumptive proteins. Their medium height of 14 nm reflects in fact what is known from 
theory [131].  
 
 
 
Figure 5.46 PMMA, Eudragit L100 and IgG. UP: topography and deflection images. BOTTOM: section 
analysis (12-15 nm) of upper image and 3D view. AFM contact mode. Image size: 12x12 µm. 
 
 
The figure 5.47 depicts some particles similar to the ones described above. In addition to 
those, more large particles are visible on the surface. The cut section reveals the height of 
these in a range between 20 to 28 nm.  
The height of these particles is quite in accord with theory [361], to the height of 
IgG/anti-IgG complex, in which the dimensions of a single immunoglobulin almost 
redouble.  
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Figure 5.47 PMMA, Eudragit L100, IgG and anti-IgG. TOP: topography and deflection images. BOTTOM 
left: cut section of a large complex particle; right: 3D image. AFM contact mode. Image size: 28x28 µm. 
 
 
A second polymer, polylactic-L-acid or PLLA, usually used in bioengineering tissues 
[336], was spread on the PMMA surface.  
On a first chip a solution of PLLA was dissolved in CHCl3 (0.01 mM) in order to create a 
polymeric structure abundant in ester groups.  
The polylactic acid created a thin smooth layer made of ester groups on the PMMA 
surface and is able to react in a  NaOH 2M to form carboxylic groups.  
The surface was then treated with an EDC/s-NHS mixture (50 µl) and a drop of 5 µl of 
IgG (1 mg/ml) was spread on the active surface, and then washed with PBS.  
Figure 5.48 evidenced two zoom images which reveal single protein detection of IgG 
antibodies and their respective cut section.  
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Figure 5.48 PMMA, PLLA and IgG. Middle: images at 30 x 30 nm of two immunoglobulins detected and 
the theoretical structure describing a shape of three balls, perfectly in accord with what is shown. Left, 
right: cut sections of IgG antibodies. AFM contact mode.                                                                
 
On a second PMMA chip treated with PLLA and IgG, a drop of 5 µl of AntiIgG-Cy5 (1 
mg/ml) was allowed to interact with the surface for 1 hour incubation time.  
In figure 5.49 is clear a disordered structure of the polymer in the background (PLLA 
matrix), in which some immunoglobulins are put in evidence inside white circles.  
A particular attention was devoted to the circle line where a more large structure was 
evident.    
 
 
 
 
 
 
 
 
 
 
Figure 5.49 PMMA, PLLA, IgG/anti-IgG. Topography, deflection and friction images. The IgG are white 
circled. The PLLA polymer is evident in the background. AFM contact mode. Image size: 10x10 µm. 
 
 
The presence of an interaction IgG /anti-IgG in a larger structure is quite clear because 
the complex is bigger.  
These clusters are mostly evident in the images reported in Figure 5.50 ere cut section 
analysis was carried out to understand the height of them (almost 30 nm). 
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Figure 5.50 PMMA, PLLA, IgG/anti-IgG. Top: topographic and deflection images. Down: cut sections of 
revealed clusters of IgG/AntiIgG of 30 nm size. AFM contact mode. Image size: 1x1 µm.  
 
 
5.10 Langmuir Blodgett evaluation of the polymer thickness 
 
In order to develop a sensing layer more effective for the immobilisation of IgG 
antibodies, a further experiment was carried out depositing a film of Eudragit L100 on 
the chip surface.  
The sensitivity of the fluorescent layer is extremely dependent on the thickness of the 
polymer, considering that the collected signal, in the case of the PMMA chip, is carried 
out by the guided light coming from the chip itself. On the other side, a deposition of 
PLLA by this method was not suggested because its closed ring structure does not permit 
a controlled deposition method.  
If a previous activation of this polymer with NaOH could partially solve the problem, the 
opened ring structure presents hydrophilic groups on both sides causing a not 
reproducible liquid condensed state, necessary condition for a reproducible film 
formation by LB method. For this reason PLLA deposition was not considered for the 
obtainment of a reproducible layer by LB method.          
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The main aim of this experiment pointed out to study the difference in terms of 
deposition between the drop method and the Langmuir-Blodgett (LB) method; hence, 
three chips were modified using Eudragit L100 polymer.  
Three different surface pressure values (Π = 20, 30, 35 mN/m) were examined to obtain a 
reproducible layer enriched in carboxylic groups.  
The chips were then analysed by means of AFM in order to understand the proper 
thickness of deposition. 
The first deposition (Π = 20 mN/m) produced a polymer thickness of 5 nm.  
The polymer appears to be homogeneous over the PMMA surface (Figure 5.51). On the 
upper image on the right, is visible also the friction image (also called lateral force, or 
lateral deflection image) which provide informations about the strength in tip-sample 
interactions.  
On the bottom images is presented in addition the Abbott curve, which shows the height 
distribution of the surface. Several roughness parameters are deduced from the Abbott 
curve. 
 
 
 
Figure 5.51 PMMA, Eudragit L100 at 20 mN/m. Top: topography, deflection and friction images. Bottom: 
thickness of the polymer (5 nm); Abbott curve; 3D image. AFM contact mode. Image size: 5 x 5 µm. 
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A second picture of the deposited coating is displayed in Figure 5.52. Further two cut 
sections of the film layer confirmed the homogeneity in the thickness of about 5 nm.  
 
 
 
Figure 5.52 PMMA, Eudragit L100 at 20 mN/m. Top: topography deflection and topography again. 
Bottom: left and right cut section views of the thickness; middle: 3D image. AFM contact mode. Image 
size: 12 x 12 µm.  
 
Higher is the surface pressure on a water-layer interface, more compressed is the film of 
polymer, and higher it is the thickness deposited on the surface.    
The second deposition (Π = 30 mN/m) produced a polymer thickness in the range 
between 7-14 nm.  
The polymer appears to be less homogeneous than in the deposition at 20 mN/m.  
In fact in Figure 5.53 and 5.54 is shown an increase (in blue) in the slope of the bearing 
area (roughness of the surface).  
This is demonstrated then by the presence on the surface of several thicknesses, caused 
by a partial overlapping of the condensed films for the enhancement of the surface 
pressure value from 20 to 30 mN/m.  
  
 165
8 nm 
7 nm 
 
 
Figure 5.53 PMMA, Eudragit L100 at 30 mN/m. Top: topography deflection and topography images. 
Bottom: left and right, section views reveal 7-8 nm of thickness; Abbott curve. AFM contact mode. Image 
size: 12 x 12 µm. 
 
 
 
 
Figure 5.54 PMMA, Eudragit L100 at 30 mN/m. Top: topography deflection and topography images. 
Bottom: section views that show 10 nm of thickness. 3D image. Other particles of different size (8, 10, 14 
nm) are shown on the right. AFM contact mode. Image size: 4 x 4 µm. 
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In the third deposition, at higher surface pressure (Π = 35mN/m), the polymer layer was 
lost and a lot of clusters made of overlapped molecules are seen on the surface (Figure 
5.55).  
Too much surface pressure, as expected, caused the collapse of the polymer into bigger 
nanoparticles (20-50 nm) which were neither useful nor reproducible.  
The result shows clearly that the deposition of a monolayer of Eudragit L100 on PMMA 
at this surface pressure is not convenient. 
 
 
Figure 5.55 PMMA, Eudragit L100 at 35 mN/m. Left: topography, deflection and section images of the 
polymer surface deposited on PMMA.Middle: 3D image and Abbott curve. Right: topography, deflection 
and section images of the polymer. AFM contact mode. Image size: 28 x 28 µm. 
 
The results obtained show that the most effective treatments of the surface were at 
20mN/m and 30mN/m.  
Treatment at 20mN/m had the advantage of keeping the sensing layer close to the PMMA 
surface with potentially better coupling of the emitted fluorescence.  
This type of deposition was chosen and transferred on channel of the PMMA cover plate 
of the multi-channel biochip.  
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Therefore the deposition by LB method at 20mN/m was tested with an IgG/Anti-IgG 
assay in order to compare it to the previous results obtained by micropipette deposition 
represented previously at fig. 5.27.  
In Figure 5.56 is shown a comparison of the calibration curve with an LB film with the 
calibration curve obtained with Eudragit L100 dropped on the PMMA surface.  
The improvement in the performance of the assay was immediately apparent and 
impressive. 
Every measured point is an average of ten measurements of the fluorescence signal 
collected in a ten seconds integration time period.  
The standard deviation for these points was calculated to be in the range of the dimension 
of the point and for this reason is not displayed on the graph.  
The standard error bar, displayed on the graph, was calculated as the ratio between:  
1) standard deviation relative to two different measurements executed on two different 
PMMA channels.  
2) the square root of the number of measurements (in this case two).  
Anyway, the standard error bar gives an idea about the reproducibility of the method.   
 
 
Figure 5.56 Eudragit L100 deposition method. Comparison between micropipette deposition at 0.01 mM 
and LB deposition at 20 mN/m.  
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Finally, a characterization by AFM imaging of IgG and anti-IgG covalently bound on a 
PMMA surface was carried out.  
The immobilisation was carried out on Eudragit L100 copolymer and on poli-L-lactic 
acid (PLLA). Eudragit L100 revealed a better and homogeneous polymer layer.  
The antibodies were photographed and their cut sections confirmed the theoretical size 
known from literature.  
An implementation of the immobilisation procedure on the PMMA chip was obtained by 
using Eudragit L100 and depositing a monolayer of 5 nm of thickness by Langmuir-
Blodgett (LB) method using a surface pressure of 20 mN/m.  
This deposition method, previously carried out on small planar square and then on a 
channel of the biochip, was compared, for an IgG/antiIgG assay, to the previous 
depositions of the polymer applied by micropipette. 
The deposition by LB method enhanced the performance of the chip of at least on order 
of magnitude in sensitivity.  
Future plans can be pointed out on the obtainment, by using Langmuir-Blodgett 
methodology, of smooth transparent surfaces with an ordered structure of monomers able 
to enhance sensitivity towards concentrations lower than 1 ng/ml.   
Deposition of LB layers involve a big variety in the research plans to obtain in the future 
more sensitive coatings. Surface pressure variation can determine a high reproducibility 
of the system and a further optimisation of the system thanks to enhanced sensitivity 
obtained by LB method and to research on low kind of autofluorescent PMMA, thus 
increasing SNR.      
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A1. Characterisation of immobilised PSII proteins on a PMMA substrate by means 
of anisotropic fluorescence, AFM and L-B methodology  
 
 
In this addendum chapter is presented a work carried out on protein extracts from spinach 
membrane fragments enriched in Photosystem II (PSII) covalently immobilised on to a 
PMMA surface at various concentrations and analyzed by means of AFM and anisotropic 
fluorescence activity. An improved sensitivity was resulted using Langmuir-Blodgett 
methodology for the deposition of the polymer which binds to PMMA and to the 
proteins.  
 
A1.1 Chlorophyll fluorescence 
 
Chlorophyll fluorescence analysys has become one of the most powerful and widely used 
techniques available to plant physiologists and ecophysiologists [363].  
Chlorophyll fluorescence can be used to study components of the photosynthetic 
apparatus and their reactions to changes in the environment as well as photosynthesis. 
This is interesting in the fact that photosynthesis is a good indicator of the adaptation of a 
plant to its surrounding environment.  
Since the measurements are non-intrusive, fast and reliable, this makes chlorophyll 
fluorescence an attractive tool for environmental research and for breeding purposes.  
In particular, the oxygen evolution of a plant is directly correlated into the estimation of 
the photoactivity of PSII. For the same reason, the fluorescence correlated to the 
concentration of these proteins can suggest several informations on the oxygen activity of 
a plant [364]. Furthermore, a close correlation has been found between change in the dark 
level of fluorescence F0 and necrosis test after heat stress in a large number of plant 
species [365]. Upon exposure to increasing temperature, the dark level of fluorescence F0 
increases. From its theoretical expression, an increase of fluorescence can be interpreted 
as a reduction of the rate constant of energy trapping by PSII centers [366].  
This is the result of a physical dissociation of light harvesting complex from PSII core as 
it has been observed in several plant species as a result of heat damage [367]. 
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A1.2 PSII proteins 
 
PSII is a trans-membrane chlorophyll-protein complex which consists of a large number 
of subunits, which catalyse the photo-oxidation of water. Light is harvested by means of 
the LHCII complex and the chlorophyll-binding subunits [368].   
PSII is embedded in the lipid matrix of the thylakoid membranes of chloroplasts coming 
from higher plants. It is also present in other microorganisms such as algae and 
cyanobacteria [369].   
PSII is one of the multisubunit protein membrane complexes which are involved in the 
“light reactions” of the photosynthesis: it strictly cooperates with Photo System I (PSI) 
and the Cytochrome b6f complex [370] (Figure A1.1).   
PSII can be extracted from chloroplast cells of spinach leaves and then stabilised as a 
suspension using a suitable buffer, according to the following steps of a standardised 
procedure [371].  
PSI and PSII contain chlorophylls and other pigments that harvest light and funnel its 
energy to a reaction centre. Energy that has been captured by the reaction centre induces 
the excitation of specialised reaction-centre chlorophylls (primary electron donors; a 
special chlorophyll pair in PSI), which initiates the translocation of an electron across the 
membrane through a chain of cofactors.  
 
Figure A1.1. Light reactions are represented by this diagram also known as “Z-scheme”. The image source 
is at http://www.bio.ic.ac.uk/research/barber/psIIimages/PSII.html  
 
 
PSII catalyses a unique process of water oxidation and provides almost all of the earth's 
oxygen. The evolution of PSII was therefore crucial for the emergence and endurance of 
aerobic organisms. The mechanism of oxygen production involves the oxidation of two 
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water molecules to make molecular oxygen (O2) in a combined mechanism that requires 
the absorption of four light quanta. Two weakly coupled chlorophylls known as P680 
function as the primary electron donor (680 nm is the peak of the lowest-energy 
absorption band of P680). After absorption of the first of the light quanta, an electron is 
translocated from P680 through accessory chlorophyll and pheophytin molecule to the 
tightly bound quinone QA, and this is followed by the reduction of a mobile quinone QB 
[372]. The oxidized P680+ has the highest redox potential observed in a biological system 
(> 1 V), and is able to oxidize a nearby tyrosine (YZ). YZ then extracts an electron (and 
perhaps a proton) from a cluster of four manganese ions, which binds two substrate water 
molecules and has a calcium ion, a chloride ion and a bicarbonate ion as necessary 
cofactors. After another photochemical cycle, the doubly reduced QB (QB2-) takes up two 
protons from the stroma to form QBH2 and is released into the lipid bi-layer to be 
replaced by an oxidized quinone from the membrane quinone pool. This pool consists of 
oxidized (PQ) and reduced (PQH2) plastoquinones (plastoquinone, rather than quinone, is 
specified when it is the predominant quinone) [373]. After two more photochemical 
cycles, the manganese cluster is provided with four oxidizing equivalents, which are used 
to oxidize two water molecules to produce O2 (photo-oxidation of water) by following 
the reaction: 2H2O + PQ + hv → O2 + 2H+ + PQH2 
PSII can have biotechnological applications in the environmental field, because it is very 
sensitive to some herbicides (derivatives of phenylurea, triazine, diazine and phenolic 
types). The triazine herbicides bind to the PSII complex, displacing the plastoquinone 
(PQ), and inhibit the light-driven electron transfer system in photosynthesis. Many 
detection methods using photosynthetic proteins, such as D1 protein [374], PSII particles 
[375], and thylakoid membranes [376], have been reported.  
Many of these assessed inhibition of the light-driven electron transport by herbicides 
[377]. The signals of herbicide binding to the photosynthetic reaction centres of the 
protein can be detected directly by measuring the reduction in photocurrent due to the 
decrease of oxygen generation.  
Thylakoid membranes are plenty enriched in photosystem II (PSII) complexes: thylakoid 
proteins, commonly present inside these membranes, are rich in chlorophyll (α, β) 
molecules with Mg2+ porphyrin fluorescent molecules that reveal an absorption signal in 
the region nearby 635 nm and an emission at 680 nm. In this work, thylakoid proteins 
extracted from spinach membranes [378] and dissolved in MNBC buffer solution (3.0 
mg/ml) were purified for the attachment on a PMMA substrate.  
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 A1.3 Experimental part 
 
The substrates used were planar square surfaces made of PMMA of 1 cm2 and thick 0.15 
cm. Drops of two different polymers (Eudragit L100 and PLLA followed by activation 
with NaOH) were deposited in order to obtain a surface enriched in carboxylic groups.  
In particular the effectiveness of the deposition method (by drop or by Langmuir-
Blodgett) of Eudragit L100 was investigated by means of fluorescence. Three different 
protocols were carried out as follow: 1) Eudragit L 100 (0.01mM in EtOH) solution was 
dropped onto the PMMA surface. 2) PLLA (0.01mM in CHCl3) was dropped onto the 
PMMA surface followed by activation with NaOH 2M. 3) Eudragit L 100 film was 
obtained by LB method with a controlled deposition at surface pressure Π= 20 mN/m. 
The activation of the surface was achieved using the EDC/s-NHS method in MES buffer 
0.1 M, pH 6.2 in order to obtain a surface enriched in carboxylic groups activated for 
protein binding.  
Protein solutions at five different concentrations (3.0, 0.3, 0.03, 0.003, 0.0003 mg/ml) 
were spread on fifteen chips (five for each polymer treatment) on the active surface using 
MNBC, which is a derivative, more rich in salt ions, of MES buffer.  
The optical system used for the characterization of the chips is shown in Figure A1.2. 
The source consisted in a He/Ne laser at 632 nm. There was no need to apply filters to the 
optical system. The detected signal was collected at fluorescence anisotropic angle [379], 
using a multimode optical fibre connected to an USB2000 Ocean Optics 
spectrophotometer and analysed using SpectraSuite software.   
 
 
Figure A1.2. Instrumental setup for fluorescence measurements. The excitation source hit the surface in the 
upper part of the chip. The fluorescence from the PMMA surface dictated the best signal collection angle of 
45° due to the effect of anisotropic emission. 
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A1.4 Results and discussion 
 
Fluorescence measurements: 
The results of the fluorescence studies are shown in Figures A1.3-A1.5.  
On the left side the optical spectra collected are shown whereas a calibration curve 
(concentration vs fluorescence) is shown on the right.  
In the region nearby 630 nm is visible the excitation signal of the He/Ne laser whereas 
the peak at higher wavelength (650-800 nm) is the fluorescence signal.  
On the right side is plotted the area of the fluorescence (in the spectral region between 
680±25 nm) versus the concentration of the protein.  
Comparing the depositions by drop method, the fluorescence signal in the case of 
Eudragit L100 (figure A1.3) was found to be three times higher than in the case of PLLA 
(figure A1.4). In particular the gap (17000 vs 47000 arbitrary units) is quite evident at 
higher concentration (3 mg/ml).  
Considering the depositions by LB method, the fluorescence signal for treatment with 
Eudragit L100 polymer (Figure A1.5), demonstrated to be really good in sensitivity and 
linearity at lower concentrations (0.3 to 0.0003 mg/ml).  
This measurement confirmed that an enhanced sensitivity of the system could be obtained 
using a LB controlled deposition method. In this case, a calibration curve was captured 
with a limit of detection of approximately 1 µg/ml. 
The optical spectra captured are the average of ten measurements collected at 10 seconds 
of integration time using spectrophotometer USB2000 from Ocean Optics Inc. 
  
Figure A1.3. Eudragit 0.01 mM dropped on PMMA chip. Left: Optical spectra were collected with the 
instrumental setup in Fig.13. Four different chips with different concentrations of proteins were deposited. 
Right: calibration curve obtained with the four concentration chips; in the y axis the fluorescence area 
between 655 and 705 nm was considered.  
 
 174
  
Figure A1.4. PLLA 0.01mM dropped on PMMA chip Left: Optical spectra were collected with the 
instrumental setup in Fig.13. Four different chips with different concentrations of proteins were deposited. 
Right: calibration curve obtained with the four concentration chips; in the y axis the fluorescence area 
between 655 and 705 nm was considered.  
 
Figure A1.5. Eudragit in EtOH deposition by LB method at 20 mN/m. Left: Optical spectra were collected 
with the instrumental setup in Fig.13. Four different chips with different concentrations of proteins were 
deposited. Right: calibration curve obtained with the four concentration chips; in the y axis the fluorescence 
area between 655 and 705 nm was considered.  
 
 
AFM measurements: 
Three different PMMA chips with the highest concentration in protein content (3mg/ml) 
were analysed by means of AFM. The first image captured is shown in Figure  
A1.6. On the upper images topography, deflection and friction pictures are displayed. On 
the PMMA matrix treated by Eudragit, some little particles are visible. Two of those, 
covalently bound on a PMMA thread, were considered for cut section analysis, in order 
to understand their effective size avoiding any dimension contribution coming from the 
net structured background. The particles measured were 4-5 nm high and 50-100 nm 
wide. Their dimensions in width reflects the dimensions of PSII proteins known from 
theory [380] but their height (in theory are reported height between 30 to 50 nm) 
suggested that these proteins were partially included inside the Eudragit matrix. When 
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Eudragit was deposited on the surface, time was waited for the evaporation of EtOH 
solvent and then after 1 hour deposition of the protein was carried out. Anyway the 
deposition of the polymer was carried out at room temperature (total evaporation of 
EtOH occurs at 79°C). So, could be possible that not all the solvent was evaporated 
leaving sacks of the solvent and the proteins inserted parts of their structure inside it. 
            
 
Figure A1.6. PMMA + Eudragit 0.01 mM by drop method. PSII proteins: Top: from left to right 
Topography, deflection and 3D images. Bottom: Relative cut section of the protein immobilized on the 
surface. AFM contact mode. Image size: 5 x 5 µm image. 
 
Figure A1.7 show the immobilization of PSII proteins on a monolayer of Eudragit 
obtained by LB deposition. The deposition of these proteins occurred several days after 
the polymer deposition so the effect previously described should be minimal. Despite 
that, the same effect of before is visible. The sacks of EtOH not evaporated do not 
explain the little dimension in height revealed by these proteins. A second explanation 
more exhaustive can be described this effect for a better understanding. These proteins 
are delicate macromolecular structures that probably suffer the immobilisation procedure 
or the tip scanning and for this reason they tend to spread their shape on the surface. This 
explanation was mainly suggested by their wide extension (400 nm), really unusual for 
their size. Anyway, it is almost clear that in these conditions the proteins possessed a 
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fluorescence activity but degraded from a three dimensional structure into a two 
dimensional flatten shape.       
 
 
 
Figure A1.7. PMMA + Eudragit L100 by LB method at 20mN/m.  PSII proteins: topography, deflection, 
3D and zoom images. Relative cut section of proteins immobilised on the surface. AFM contact mode. 
Image size: 2.5 x 2.5 µm.  
 
 
Figure A1.8 show the proteins immobilised on to a PLLA matrix, revealing an height of 
1-2 nanometer and a width section of 50-200 nm.  
To regulate the force of tip is enough to adjust the force of set point values.  
A curious experiment was conducted by manipulating the proteins using the AFM tip as a 
nanoscale arm that can move proteins from point to an external side of the image.  
This experiment is shown in figure A1.9, where two proteins were detected on the surface 
and one of these was moved on one side (out of image) leaving an empty hole on the 
PLLA polymer.        
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Figure A1.8..PMMA + PLLA 0.01mM by drop method. Topograpy, 3D and deflection images. Relative 
cut sections of the proteins detected on the surface. AFM contact mode. Image size: 2.5 x 2.5 µm. 
 
 
 
Figure A1.9. PMMA + PLLA 0.01mM dropped and activated by NaOH (2M) on PMMA chip. Top:: 
topography, deflection and 3-D images. Bottom: Relative cut section and zoom in of one protein and of one 
hole leaved by one protein removed by AFM tip. AFM contact mode. Image size: 2.5 x 2.5 µm. 
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A1.5 Well experiment 
 
Dip-Pen Nanolithography (DPN) is a scanning probe nanopatterning technique in which 
an AFM tip is used to deliver molecules to a surface via a solvent meniscus, which 
naturally forms in the ambient atmosphere.  This direct-write technique offers high-
resolution patterning capabilities for a number of molecular and biomolecular 'inks' on a 
variety of substrates, such as metals, semiconductors, and monolayer functionalized 
surfaces. It's becoming a work-horse tool for the scientist interested in fabricating and 
studying soft- and hard-matter on the sub-100nm length scale [381].  
DPN allows one to precisely pattern multiple patterns with near-perfect registration. It's 
both a fabrication and imaging tool, as the patterned areas can be imaged with clean or 
ink-coated tips. The ability to achieve precise alignment of multiple patterns is an 
additional advantage earned by using an AFM tip to write, as well as read nanoscopic 
features on a surface.  These attributes make DPN a valuable tool for studying 
fundamental issues in colloid chemistry, surface science, and nanotechnology [382].  
The possibility to build, by scratching with an AFM tip, controlled wells on a nanometer 
scale for multi-analyte detection can offer several interesting solutions, especially in a 
“lab on a chip” technology.  
Biomedical science needs to obtain biosensors for virus diseases (AIDS-HIV, HPV ecc.) 
which involves multi-genotypes detection, where more than one hundred of different 
genes are involved in biorecognition of sample analytes.    
So, previously acquired capabilities in the manipulation of proteins (Figure A1.9), 
suggested a research work which was orientated into the realisation of a substrate 
characterised by wells in a specific region, in order to understand the control possibilities 
of etching by AFM tip in terms of resolution and depth. 
The image in Figure A1.10 shows the results of experiments conducted on the PMMA 
surface and demonstrated that it can easily be scratched by an AFM tip and modelled for 
specific purposes. The procedure consists into take a picture of a 1 micron length in an 
unexplored zone. By adjusting the force of the set point value was possible to take 
another image with a lower force on the tip across a 5 micron length.  
Finally, an image was taken across a 10 micron length, revealing everything that was 
scratched before using a lighter atomic force. The cut section revealed a depth in the 
central square hole of 25 nm and 15 nm in the external square one. 
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Figura A1.10. Bare PMMA. Building a well of 1µm2 inside a 5 micron side square pool using atomic force 
set point is possible to scratch PMMA with the tip of AFM. The pool where the well was built is 15 nm 
deep and the well is 25 nm deep. AFM contact mode, Cranfield University. Image size: 10 x 10 µm. 
 
A second experiment similar was carried out with the AFM tip to understand the level of 
control of the instrumentation on an x-y region for a controlled scratching of the surface 
to obtain multi-wells (Figure A1.11).  
Starting from a central well of 1 µm2, the tip was moved 2 µm in x direction to the right 
and 2 µm in y direction to the top to build a second well.  
This type of movement did not excelled in perfection (see figure A1.11). The force on the 
tip was kept constant and moving just only the x direction of 4 µm on the left a third well 
was built. The cut section revealed that keeping the same force on the tip (keeping the 
same set point value), a reproducible well in terms of depth is obtainable.  
This fact had a confirmation in the building of a fourth micro-well (just moving to down 
in y direction for 4 µm) when the same tip force was maintained. In the fifth and last 
micro-well, moving again on x direction for 4 µm to the right, the force tip was 
diminished, determining a change in depth from 150 nm to 100 nm.  
This result suggested that further studies will be required to discover the dependence for 
PMMA between the force set point values and the depth of the holes in order to arrange a 
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perfect combination between the geometry of the substrates and its possibility in multi-
genotypes detection.  
 
Figure A1.11. Bare PMMA. Topography images of 5 wells of 1µm2 scratched on a bare PMMA surface. 
Relative cut section analysis are captured. AFM contact mode. Image size: 10 x 10 µm. 
 
In the figure A1.12 is shown a PMMA scratched surface with holes of 100 x 100 nm, 100 
x 200nm, 300 x 300 nm and 500 x 500 nm dipped using different set point values and 
creating different holes with a controlled depth.  
 
Figure A1.12. Bare PMMA. Topograhy, deflection and topography images. The depth of the wells was 
controlled by adjusting the set point value of the tip force tip.  
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A1. Conclusions 
 
In this final chapter of the thesis a work carried out on protein extracts from spinach 
membrane fragments enriched in Photosystem II (PSII) covalently bound on to a PMMA 
surface and analyzed by means of AFM and fluorescence activity at various 
concentration was presented.  
Two different polymers were evaluated, Eudragit L100 and PLLA; the first one 
demonstrates, by fluorescence evidence, a protein binding capacity three times superior 
than the second. A comparison between a drop deposition and a Langmuir-Blodgett 
deposition was carried out by means of fluorescence and the second method was 
considered the most effective, especially for lower concentration of the proteins. 
Detection by AFM imaging was also carried out and revealed the presence of these 
proteins attached on the surface on a flatten position and confirmed the effectiveness of 
the immobilisation method on this substrate.  
Moreover, the last images revealed that manipulation of these proteins on a nanometer 
scale on a surface was also possible by the control in position and strength of the tip.  
By adjusting the force of the tip is conceivable to build micro and nano-wells on the 
PMMA surface to develop ordered substrates for biosensors multi-purposes.             
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 CONCLUSIONS 
 
Object of this Ph.D. thesis was the development of a novel optical chip for affinity 
biosensors. The research carried out was highly interdisciplinary since not only were 
chemical and biochemical aspects faced during the course of the three years, but the 
activity also dealt with optical aspects. The main results achieved are summarized 
below: 
1) A novel fluorescence-based optical platform for multiple bioassay was designed and 
developed in order to optimise the collection of the fluorescence emitted by the sensing 
layer. The fluorescence anisotropy, which is exhibited whenever a discontinuity of 
refractive index is present, was used to develop a novel optical configuration 
characterized by high collection efficiency and a very good separation between 
excitation and emission. In principle, the optical efficiency of the system could be 
improved further improved if the spectrum analyser were replaced by a photomultiplier 
or a powerful detector, without discriminating the detected wavelength. On the other 
hand the described system, equipped with the spectrum analyser, was essential in the 
identification of the better working wavelengths and in the discrimination of the optical 
signal coming from the chip (fluorescence and scattered light). It is also important to 
stress the particular configuration of the chip with multiple channels which was 
potentially useful for multi-analyte assay, with each single channel designed for the 
detection of different analytes. 
2)  A careful study on the optimisation of the substrate for the immobilisation of the 
bioreceptor was carried out in order to identify the best chemical treatment of the 
surface: the best polymer was found to be 0.01mM Eudragit L100  for drop deposition; 
PLLA was another affordable solution. Eudragit L100 was also shown to be an 
appropriate solution for a reaction with an amino-linker. Further studies, verified by 
chip measurements, demonstrated that the optimal concentration by drop deposition 
was 0.01 mM. The best method for deposition of Eudragit L100 was by using the 
Langmuir Blodgett method with 20mN/m surface pressure in order to obtain a thin 
monolayer of 5 nm. This increased by at least one order of magnitude the sensitivity of 
the entire optical system. 
3)  The system was fully characterised with the IgG/anti-IgG direct assay with the 
 definition of a protocol for the implementation of the assay. IgG and Anti-IgG 
interactions were plenty characterized also by atomic force microscopy imaging. The 
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increased efficiency of the optical system by Langmuir-Blodgett deposition was 
obtained for this type of assay.     
4) The potential of the optical platform was tested with a sandwich assay for NF-kB1, 
 using a double stranded DNA (dsDNA) sequence as the specific capture bioreceptor    
 immobilised on the PMMA surface and a Cy5-labelled antibody (clone C-19) as 
 detection bioreceptor. 
5) The hybridization of the RNA/RNA duplex for the MGMT detection was verified on 
 the optical platform detecting target 7 in flow, after the immobilization of the suitable 
probe (probe 7) on the PMMA surface.  
6)  The optimised immobilization procedure of proteins on PMMA was also used for the  
detection of PSII proteins extracted from thylakoid membranes of spinach leaves. A 
characterization of these surfaces was carried out by measurements of anisotropic 
fluorescence and by means of atomic force microscopy. 
The significance of this work can be summarised as the title of this thesis declares. A 
novel optical biochip for multi-analyte detection is born.  
This biochip represent the core part of the integrated project called CARE-MAN 
(HealthCARE by Biosensor Measurements And Networking) of the 6th EU RTD 
Framework Programme.  
Integration of potentials in nanotechnology and information technology is an urgent 
objective in the economy of Europe, aiming at the transition towards a knowledge-
based society and sustainable development.  
Accordingly, support of e-health by development of new diagnosis equipment for 
healthcare based on biosensing with integrated data pre-treatment and networking 
capabilities is intended by the joint call IST-NMP-2 in the Sixth Framework 
Programme and considered within eEurope2002 Action Plan Health.  
The achievement of the objectives of the Integrated project CARE-MAN will provide 
significant benefits to the effectiveness of the European healthcare in general as well as 
to large segments of the European population profiting from the knowledge generated 
within this project because of its focus on major diseases prevailing in European 
societies. As these diseases are closely linked to the issue of the ageing European 
population, CARE-MAN will contribute to meet this major societal challenge.  
At present, diagnostics at hospitals is based either on large-scale automated equipment 
or ELISA techniques based on bioassays which are not suitable for bedside and 
emergency medicine. To overcome these restrictions, the Integrated Project CARE-
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MAN has first a long-term objective as the development of a new medical instrument 
being an intelligent diagnosis equipment for healthcare, representing a development for 
the future and the potential of down-scaling for the use in general practices, and second 
the vision to provide a new automated, self-controlled equipment for patient homecare, 
either in case of post-operative checks or for permanent surveillance in case of chronic 
diseases. CARE-MAN will provide a validated, intelligent, fully automated diagnostic 
device with a modular technological system based on biosensor technology, combining 
successful transduction principles, biochemical recognition methods and 
communication capabilities to allow a multi parameter measurement characterising 
diseases defined by doctors and needs in hospitals, like cardiovascular disease, 
coagulation disorders, chronic/acute inflammation, cancer, thyroid disorders.  
The CARE-MAN 5-year project has a total budget of nearly € 18 million of which 
about € 11.55 million is funded by the European Commission.  
CARE-MAN integrates partners from academia, industry and medical science into a 
coordinated interdisciplinary research between nanotechnology, nanoscience and 
information technology.  
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